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ABSTRACT

DOPAMINE TRANSPORTER (DAT), NICOTINIC ACETYLCHOLINE RECEPTOR
(nAChR), AND METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2) IRREVERSIBLE
PROBES FOR IDENTIFYING ANTI-PSYCHOSTIMULANT THERAPEUTICS

By
Shaili Aggarwal
December 2014
Dissertation supervised by Dr. David J. Lapinsky
Numerous in vitro and in vivo studies implicate that certain ligands that interact with
DAT, nAChRs, and mGlu2 have tremendous potential as anti-addiction therapeutics. However,
understanding how these promising anti-addiction compounds interact with their major drug
targets at the molecular level is limited because of the absence of human DAT, nAChRs, and
mGlu2 x-ray crystal structures. This knowledge gap is important towards rationally designing
new therapeutics for psychostimulant abuse and addiction. The objective of this research was to
develop irreversible chemical probes based on promising anti-addiction lead compounds (i.e.,
pyrovalerone, bupropion, BINA, etc) to map their binding sites and poses within the DAT, select
nAChR subtypes, or mGlu2.

The central hypothesis was that these compounds could be

rationally derivatized, without significant alteration in their pharmacological activity, with a
photoreactive group capable of forming a covalent bond to their target protein and a tag for

iv

application of a “Binding Ensemble Profiling with (f)Photoaffinity Labeling (BEProFL)”
experimental approach.

BEProFL rationally couples photoaffinity labeling, chemical

proteomics, and computational molecular modeling to allow structure-function studies of the
target proteins.

This central hypothesis was tested by pursuing three specific aims: 1.)

Identification of non-tropane photoprobes based on pyrovalerone (PV) suitable for DAT
structure-function studies, 2.) Identification of bupropion (BP)-based photoprobes suitable for
DAT, and nAChR structure-function studies, and 3.) Identification of irreversible mGlu2 PAM
ligands as chemical probes suitable for mGlu2 structure-function studies. In the first aim, PV, a
non-tropane DAT inhibitor, was structurally modified to contain a photoreactive group (i.e., an
aryl azide) and a tag (i.e.,

125

I). These photoprobes were then pharmacologically evaluated to

identify suitable candidates for DAT structure-function studies. In the second aim, BP was
structurally modified to contain an aryl azide and

125

I. This probe successfully identified the

exact location of the bupropion-binding site within the Torpedo nAChR. Under the third aim,
biphenyl-carboxylic acid indanone- and pyridone-based mGlu2 PAMs were structurally
modified to contain a photoreactive group (e.g., aryl azide, acetophenone) and a tag (e.g.,
terminal alkyne, aliphatic azide). These compounds, at present, are being subjected to mGlu2
pharmacological evaluation to identify suitable chemical probe candidates for mGlu2 structurefunction studies.

v
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CHAPTER ONE
1. Biological Literature Review
1.1. The Problem of Drug Addiction
Substance abuse is characterized by a compulsive, incontrollable need to seek and intake
a psychostimulant despite its deleterious effects on the personal and social well being of the
individual. It is a chronic condition leading to severe medical, psychiatric, and psychosocial
problems (LeMoal and Koob, 2007; Koob and Volkow, 2010). According to the 5th edition of
Diagnostic and Statistical Manual of Mental Disorders (DSM) from the American Psychiatric
Association (ASA), substance dependence is characterized by a loss of control in limiting abuse,
and the emergence of a negative emotional state, (e.g. anxiety and irritability due to withdrawal)
when access to a substance is prevented. It demonstrates the presence of an acquired abnormal
state wherein regular administration of an adequate amount of a substance is essential to
maintain normal physiological equilibrium. According to the 2012 National Survey on Drug Use
and Health (NSDUH), about 27 million people in the US alone suffer from drug addiction;
approximately 200,000 people died due to drug abuse in 2012 (Kobeissy et al., 2014).
Therefore, development of effective strategies for treatment of substance abuse and dependence
is essential considering its negative impact on the individual and society, as well as the
unprecedented economic burden attributed to health care costs, loss of productivity and legal
system expenditures.

Figure 1.1. Chemical structures of some major drugs of abuse
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Some of the most commonly abused drugs include cocaine ((-)-1.1), amphetamine ((±)1.2), cathinone ((±)-1.3) and nicotine ((-)-1.4) (Klein and Rowland, 2013; Figure 1.1). These
drugs of abuse cause long-term neuroadaptive changes in the mesocorticolimbic region of the
brain, ultimately leading to the problems of substance abuse, dependence, tolerance, and relapse
(Hyman and Malenka, 2001; Hyman et al., 2006). Apart from severe socioeconomic losses
faced by drug addicts, such individuals also suffer from acute CNS effects including euphoria,
insomnia, increased libido, tremors, and convulsions.
Cocaine (1.1, Figure 1.1) is a tropane alkaloid originally obtained from the leaves of the
coca plant Erythroxylum coca in 1855. It is a Schedule II drug and one of the most potent
psychostimulants known, possessing very high addictive properties (Freye, 2010). More than 1.6
million Americans were addicted to cocaine in 2012 according to a report by the US Department
of

Health

and

Human

Services

(see

http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHr
esults2012.htm). The hydrochloride salt of cocaine is administered intravenously, whereas its
free base is used via inhalation. Cocaine, upon administration, elicits physiological effects such
as euphoria, increased cardiovascular activity, hypothermia, and hypertension, with chronic
abuse leading to a higher risk for stroke, heart, and pulmonary diseases.

Furthermore,

individuals who abuse cocaine are also more susceptible to infectious diseases such as
HIV/AIDS, Hepatitis B, and Hepatitis C (Parikh et al., 2012; Zimmerman, 2012). In addition,
cocaine withdrawal results in severe stages of depression, paranoia, and hallucinations, and
addicts require a strong desire and tremendous willpower to quit. In most cases, severity of
cocaine withdrawal symptoms forces addict to ultimately relapse. Currently, effective FDAapproved pharmacotherapies to treat cocain addiction are non-existent, and the addicts have to
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rely mainly on behavioral therapies for treating cocaine abuse and addiction (Herdener et al.,
2012).
Phenethylamine-containing

psychostimulants

(i.e.,

amphetamine

((±)-1.2),

methamphetamine ((±)-1.5) and MDMA (3,4-methylenedioxy-N-methylamphetamine, ((±)-1.6
or “ecstasy”), as well as their -keto derivative, cathinone ((±)-1.3) and its synthetic analogs
(also called “designer cathinones” or “bath salts”) are another category of psychostimulants with
severe abuse potential (see Figure 1.2) (Banks et al., 2014; Iversen et al., 2014).

Figure 1.2. Chemical structures of the amphetamine-class of psychostimulants.

Amphetamine ((±)-1.2) addiction causes severe loss of appetite, agitation, paranoia,
hallucinations, and delusions (Goncalves et al., 2014). The N-methyl analog, methamphetamine
((±)-1.5, METH) is even more potent and toxic than amphetamine. METH is highly lipophilic,
less prone to enzymatic degradation, with a half life of 10-12 hours, and reaches the brain faster
than any other psychostimulant (Cruickshank and Dyer, 2009; Schep et al., 2010). METH abuse
is a major public health problem in the U.S. The 2012 NSDUH reported 1.2 million people
using

METH,

with

440,000

users

in

a

single

month

(see

http://www.drugabuse.gov/sites/default/files/methrrs_web.pdf). METH exists in several physical
forms and can be smoked, inhaled, injected, or orally ingested. The short-term effects of METH
abuse include increased attention, decreased fatigue, increased activity and wakefulness,
decreased appetite, euphoria, and hyperthermia. Consequently, chronic long-term METH use
leads to memory loss, fatal seizures, psychosis, impaired motor skills, aggressive and violent
behavior, weight loss, hemorrhage, depression, and death. The abusive intake of MDMA ((±)3

1.6 or “ecstasy”), another amphetamine analog, can cause damage to the brain, kidney, liver, and
heart tissue. Its long term effects include myocardial infarction, multiple organ failure, and
ultimately death (Reid et al., 2007). In addition, MDMA ((±)-1.6) metabolizes systemically into
a variety of reactive quinone or thioether precursors, that produce free radicals that can cause
further damage to the physiological system (Green et al., 2003).

Figure 1.3. Chemical structures of cathinone and its synthetic derivatives.

Cathinone ((±)-1.3, Figure 1.3), found in the plant Catha edulis, or “khat”, is a naturally
occurring -keto analog of amphetamine that producing psychostimulant effects similar to the
amphetamines but with greater potency (Al'Absi and Grabowski, 2012; Al Suwaidi et al., 2013).
Its first synthetic analog, methcathinone ((±)-1.8) discovered through structure-activity studies of
(±)-1.3, was found to be as potent as METH, and is presently widely abused (Glennon et al.,
1987; Calkins et al., 1995; Bonano et al., 2014). Between 2005 and 2011, several synthetic
analogs of cathinone with a common -aminophenylketone moiety emerged called as “designer
cathinones” (or “bath salts” or “legal highs”). Most of these drugs are now being sold legally on
the internet under different street names (German et al., 2014).

Due to their convenient

accessibility via chemical synthesis and inadequate regulatory policies to limit their illegal use,
these designer drugs have posed growing health risks. Many cases of severe neurological
4

disorder and deaths due to their overdose have been increasing at an alarming rate (Johnson et
al., 2013). Moreover, the synthetic cathinone derivatives are relatively easier to synthesize and
several analogs with subtle structural changes versus cathinone can be generated to evade legal
constraints (Coppola and Mondola, 2012; Gunderson et al., 2013; Simmler, Buser et al., 2013;
Zawilska and Wojcieszak, 2013). Among the designer cathinones, the most popularly abused are
mephedrone ((±)-1.9), methylone ((±)-1.10) and methylenedioxypyrovalerone ((±)-1.11, MDPV)
which were labeled as Schedule I controlled substances in 2011 (Bonano et al., 2014). These
synthetic cathinone derivatives, despite slight structural divergence from cathinone, can either
have pharmacological effects similar to methamphetamine, cocaine, MDMA, and cathinone, or
can produce completely unknown complex neurological and cardiovascular effects that can last
up to days (Marinetti and Antonides, 2013).
Physiologically, the psychostimulant effects of the aforementioned drugs of abuse, (i.e.,
cocaine, amphetamine-like compounds and synthetic cathinones) are mediated through direct or
indirect stimulation of the dopaminergic or glutamatergic nervous systems (Nestler, 2005).
Another form of drug addiction is tobacco dependence from cigarette smoking.

L-

nicotine ((-)-1.4, Figure 1.1), a tertiary amine alkaloid, is the main psychoactive constituent of
tobacco. Nicotine mediates its psychoactive actions such as mood elevation, increased arousal,
improved attentiveness, and muscle relaxation, by activating nicotinic acetylcholine receptors
(nAChRs), thereby causing stimulation of the cholinergic nervous system, which in turn affects
dopaminergic neurotransmission (Benowitz, 2009).

Despite the harmful consequences of

tobacco smoking, which is known to increase the risks of cardiovascular diseases, stroke, and
cancer, the compulsive use of tobacco is the major cause of deaths associated with addiction in
developing countries (George and O'Malley, 2004).
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Treatment of psychostimulant abuse currently remains a major challenge.

No

medications have yet been approved by the Food and Drug Administration (FDA) for treatment
of cocaine or methamphetamine abuse. In addition, smoking cessation therapies available for
nicotine addiction, such as nicotine replacement products, varencline (Chantix®), and bupropion
(Zyban®) are inadequate, as 80% of addicts relapse within a month of treatment (Benowitz,
2009). Furthermore, the growing number of more potent, newer synthetic cathinones with
continuously changing names, many routes of administration, several preparations with diverse
drug constituents, and the difficulties in legally controlling them, are leading to overdose deaths.
This observation warrants the urgent need for discovery and development of psychostimulant
abuse therapeutics. As a result, over the past many years, numerous studies have focused on
elucidating the detailed structural and functional properties of protein targets that control the
neurotransmission within the dopaminergic, glutamatergic, and cholinergic systems, which are
directly implicated in drug addiction.

1.2. The Dopaminergic System
The dopaminergic system refers to the mesocorticolimbic pathway (Figure 1.4) which
includes dopaminergic neurons projecting from the midbrain region, comprised of the ventral
tegmental area and substantia nigra (Arias-Carrion et al., 2010).
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Figure 1.4. Overview of the mesocorticolimbic system of the human brain containing the dopaminergic projections
passing through different regions of the human brain (Arias-Carrion et al., 2010. Reprinted with permission from
Int. Arch. Med. 2010, 3, 24. Copyright 2010, BioMed Central).

These neurons, originating from the ventral tegmental area and the substantia nigra,
synthesize and release dopamine as a chemical messenger into the nucleus accumbens, frontal
cortex and the striatum.

Dopamine (1.13, Figure 1.5) is a catecholamine neurotransmitter

biosynthesized from tyrosine by tyrosine hydroxylase and is stored in vesicles of presynaptic
neurons (Tritsch and Sabatini, 2012).

Figure 1.5. Chemical structure of dopamine (1.13) as a neurotransmitter.

Dopamine, released from presynaptic neurons into the synaptic cleft due to Ca2+ influx,
activates G protein-coupled dopamine receptors located on postsynaptic neurons.

In turn,

dopamine regulates important brain functions such as reward, addiction, attention, memory,
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cognition, and motor control by activating dopamine receptors (Di Chiara and Bassareo, 2007).
Dopamine is then slowly cleared from the synaptic cleft by reuptake into presynaptic neurons,
where it is metabolized by monoamine oxidase (MAO).

Figure 1.6. Dopaminergic neurotransmission (Reprinted with permission from
https://www.cnsforum.com/educationalresources/imagebank/substance_abuse/mao_cocaine. Copyright 2014,
accessed on 11/02/2014).

The duration and intensity of dopaminergic neurotransmission mediated by dopamine is
controlled by the dopamine transporter (DAT) (Jaber et al., 1997). The DAT belongs to the
family of Na+/Cl- dependent transporters.

It is a plasma membrane protein located

presynaptically that rapidly terminates dopamine neurotransmission by facilitating dopamine
reuptake into the presynaptic terminals of dopaminergic neurons (Figure 1.6). Therefore, the
8

DAT plays a pivotal role in controlling the signal amplitude and duration of dopaminergic
neurotransmission by altering dopamine concentration.

1.2.1. Role of the DAT in Drug Addiction
The mesocorticolimbic dopamine pathway in the brain is implicated in the acute
rewarding actions of all psychostimulants by direct or indirect influence (Pierce and Kumaresan,
2006; Zhu and Reith, 2008; Schmitt and Reith, 2010). In particular, cocaine and amphetaminelike compounds stimulate the dopaminergic system by directly controlling DAT function and
expression through different mechanisms (Caron, 1996; Figures 1.7 and 1.8).

Figure 1.7. Inhibition of dopamine reuptake upon binding of cocaine to the DAT (Reprinted with permission from
https://www.cnsforum.com/educationalresources/imagebank/substance_abuse/drug_amphet_low. Copyright 2014,
accessed on 11/02/2014).
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In particular, various in vitro and in vivo studies have established the DAT as the key
protein for cocaine binding (Woolverton and Johnson, 1992). According to the widely accepted
mechanism for cocaine-mediated increase in dopamine neurotransmission, cocaine binds to the
DAT within presynaptic neuronal membranes of dopaminergic neurons, competitively blocking
the reuptake of dopamine from the synaptic space. This results in an increase in extracellular
dopamine concentration, that mediates the rewarding and reinforcing effects of cocaine by the
activation of dopamine receptors located on postsynaptic neurons. Another potential mechanism
of action of cocaine recently being explored is that cocaine might be acting as a DAT “inverse
agonist” that “allosterically” reverses the direction of DAT transport, thereby releasing dopamine
into the synaptic cleft (Heal et al., 2014).
Consequently, chronic use of cocaine results in a long-term functional upregulation of
DAT in the presynaptic neurons by increasing its cell surface expression, which in turn reduces
the basal levels of extracellular dopamine, thus leading to decreased rewarding or stimulatory
effects (Letchworth et al., 2001; Daws et al., 2002). This leads to self-administration of cocaine
to experience the rewarding effects, which ultimately results in chronic cocaine dependence and
addiction. The cocaine-induced elevated DAT membrane expression further creates abnormal
neurobiological conditions that are responsible for causing severe withdrawal symptoms, and
ultimately relapse after discontinuation of cocaine use (Kuhar, et al., 1991; Kuhar and Pilotte,
1996; Kalivas et al., 1998; Kahlig and Galli, 2003).
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Figure 1.8. Mechanism of action of amphetamine (Adapted with permission from
https://www.cnsforum.com/educationalresources/imagebank/substance_abuse/drug_amphet_low. Copyright 2014,
accessed on 11/02/2014).

On the other hand, amphetamine-like psychostimulants, due to their structural similarity
to dopamine, act as DAT substrates and are translocated into dopaminergic neurons. This
triggers efflux of dopamine, thus resulting in an elevated dopamine concentration in the synapse
(Kahlig et al., 2005) (Figure 1.8).

Furthermore, amphetamines also act as substrates for

vesicular monoamine transporters (VMAT), triggering a release of dopamine stores from the
vesicles into the intracellular environment that further promotes dopamine efflux (Sulzer et al.,
1995; Partilla et al., 2006). Likewise, synthetic cathinones like mephedrone and methylone have
amphetamine-like action on the DAT and stimulate the synaptic efflux of dopamine (Baumann et
11

al., 2012; Simmler, Rickli et al., 2013). MDPV ((±)-1.11), on the other hand, is a potent blocker
of the DAT and increases dopamine neurotransmission by a mechanism similar to cocaine
(Baumann et al., 2013).
In conclusion, the DAT is a major target for psychostimulants and plays a key role in
mediating their reward and stimulant behavioral effects, principally by controlling dopamine
levels in the brain (Zhu and Reith, 2008). It is therefore important to understand the structural
and functional features of the DAT, in particular, the binding sites of drugs of abuse within the
DAT. A better understanding of DAT binding sites is expected to enable efforts to discover and
develop new and improved therapeutics for the treatment of addiction associated with cocaine,
amphetamines, and cathinones.

1.3. The DAT
1.3.1. Structural and Functional Features of the DAT
The DAT belongs to the neurotransmitter:sodium symporter (NSS) or solute carrier 6
(SLC6) family of Na+/Cl- dependent membrane transporters (Pramod et al., 2013).

Other

members of this family include the serotonin (SERT) and norepinephrine transporters (NET)
(Torres et al., 2003). The DAT is an approximately 80,000 dalton protein composed of 620
amino acids. It contains 12 transmembrane (TM) domains with both N- and C-termini located
on the intracellular side of the membrane (Figure 1.9). The large extracellular loop (Loop e2,
Figure 1.9) connecting TM3 and TM4 contains several N-glycosylation sites for the stability and
plasma membrane trafficking of the DAT, whereas TM1 and TM6 are considered to be critical
for ions, substrate, and cocaine binding as shown in Figure 1.9 (Chen and Reith, 2000).
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Figure 1.9. Diagram of membrane topology of the hDAT based on bacterial leucine transporter (LeuT) crystal
structures. Full TM helices are numbered 1–12 and intra- and extracellular loops are numbered 1–5 with prefixes
either ‘i’ or ‘e’ respectively (Schmitt et al., 2008. Reprinted with permission from J. Neurochem. 2008, 107, 928940. Copyright 2008, International Society for Neurochemistry).

Many aspects of the 3-D structure of human DAT (hDAT) currently remain unknown.
As a result, approaches such as site-directed mutagenesis, photoaffinity labeling, and computeraided homology models of hDAT have provided extensive information on DAT structure,
transport mechanism, and binding sites. In particular, x-ray crystal structures of the bacterial
(Aquifex aeolicus) leucine transporter (LeuT) (Yamashita et al., 2005; Zhou et al., 2007 and
2009; Singh et al., 2007 and 2008; Quick et al., 2009; Nyola et al., 2010; Krishnamurthy and
Gouaux, 2012; Loland, 2014; Penmatsa and Gouaux, 2014), possessing with 22% sequence
homology to hDAT, and the recent Drosophila melanogaster DAT crystal structure (Penmatsa et
al., 2013), with greater than 50% homology with hDAT, have provided a more detailed
understanding of DAT 3-D structure. Furthermore, several groups have generated homology
models of the hDAT using the high resolution LeuT-crystal structure to predict the hDAT’s
13

tertiary structure (e.g., Huang and Zhan, 2007; Indarte et al., 2008; Manepalli et al., 2012). Such
studies have suggested that LeuT and hDAT share several common structural features, including
the presence of a substrate binding pocket between TM1 and TM6. In addition, site-directed
mutants of hDAT with single and multiple amino acid substitutions have been employed to study
hDAT/cocaine interactions (Kitayama et al., 1992; Uhl and Lin, 2003; Wu and Gu, 2003; Chen
et al., 2004; Loland et al., 2004; Volz and Schenk, 2005). Photoaffinity labeling studies of the
DAT with photoreactive compounds based on cocaine, its analogs, and several other known
DAT inhibitors have also been utilized in elucidating the location of binding sites within the
DAT (Grigoriadis et al., 1989; Kline et al., 1994; Vaughan, 1998, 1999, 2001, 2005 and 2007;
Dutta et al., 2001; Zou et al., 2001; Newman et al., 2006; Parnas et al., 2008; Dahal et al., 2014).
Despite these efforts, the molecular mechanism and exact binding site of cocaine and other DAT
inhibitors, as well as the molecular determinants of inhibitor selectivity, remain largely
unknown.

In particular, direct and indirect effects of mutations on substrate and inhibitor

binding are difficult to predict with the absence of an accurate hDAT 3-D structure (Beuming et
al., 2008). Furthermore, the LeuT structure, despite its many similarities to hDAT, also shows
several distinct functional features. For instance, DAT homology models built using co-crystal
structures of LeuT with desipramine and other tricyclic antidepressants (Singh et al., 2007; Zhou
et al., 2007) do not provide reliable information on substrate interaction with the DAT, since
tricyclic antidepressants show low affinity for hDAT (Schmitt et al., 2008). In addition, cocaine,
which is a potent DAT inhibitor, does not display inhibitory potency against LeuT.

The

comparison of LeuT crystal structure with the recently discovered dDAT crystal structure
(Penmatsa et al., 2013) in complex with tricyclic antidepressant nortriptyline further provides
many direct evidences of disparaties between the two transporters. In particular, the primary or
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S1 binding site in dDAT is occupied by nortriptyline in contrast to LeuT-antidepressant cocrystal structures in which the TCAs inhibit LeuT via non-competitive mechanism by binding to
the S2 binding site. The interactions made by Asp46 residue present in the TM1 region of dDAT
compensates for the absence of carboxylate group present in the biogenic amine substrates as
compared to the binding interactions of leucine substrate within LeuT. In dDAT, a hydrogen
bond formed between the Asp46 side chain and the hydroxyl group of Tyr124 is similar to the
interactions between the carboxylate group of leucine substrate and Tyr108 within the LeuT
substrate binding pocket. The intracellular cytoplasmic gate in dDAT is capped by a carboxyterminal helix like a latch which is absent in LeuT. Moreover, unlike in LeuT crystal structures,
a cholesterol molecule is present in dDAT crystal structure between TMs 1a, 5 and 7 which is
critical for its stabilization in an outward-open conformation. Such observations indicate the
disparate features in the structure of dDAT and LeuT, and possibly between hDAT and LeuT,
and warrant the need for more direct and valid experimental approaches for hDAT structure and
function elucidation.

1.3.2. Proposed Conformational Cycles and Reuptake Mechanism of the DAT
The transport of dopamine by the DAT is favored by the energy gradient produced by the
movement of Na+ ions inside the cell, and driven by the concentration gradient created by
Na+/K+ ATPase. DAT co-transports two Na+ ions and a Cl- ion with each dopamine molecule
through a series of sequential binding and conformational changes to facilitate influx (Sonders et
al., 1997; Gether et al., 2006; Forrest et al., 2011). This sequence begins with initial binding of
Na+ ions on the extracellular side of the membrane, followed by binding of dopamine, which
triggers conformational changes in the protein.
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The very first model of DAT substrate uptake was proposed by Jardetzky almost half a
century ago, wherein DAT was proposed to exist in outward- (open to extracellular side) and
inward-facing (open to intracellular side) conformation (Jardetzky, 1966) (see Figure 1.10, A and
E). Initially, ions and dopamine bind to the open-outward conformation (as shown in Figure
1.10, A and B), which triggers a rearrangement sequence, subsequently closing the outward
opening while simultaneously exposing the bound substrate to the intracellular side of the
membrane, thus leading to dissociation of substrate in the intracellular milieu via diffusion. The
subsequent discovery of crystal structures of the LeuT, followed by molecular dynamic studies
and molecular simulations via DAT homology models, validated and further refined the
alternating access model of Jardetzky (Yamashita et al., 2005; Schmitt et al., 2013). These
studies revealed that the putative dopamine-binding site within DAT (called the S1 site or the
primary binding site) lies in the center of the membrane channel, and is large enough to hold two
Na+ ions and the dopamine (Singh et al., 2008). Furthermore, LeuT crystal structures have also
revealed a third low-energy conformational state: a dually occluded, substrate bound state in
addition to the outward- and inward-conformational states of the Jardetzky model for NSS
proteins (Figure 1.10, C). According to this newer, three conformational state model, the initial
outward-facing DAT conformation exposed to the extracellular milieu promotes the binding of
Na+ ions to stabilize the outward-open conformation (Claxton et al., 2010; Krishnamurthy and
Gouaux, 2012). This ion-bound, open conformation then facilitates the binding of dopamine to
the S1 site. Once the dopamine is bound to the S1 site, the extracellular gate closes leading to
the dopamine-bound occluded state, where both the ions and dopamine are in the middle of the
channel protected from both the periplasmic and the cytoplasmic space by gating networks
(Nyola et al., 2010; Forrest et al., 2011) (Figure 1.10, C). In hDAT, the extracellular gate
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consists of a salt bridge between Arg85 and Asp476, and a cation-π interaction between Phe320
and Arg85. In addition, the aromatic rings of Tyr156 and Phe320 obstruct the S1 site during the
occluded state by forming a lid with the help of a hydrogen bond interaction between Tyr156 and
Asp79. The intracellular side of the S1 site also consists of a series of gating networks (i.e., saltbridge between Arg60 and Asp436, cation-π interaction between Arg60 and Tyr335, and
hydrogen bond interaction between Glu428 and Tyr335). Next, the occluded state is followed by
the opening of the intracellular gate, leading to an inward-open conformation (Figure 1.10, D),
which releases the ions and dopamine into the cytoplasm via diffusion facilitated by hydration of
the site (Zhao, et al., 2010 and 2011; Zhao and Noskov, 2011).

Figure 1.10. Putative conformational cycle of the DAT protein for translocation of dopamine (DA) (Schmitt et al.,
2013. Adapted with permission from J. Pharmacol. Exp. Ther. 2013, 346, 2-10. Copyright 2013, JPET Online by
American Society for Pharmacology and Experimental Therapeutics).
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Though the three-state, alternating access model proposes the presence of a single,
putative substrate binding site, (i.e., the primary or the S1 site), Shi and coworkers, through
molecular dynamic simulations, predicted the presence of a secondary, high-affinity allosteric
site (S2) in LeuT occupied by a second leucine molecule (Figure 1.10, C) (Shi et al., 2008;
Quick et al., 2012). This site was proposed to be present approximately 11Å above the S1 site
towards the extracellular side of the membrane. The S2 site in LeuT has been shown to
accommodate a wide variety of ligands such as tricyclic antidepressants, selective serotonin
reuptake inhibitors (Zhou et al., 2007 and 2009), and alkylglucoside detergents (Quick et al.,
2009). However, the existence of a similar S2 site in the human DAT, and its relevance, is
highly controversial, and is currently a topic of debate in the scientific community. Some
mutagenesis, comparative modeling, and photoaffinity studies support the hypothesis that DAT
inhibitors like cocaine interact with the S1 site and competitively inhibit the substrate binding
(Beuming et al., 2008; Bisgaard et al., 2011; Dahal et al., 2014), whereas other studies propose
that cocaine binds to the S2 site and allosterically modulates binding at the substrate-binding site
(Huang et al., 2009; Heal et al., 2014). Another hypothesis proposes that cocaine initially binds
to the low affinity S2 site, and then transitions into a high affinity S1 site through conformational
movements (Schmitt et al., 2013).

1.4. DAT Ligands
1.4.1. DAT Substrates
Amphetamine ((±)-1.2, Figure 1.2) and its analogs are drugs of abuse that cause euphoric
actions by excessively increasing extracellular dopamine concentrations in the brain.
Amphetamines, due to their structural similarity to dopamine (1.13), act as exogenous substrates

18

for the DAT.

They are transported into presynaptic neurons causing reverse transport of

dopamine into the synapse (Sitte et al., 1998; Sulzer et al., 2005). This is triggered by the fact
that Na+ influx accompanying the uptake of amphetamine increases the intracellular Na+
concentration that promotes dopamine efflux (Sulzer et al., 1995). In addition to causing efflux
of dopamine, amphetamines also compete with dopamine for the unoccupied DAT binding site,
which prevents dopamine reuptake from the synapse, thus resulting in a further increase in
dopamine concentration.

Furthermore, these drugs also act as substrates for vesicular

monoamine transporters (VMAT), triggering a release of dopamine stores from vesicles into the
intracellular environment that further promote dopamine efflux (Pifl et al., 1995; Nickell et al.,
2014).

1.4.2. DAT Inhibitors
One proposed strategy to treat cocaine addiction has been to generate competitive
inhibitors of cocaine binding without inhibiting dopamine reuptake. Ideally such a medication is
expected to serve as a cocaine substitute with respect to its pharmacological actions and abuse
liability, but should be able to gradually eliminate self-administration of cocaine without having
any reinforcing effects (Rothman et al., 1989; Carroll, et al., 1999). In addition, compounds that
have a slow onset of action and longer durations of actions are also considered as promising
candidates for cocaine abuse treatment (Froimowitz et al., 2000). Such an approach to find
treatments for cocaine abuse has been challenging due to poor understanding of DAT’s 3D
structure and binding sites, which limits rational structure-based drug design of DAT ligands.
Therefore, all DAT inhibitors to date have been developed by ligand-based drug design using
known DAT ligands as lead compounds. In particular, such compounds can be categorized as
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tropane- or non-tropane inhibitors based on their chemical structure. These compounds can be
further differentiated based on their distinct behavioral effects as “cocaine-like” or “atypical”
inhibitors.

1.4.2.1. Tropane Class of DAT Inhibitors

Figure 1.11. Chemical structures of tropane-based DAT inhibitors

Cocaine is a tropane analog that mediates its psychostimulant effects by binding to the
DAT and inhibiting dopamine uptake (hDAT Ki = 285 ± 27 nM, DA uptake IC50 = 230 ± 40 nM;
Zou et al., 2003). SAR studies via a large number of cocaine analogs containing the tropane
moiety have been conducted to find antagonists that can compete with cocaine for DAT binding
sites, but do not inhibit dopamine uptake (Carroll et al., 1992; Newman et al., 1994). Such
efforts have led to the identification of tropane analogs such as WIN-35,428 (1.15) and
benztropine (1.16) (Figure 1.11). WIN-35,428 (hDAT Ki = 37 ± 30 nM; DA uptake IC50 = 30 ±
4 nM) is a highly potent competitive inhibitor of cocaine with 8-fold greater affinity at the DAT
as compared to cocaine, and displays strong cocaine-like stimulatory effects in vivo (Clarke et
al., 1973; Madras et al., 1989). WIN-35,428 is a cocaine analog without the metabolically labile
benzoate ester of cocaine, thus making it a more stable analog with a longer half-life relative to
cocaine. Therefore, a radioactive version of WIN-35,428 (i.e., [3H]-WIN-35,428) is used in
pharmacological assay studies of DAT ligands (Carroll et al., 1991 and 1994). Benztropine
(1.16, Cogentin®) is another tropane analog that inhibits the dopamine transporter (hDAT Ki =
20

118 ± 10.6 nM; DA uptake IC50 = 66 ± 25 nM; Zou et al., 2003). It is also an anticholinergic
agent and is used clinically for symptomatic treatment of Parkinson’s disease. In contrast to
cocaine, benztropine analogs, despite having high affinity for the DAT, do not demonstrate
cocaine-like behavioral effects in animal models of cocaine abuse (Katz et al., 2001; Ukairo et
al., 2005; Schmitt et al., 2008). This class of atypical inhibitors does not effectively stimulate
locomotor activity in mice relative to cocaine. In addition, benztropines failed to substitute for
cocaine in discriminative stimulus studies in rats (Hiranita et al., 2009). Moreover, benztropine
analogs have a slower onset of action and a longer duration than cocaine when administered i.p..
Furthermore, benztropine is not self-administered in rhesus monkeys as effectively as cocaine
(Woolverton et al., 2000). Therefore, owing to their non-addictive behavior profile, benztropine
analogs have been actively explored for the treatment of cocaine dependence (Katz et al., 2001
and 2004; Rothman et al., 2008; Kopajtic et al., 2010).

1.4.2.2. Non-Tropane Class of DAT Inhibitors

Figure 1.12. Structures of non-tropane DAT inhibitors.
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1.4.2.2.1. GBR-12909. GBR-12909 (1.17; Figure 1.12) is a non-tropane DAT inhibitor with a
significantly different behavioral profile than cocaine (Tella et al., 1996). Furthermore, GBR12909 (hDAT Ki = 3.7 nM) is a highly potent and selective DAT inhibitor with a slow onset and
a long duration of action (Rothman et al., 2008). GBR-12909 has been shown to reverse the
cocaine-induced upregulation of DAT and reduces dopamine levels in the mesolimbic system
(Tella et al., 1996).

However, despite GBR-12909’s ideal pharmacokinetic and

pharmacodynamic properties as a psychostimulant abuse treatment, it was discontinued after
Phase 1 clinical trial in cocaine-dependent subjects because it caused undesirable prolongation of
the QTc interval, which can cause ventricular arrhythmias (Goldsmith et al., 2007).

1.4.2.2.2.

Methylphenidate.

Another non-tropane DAT inhibitor, methylphenidate (1.18,

Concerta®, Ritalin®; Figure 1.12), is a marketed drug for attention-deficit hyperactivity disorder
(ADHD). Methylphenidate is a potent DAT inhibitor with affinity 2-fold higher than cocaine.
Despite methylphenidate’s similar structural features to cocaine (i.e., a methyl ester, basic
nitrogen, and an aromatic ring), its reinforcing effects in humans are much lower than cocaine.
As a result, methylphenidate has gathered significant attention as the potential agent for the
treatment of cocaine addiction (Misra et al., 2010).

1.4.2.2.3. Pyrovalerone. Pyrovalerone ((±)-1.19; PV; Figure 1.13) is a high affinity and potent
DAT inhibitor (hDAT Ki = 21.4 ± 4.6 nM; DA uptake IC50 = 52.0 ± 20 nM) and NET inhibitor
(NET Ki = 195 ± 26 nM; NE uptake IC50 = 28.3 ± 8.1 nM) with little effect on serotonin
trafficking (SERT Ki = 3770 ± 560 nM; SER uptake IC50 = 2780 ± 590 nM) (pharmacology data
from Meltzer et al., 2006). Additionally, being structurally similar to rapidly emerging, highly
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abusive designer cathinones (also called “bath salts”; Simmler et al., 2013; Zawilska and
Wojcieszak, 2013; Bonano et al., 2014; Glennon, 2014) (see Figure 1.13), as well as the
amphetamines, pyrovalerone possesses significant abuse and addiction liability. In particular,
pyrovalerone is known to produce psychostimulant effects similar to amphetamine in humans
(Holliday et al., 1964) and is a schedule V controlled substance in the United States.

Figure 1.13. Structural comparison of the DAT inhibitor pyrovalerone ((±)-1.19) to DAT-interactive
psychostimulant drugs of abuse (e.g., (±)-1.3, (±)-1.11, and (±)-1.9) and the marketed drug bupropion ((±)-1.20;
Wellbutrin, Zyban, featuring the common -aminopropiophenone moiety), and amphetamine ((±)-1.2) bearing the
phenethylamine moiety.

Methylenedioxypyrovalerone (MDPV, (±)-1.11, Figure 1.13), a close pyrovalerone
analog with a dioxole moiety, is a common constituent of “bath salts” and is a highly abused
cathinone derivative currently posing a substantial threat for compulsive use that is potentially
greater than that for METH (Meyer et al., 2010; Baumann et al., 2013; Cameron et al., 2013;
Marusich et al., 2014; Watterson et al., 2014). PV and MDPV are potent DAT inhibitors that
block dopamine uptake resulting in an excessive increase in dopamine concentration in the
mesolimbic system, thus causing reinforcing/stimulatory effects. However, due to its notable
structural resemblance to the non-addictive marketed drug bupropion ((±)-1.20, Figure 1.13), and
20-fold greater DAT affinity than cocaine ([125I]-RTI-55 binding inhibition; hDAT Ki = 432 ± 29
23

nM for cocaine versus hDAT Ki = 21.4 ± 4.6 nM for PV), pyrovalerone has garnered interest as a
potential scaffold to search for new and potent DAT inhibitors devoid of stimulatory properties
for treatment of treat cocaine dependence. In this regard, Meltzer and colleagues reported a host
of pyrovalerone analogs for their evaluation as potential cocaine abuse therapeutics (Meltzer et
al., 2006).

Table 1.1. Structure-activity relationship studies of some pyrovalerone analogs reported by Meltzer et al. 2006.

Results showed that pyrovalerone enantiomer (2S)-1.19 (hDAT Ki = 18.1 ± 3.0 nM, DA
uptake IC50 = 16.3 ± 2.3 nM) was more active at DAT with affinity and potency 100-fold greater
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than that of (2R)-1.19 enantiomer (hDAT Ki = 1330 ± 300 nM, DA reuptake IC50 = 1790 ± 320
nM). Pharmacological results of various pyrovalerone analogs with different substitutions at the
aromatic ring suggested high tolerability of this ring to a variety of functional groups. For
example, changing the para-methyl group of lead (±)-1.19 to the ortho- ((±)-1.21) or the metaposition ((±)-1.22) did not have any drastic change in the potency of the compounds, with only
2-fold loss in DAT affinity of both (±)-1.21 (hDAT Ki = 59.7 ± 9.0 nM) and (±)-1.22 (hDAT Ki
= 51.0 ± 14 nM) versus (±)-1.19 (hDAT Ki = 21.4 ± 4.6 nM), while dopamine uptake inhibition
potency remained unchanged. Notably, compound (±)-1.23, which is completely devoid of any
substitutions on the phenyl ring retained the affinity and potency of the lead compound. On the
other hand, different halogen substitutions at the para-position failed to provide any discernible
correlation of DAT affinity and potency with variations in the electronics or bulk of the phenyl
ring. For example, though the 4'-bromo substitution in (±)-1.24 (hDAT Ki = 51.0 ± 6.7 nM, IC50
= 39.5 ± 7.5 nM) slightly reduced the affinity towards DAT as compared to PV, this substitution
did not drastically affect the potency of dopamine uptake inhibition.

Furthermore, while

compound (±)-1.26 with a 4'-iodo functional group was equipotent to (±)-1.25 with a 4'-fluoro
substituent in terms of DAT affinity, the functional potency difference between the two
compounds was almost 6-fold different. In addition, though the 3'-iodo substitution ((±)-1.27,
hDAT Ki = 109 ± 32 nM, DA reuptake IC50 = 52.0 ± 16 nM) showed a 5-fold loss in DAT
affinity as compared to pyrovalerone, it still retained dopamine uptake inhibition. The most
potent compound in terms of affinity in this series was 3',4'-Cl2 substituted (±)-1.28 (Ki = 11.5 ±
1.4 nM, IC50 = 43.0 ± 20 nM). Furthermore, large and more polar functional group substitutions
at the para-position lacked impressive potency at the DAT.

For example, an electron

withdrawing 4'-nitro group ((±)-1.29), electron donating 4'-methoxy ((±)-1.30), and the 4'-
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methylester ((±)-1.31) substitutions resulted in more than 10-fold loss in potency, which further
makes it difficult to draw a correlation between the preferred electron density of the ring and the
corresponding biological activity. However, (±)-1.32 with a 4'-amide replacement showed quite
a different profile with respect to both DAT affinity and dopamine uptake inhibition potency,
almost equivalent to pyrovalerone.

Nevertheless, a subset of pyrovalerone analogs with

promising pharmacological activity displayed a dose-dependent stimulation of locomotor activity
in mice. In addition, a few compounds were also progressed into in vivo studies in rat for
behavioral pharmacological evaluation, the results of which currently remain undisclosed
(Meltzer et al., 2006).

1.4.2.2.4. Bupropion. Bupropion (BP, (±)-1.20, Figure 1.13), an aminoketone, is a well-known
FDA-approved drug marketed for the treatment of major depressive disorder and seasonal
affective disorder (as Wellbutrin®) (Dhillon et al., 2008), and also as a smoking cessation aid
(Zyban®) (Fava et al., 2005; Tong et al., 2006). Furthermore, clinical studies of bupropion on
cocaine and methamphetamine dependence have indicated its effectiveness in reducing drug
cravings in light abusers either alone or in combination with methadone (Poling et al., 2006;
Newton et al., 2006; Elkashef et al., 2008). Though its antidepressant actions and smoking
cessation properties are mainly attributed to norepinephrine reuptake inhibition and noncompetitive inhibition of select nAChRs, bupropion’s weak dopamine reuptake inhibitory action
via DAT binding was suggested to be responsible for reducing drug cravings during withdrawal
(Stahl et al., 2004). Interestingly, despite having structural similarities with highly abusive
amphetamine ((±)-1.2), cathinone ((±)-1.3) and pyrovalerone ((±)-1.19) (see Figure 1.13),
bupropion shows no undesirable psychostimulant activity in humans at low doses. As a result,
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bupropion has been disclosed as a clinically promising lead compound for potential development
into a pharmacotherapeutic for cocaine and methamphetamine dependence (Reichel et al., 2009;
Heinzerling et al., 2014). In this regard, Carroll and coworkers reported the synthesis and
pharmacological properties of a number of bupropion analogs as potential treatments for cocaine
and methamphetamine dependence in addition to smoking cessation (Carroll et al., 2009 and
2014) (Table 1.2).

Table 1.2. Structure-activity relationship studies of some bupropion analogs with respect to DAT inhibition and
dopamine reuptake inhibition (Carroll et al., 2009).
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The goal of this study was to find bupropion analogs with stronger dopamine reuptake
inhibition (i.e., lower IC50 values), slow onset and longer duration of action leading potentially to
low abuse potential. Such compounds were expected to show promise as pharmacotherapies for
cocaine and methamphetamine addiction. Bupropion analogs (±)-1.35 to (±)-1.47 (Table 1.2),
featuring a wide range of hydrophobic substitutions on the phenyl ring, displayed varying DAT
inhibitory activity patterns.

For example, (±)-1.43 with a 3',4'-dichlorophenyl substitution

([3H]DA IC50 = 271 ± 96 nM) and (±)-1.44 with 3'-chloro-4'-methylphenyl substitution ([3H]DA
IC50 = 650 ± 150 nM) inhibited dopamine reuptake 3.5- and 1.5-times more potently than
bupropion ([3H]DA IC50 = 945 ± 213 nM) respectively. However, 3'-bromophenyl ((±)-1.37,
[3H]DA IC50 = 950 ± 210 nM) and 4'-bromo-3'-methylphenyl ((±)-1.45, [3H]DA IC50 = 950 ±
310 nM) analogs were as potent as BP ([3H]DA IC50 = 945 ± 213 nM) in inhibiting dopamine
reuptake. Further investigations of substituent tolerance on the phenyl ring showed that (±)-1.35
with an unsubstituted phenyl ring or (±)-1.36 with a 3'-F substituent led to reduced potency.
Single substitutions at the para-position (i.e., in (±)-1.39 (4'-Cl) and (±)-1.40 (4'-Br)) were not
tolerated, as these changes resulted in a significant decrease in DAT affinity (IC50 = 2319 ± 429
nM for (±)-1.39; IC50 = 1295 ± 375 nM for (±)-1.40). Compound (±)-1.41 (4'-Me) showed a
complete loss in DAT inhibitory activity. Difluoro substitutions in (±)-1.42 (3',4'-diF) and (±)1.46 (3',5'-diF) also failed to provide potent DAT inhibitors. Overall, these results suggested
that, in contrast to the pyrovalerone scaffold, which was less sensitive to lipophilic aromatic
substitutions (Section 1.2.4.2.2.3), bupropion analogs containing a di-substituted phenyl ring
with lipophillic functional groups (i.e. –Me, -Br and –Cl) were, in general, more potent (with the
exception of di-fluoro compounds (±)-1.42 and (±)-1.46) than mono-substituted compounds.
Furthermore, replacement of the -methyl group of bupropion with bulkier ethyl and propyl
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groups gave analogs (±)-1.48 and (±)-1.49, respectively, showing remarkably reduced IC50
values compared to BP ([3H]DA IC50 = 31 ± 9 nM for (±)-1.48, [3H]DA IC50 = 33 ± 7 nM for
(±)-1.49 versus [3H]DA IC50 = 945 ± 213 nM for BP). In conclusion, bupropion analogs (±)1.43 (2',3'-dichloro), (±)-1.48 (ethyl side chain) and (±)-1.49 (propyl side chain) represented the
most potent dopamine uptake inhibitors in the series relative to BP. In addition, these analogs
were also tested for their NE uptake properties to develop compounds with lower noradrenergic
activity to reduce the potential of cardiotoxicity.

The results indicated that (±)-1.43 (NE

reuptake IC50 = 2100 ± 380 nM) and (±)-1.48 (NE reuptake IC50 = 969 ± 410 nM) displayed 5fold and 2-fold reduced NE uptake inhibition, respectively, when compared to BP (NE reuptake
IC50 = 443 ± 245 nM) whereas NE inhibition potency remain unchanged for (±)-1.49 (NE
reuptake IC50 = 472 ± 93 nM). Subsequently, promising analogs (±)-1.43 and (±)-1.48 with
desirably higher dopamine reuptake potency (i.e., lower IC50 values) and lower NE inhibition
were further evaluated for their effect on locomotor activity and drug discrimination tests in
cocaine administered rats. The resulting animal behavior profile of the analogs failed to provide
any correlation with the in vitro data and further studies are required to evaluate the effect of the
nature of metabolites on different behavioral profiles (Carroll et al., 2014).

1.4.3. Unique Behavioral Responses of DAT Inhibitors
Though the widely accepted mechanism of cocaine’s psychostimulant behavioral effects
have been attributed to an increase in perisynaptic dopamine concentration by inhibition of the
DAT, the discovery of several other potent DAT inhibitors which lack cocaine’s abuse liability is
suggestive of a different mechanism involved in eliciting reinforcing or stimulatory effects.
DAT inhibitors such as GBR12909, bupropion, and benztropine do not share a stimulatory
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behavioral profile and high abuse potential when compared to cocaine (Desai et al., 2005;
Schmitt et al., 2008). Such findings have suggested that different structural classes of DAT
inhibitors display contrasting psychostimulant effects due to the disparate nature of their
molecular interactions with the DAT. This means that DAT inhibitors may induce unique
transporter conformational states of the DAT, which in turn could dictate their addictive liability
(Reith et al., 2001). Many researchers have supported this concept of conformation-specific
activity by presenting experimental evidence that cocaine and benztropine have different effects
on the accessibility of cysteine residues present near DAT’s extracellular side towards reaction
with sulfhydryl reducing reagents (Ferrer and Javitch, 1998; Reith et al., 2001). Consequently,
site-directed mutagenesis studies provided further verification of this theory. In particular, Chen
and coworkers showed that DAT mutants W84L and D313N, producing a stabilized outwardopen conformation had greater affinity for cocaine and methylphenidate but not for nonaddictive benztropine, GBR-12909 and bupropion, while still maintaining binding affinity of
DAT substrates such as dopamine and amphetamine (Chen et al., 2001 and 2004). On the other
hand, the mutation Y335A, which stabilizes the inward-facing DAT conformational state,
increased the affinity of benztropine analogs, but decreased the efficacy of cocaine the indicating
that atypical DAT inhibitors that lack the addiction potential apparently have preferential binding
for an inward-facing closed DAT conformation (Loland et al., 2002 and 2008). One possible
explanation proposed for how atypical DAT inhibitors access the inward-conformation might be
that they enter the extracellular DAT vestibule, and then are partially translocated in DAT in a
manner similar to the substrates, but eventually stabilize the inward-facing conformation and are
released slowly into the intracellular side (Schmitt et al., 2013). This, to some extent, might also
further explain the in vivo slow onset of action of these agents which ultimately result in their
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reduced behavioral reinforcing effects (Wee et al., 2006).

These results corroborate the

hypothesis that “atypical” DAT inhibitors have either low abuse potential or are completely
devoid of “cocaine-like” stimulatory and rewarding effects because of their preferential
interactions with the inward-facing DAT conformational state (Loland et al., 2008; Kopajtic et
al., 2010; Schmitt and Reith, 2011).
In conclusion, additional structural studies to elucidate detailed molecular requirements
of “cocaine-like” and “atypical” DAT inhibitors are needed in order to determine their binding
profile and addiction liability, which can further facilitate the development of therapeutics for
cocaine addiction.

1.5. The Cholinergic Nervous System

Figure 1.14. Chemical structure of the neurotransmitter acetylcholine (1.50).

The cholinergic system comprises two broad classes of cholinergic receptors: muscarinic
acetylcholine receptors (mAChRs) and nicotinic acetylcholine receptors (nAChRs).

Both

receptors are activated by the endogenous neurotransmitter acetylcholine (ACh), which is present
in the peripheral and central nervous system. These receptors mediate neurotransmission by
converting a chemical response characterized by ACh release from the nerve ending into a
electrical response via ion flux through the cellular transmembrane in neurons or muscles
(Jensen et al., 2005). Muscarinic acetylcholine receptors, activated by the toxin, muscarine, are
G-protein coupled receptors which once activated, mediate slow synaptic transmission of ACh
through reduced cAMP formation, phospholipase c stimulation and increased K+ conductance.
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On the other hand, nicotinic acetylcholine receptors (nAChRs), are ligand-gated ion
channels activated by the exogenous tertiary alkaloid nicotine, and mediate a fast stimulatory
response (Jensen et al., 2005). nAChRs are further classified into muscle and neuronal subtypes
based on their locations. The muscle type is located at all neuromuscular junctions and is mainly
present postsynaptically. Their function is to control and mediate electrical transmission through
neuromuscular junctions to maintain skeletal muscle tone. As a result, they are the targets of
several known muscle relaxants. On the other hand, neuronal nAChRs are located both pre- and
postsynaptically throughout the CNS and in autonomic ganglia. Their function is to control
several processes such as cognitive function, learning, and memory, reward, and arousal
principally by modulating the postsynaptic neuronal transmission and also by facilitating Ca2+dependent release of other neurotransmitters such as dopamine and glutamate (Albuquerque et
al., 2009).

1.5.1. Structural and Functional Features of nAChRs
nAChRs are allosteric proteins composed of multiple subunits and contain multiple
orthosteric and allosteric binding sites through which they modulate their function. Studies from
x-ray crystallographic structures of nAChRs from different species, such as nAChRs from the
fish Torpedo (Miyazawa et al., 2003; Rucktooa et al., 2009), Ach-binding proteins (AChBP)
from the snail Lymnaea stagnalis (Celie, Kasheverov, et al., 2005), Aplysia californica
(Rucktooa et al., 2012; Atkinson et al., 2014), and Bulinus truncatus (Celie, Klaassen, et al.,
2005), have provided a great deal of information regarding the 3-D structural features of human
nAChRs. The general structure of nAChRs includes a heteropentameric arrangement created by
any five subunits (, and assembled in different stoichiometries to form a central pore
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permeable to Na+, K+, and Ca+ ions (Figure 1.15, B). To date, 17 nAChR subunits are known,
which are divided into muscle types (, and ) and neuronal types (and
) (Lukas et al., 1999). All the subunits have the following common structural features:
an ~200 amino acid-containing, highly conserved extracellular N-terminal domain connected to
three transmembrane domains (TM1 to TM3), which lead to an intracellular cytoplasmic loop
connecting TM4, whose size and composition varies in different types of subunits (Figure 1.15,
A). The orthosteric binding site for ACh is located in the N-terminal domain located between
adjacent subunits. The N-terminal domain of all  subunits contain a cystein-loop that is critical
for agonist binding. TM2 of all five subunits line the central ion channel and TM1-3 lie in the
periphery to protect TM2 from the lipid bilayer (Figure 1.15, B; Corringer et al., 2000). About
90% of neuronal nAChRs in the CNS are heteropentameric  receptors that have high
affinity for nicotine (Figure 1.15, D). In contrast, receptors (Figure 1.15, D) are mainly
located in autonomic ganglia, the adrenal medulla and in few selected parts of CNS neurons.
Heteromeric nAChRs contain two orthosteric binding site each located at the interface between 
and  subunits. Another type present in the CNS are homopentameric  nAChRs containing
only  subunits (Figure 1.15, C).
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Figure 1.15. Pictorial representation of structural and functional organization of nAChR subtypes. A. Schematic
representation of four transmembrane domains (TM1-4) with extracellular N- and C-terminal. B. Organization of
five subunits to form central channel for ion permeability. C. Arrangement of subunits in 7 nAChR subtype with
five Ach binding sites. D. Arrangement of subunits in  and  nAChR subtypes with two Ach binding sites
at the interface of  and  subunits (Hendrickson et al., 2013. Adapted with permission from Front. Psychiatry
2013, 4, 1-16. Copyright 2013 Hendrickson, Guildford and Tapper).

The intracellular and extracellular ends of the ion channel are lined with negatively
charged residues and the central portion is composed of a number of non-polar amino acid
residues to facilitate the influx and passage of cations. Allosteric binding sites for nAChRs are
presumably located within the ion channel (Albuquerque et al., 2009). nAChRs exist in three
conformational transition states: a resting state (or closed) in which the ion channel remains
closed and is stabilized by competitive antagonists; an active (or open) state with low affinity for
agonists, which when agonist-bound results in channel-opening to allow passage of ions; and the
desensitized state which is occupied by competitive agonists, but the ion channel remains closed
(Monod et al., 1965; Jackson, 1984 and 1990; Changeux and Edelstein, 1998; Hurst et al., 2013).
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Figure 1.16. Chemical structures of some irreversible chemical probes utilized in nAChR structure-function
studies.

Though the homology models of human nAChRs based on x-ray crystal structures of
bacterial and invertebrate pentameric receptors coupled with mutagenesis studies (for
representative examples, see Pavlovicz et al., 2011; Grishin et al., 2013; Marotta et al., 2014) has
been worthwhile in predicting molecular organization, structure, and location of binding sites,
the accuracy and usefulness of these models are still in question for structure based drug
discovery. Photoaffinity labeling studies using irreversible chemical probes (for e.g., Hamouda,
Steward et al., 2014; Liu et al., 2014; Sanghvi et al., 2008; Zhang et al., 2003; Figure 1.16), on
the other hand, have provided more direct identification of location and amino acid composition
of many orthosteric and allosteric sites within nAChRs (reviewed in Hamouda, Jayakar et al.,
2014).
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1.5.2. The Role of nAChRs in Drug Addiction
Nicotine (1.4, Figure 1.1) is the main psychoactive component of tobacco used in
cigarette smoking. Nicotine mainly acts on neuronal nAChRs to manifest its stimulatory or
reinforcing effects on the human brain. Due to nicotine’s high lipophilicity, it crosses the bloodbrain barrier rapidly and accumulates in the brain near nAChRs for a much longer time than
ACh. Furthermore, unlike ACh, nicotine is not metabolized by acetylcholinesterase enzymes
present in the CNS, which further prolongs its duration of action.
Nicotine addiction progresses in three different stages: initiation of addiction,
neuroadaptations, and withdrawal (De Biasi and Dani, 2011). The midbrain region, consisting of
dopamine neurons, express as nAChRs that are mainly composed of  subunits in combination
with  or occasionally  subunits. Activation of nAChRs, located on dopaminergic cells in
the VTA by nicotine provides the excitatory drive to release dopamine in high concentrations in
the mesolimbic region, which initiates the development of addiction and reward behavior, and
ultimately nicotine dependence (Benowitz, 2008). Recently, the role of the  subunit has been
irrefutably proved by studies using knockout mice, which lacked nicotine induced dopamine
release and did not show reinforcing effects to nicotine (Simmons and Gould, 2014).
Furthermore, prolonged exposure to nicotine and the continued process of its addiction produces
neuroadaptations in neuronal cells that include the upregulation of nAChRs (De Biasi and Dani,
2011). The upregulation of nAChRs occurs due to the fact that the presence of nicotine for
prolonged periods favors excessive desensitization of nAChRs. To counteract this phenomenon,
the cellular machinery upregulates nAChRs as part of the homeostatic response in the cortex,
midbrain, and hypothalamus regions of the brain (Colombo et al., 2013). Consequently, since
nAChRs regulate the release of other neurotransmitters in the brain, (i.e., increase in dopamine
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and glutamate as well as decrease in GABA transmission), their excessive upregulation
subsequently creates a widespread irregularity in neurotransmission. In particular, the receptors
that exhibit the highest level of upregulation are  nAChRs, which contain high-affinity
nicotine binding sites. Consequently, due to such neuroadaptations during chronic nicotine
exposure, the brain eventually adapts to this new environment and requires the presence of
nicotine for continued maintenance. This creates a state of imbalance in brain neurochemistry
and leads to a withdrawal state when the nicotine consumption is discontinued (Koob and
Volkow, 2010).

Withdrawal symptoms are often characterized by anxiety, anger, sleep

disturbances, weight gain, and irritability.
In conclusion, since nAChR-mediated nicotine addiction significantly impairs cognitive
activities such as decision making, behavioral inhibition, and problem solving, nAChR targeted
compounds have garnered considerable attention in order to develop therapeutics to counteract
tobacco addiction.

1.6. nAChR Ligands and Their Significance in Smoking Cessation

Figure 1.17. Chemical structure of nAChR ligands used as marketed therapies for the treatment of nicotine
addiction.

Medicinal chemistry efforts towards the development of nAChR ligands as agonists,
competitive antagonists and allosteric modulators have shown promise as therapeutic agents
targeting a wide range of disorders such as nicotine and alcohol dependence, depression,
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schizophrenia, Alzheimer’s disease, ADHD, Parkinson’s disease, pain, and inflammation
(Holladay et al., 1997).

1.6.1. Mecamylamine. Mecamylamine (1.51), a potent nAChR antagonist, blocks the effects of
nicotine in the human brain (Reid et al., 1999). Mecamylamine has been shown to be an
effective smoking cessation agent when co-administered alongside a transdermal nicotine patch
during the pre-clinical studies (Rose et al., 1994).

1.6.2. Varencline. Varencline (1.52, Chantix® and Champix®), a marketed therapy for tobacco
dependence, is a partial agonist of  nAChRs, which effectively reduces nicotine withdrawal
effects and at the same time provides rewarding effects by moderately releasing dopamine in the
mesolimbic region (Coe et al., 2005).

1.6.3.

Bupropion.

Bupropion ((±)-1.20), initially developed as an antidepressant (as

Wellbutrin®), was later serendipitously found to have smoking cessation properties (Balfour,
2001). Apart from its norepinephrine (NE) and dopamine (DA) reuptake inhibitor activity,
bupropion is also a moderately potent noncompetitive antagonist of nAChRs, in particular the
 and sutypes Studies in rodents have shown that bupropion decreases the reinforcing
properties of nicotine and also relieves withdrawal symptoms associated with nicotine (Shiffman
et al., 2000; Cryan et al., 2003; West et al., 2008). Although there is no experimental evidence
to precisely determine whether bupropion’s smoking cessation activity resides in its monoamine
uptake inhibition or nAChR inhibition, it has been suggested that since the inhibition of DAT
and NET alone cannot alleviate nicotine’s reinforcing effects, the noncompetitive antagonism of
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nAChRs might be playing a more important role in inhibiting upregulated nAChRs during
nicotine dependence and help prevent nicotine relapse (Arias, 2009).
However, despite its status as a FDA-approved drug for major depressive disorder,
seasonal affective disorder, and an aid to help people stop smoking by reducing cravings and
other withdrawal effects, the molecular determinants of how bupropion interacts with select
nAChR subtypes remains unknown. As a result, in order to identify improved therapeutics
targeting nAChRs, it is important to understand, in detail, how clinically approved ligands like
bupropion interact with binding sites within select nAChR subtypes.

This information is

currently lacking in the nAChR field due to the unavailability of high-resolution x-ray crystal
structures of human 42 and 34 nAChR subtypes. Despite predictions that bupropion binds
near the middle of the nAChR ion channel between M2-6 and M2-13 by pharmacological,
electrophysiological, and computational approaches (Arias et al., 2009 and 2010), currently
there is a dearth of direct experimental evidence regarding the precise location of bupropionbinding sites within the DAT and select nAChR subtypes. Pharmacological studies in nAChRs
expressed in HEK-293 cells have shown that bupropion exhibits differential inhibition towards
two different conformational states of nAChRs (Arias et al., 2009 and 2010).

Bupropion

apparently binds preferentially to the resting or desensitized state of nAChRs within the lumen of
the ion channel and promotes the conformational transition to the desensitized state.
Furthermore, Unwin and Fujiyoshi in 2012 provided a much more direct observation regarding
the possible mechanism of bupropion’s inhibition of nAChRs (Unwin and Fujiyoshi, 2012).
These researches showed that during the resting / closed state, the M2 helices of nAChRs are
bent towards each other and are stabilized by helix-to-helix interactions, thus obstructing the
passage of ions through the ion channel. When an agonist (e.g., nicotine or acetylcholine) binds
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to the orthosteric-binding site, the helix-to-helix interactions are disrupted by causing a
conformational change in the receptor’s 3-D structure which results in opening of the ion
channel. On the other hand, when bupropion binds to its allosteric site present within the nAChR
ion-channel, it further reinforces or facilitates M2 helix-to-helix interactions, thereby stabilizing
the ‘bent’ conformation of the M2 helices that result in ion channel blockade.
Despite the growing global health problem of nicotine dependence, currently available
pharmacotherapies for treating tobacco use are inadequate in helping smokers maintain long term
abstinence (Johnston et al., 2002). This warrants an urgent need for new and improved drugs for
the treatment of tobacco abuse. Due to the promising effects of bupropion as smoking cessation
aid, structure activity studies have been conducted to further develop more potent bupropion
analogs in order to create much more superior smoking cessation aids that are more effective in
maintaining long term abstinence in smokers. Since the smoking cessation activity of bupropion
is mediated through a combination of DAT/NET inhibitory activity and nAChR antagonistic
activity, the goal for developing improved pharmacotherapies for nicotine dependence relies on a
multi-targeted approach. In this regard, bupropion analogs that were previously explored for
cocaine and methamphetamine abuse treatment (see Section 1.4.2.2.4) by Carroll and coworker,
were also evaluated against nAChR subtypes, as well as DA/NE reuptake inhibition, in order to
find ligands with better smoking cessation properties (Carroll et al., 2010).
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1

Values for mean ± standard error of three independent experiments, each conducted with triplicate determination.
Mean micromolar IC50 values from three independent experiments for inhibition of functional responses to an EC80EC90 concentration of carbamylcholine mediated by nAChR subtypes composed of the indicated subunits (where the
asterisk (*) indicates that additional subunits are or may be additional assembly partners with the subunits specified.

2

Table 1.3. Structure-activity relationship studies of bupropion and some of its analogs: monoamine reuptake
inhibition and select nAChR inhibition (Carroll et al., 2010).

All of these bupropion analogs were synthesized and pharmacologically evaluated as
their racemic mixtures since bupropion is also marketed as a racemic mixture. Exploration of
aromatic substitutions on the phenyl ring led to analog (±)-1.43 with a 3',4'-dicloro substitution
that showed higher inhibitory potency for dopamine and norepinephrine uptake than the 3'-Cl
substitution in BP ([3H]DA IC50 = 463 ± 104 nM, [3H]NE IC50 = 1670 ± 250 nM for (±)-1.43
versus [3H]DA IC50 = 658 ± 178 nM, [3H]NE IC50 = 1850 ± 300 nM for BP). In addition, (±)41

1.37 (3'-Br) was the most selective dopamine reuptake inhibitor in this series versus
norepinephrine uptake inhibition ([3H]DA IC50 = 511 ± 33 nM, [3H]NE IC50 = 5600 ± 1300 nM).
The overall results in nAChR inhibition indicated that all of these BP analogs were more
selective towards the inhibition of  nAChRs as compared to the  subtype. The 6-fold
selectivity of BP for  nAChR (IC50 = 1.8 M) over  (IC50 = 12 M) increased to 11fold for 3'-bromo analog (±)-1.37 ( IC50 = 1.3 M;  IC50 = 15 M), 13-fold for 3'-Me
analog (±)-1.38 ( IC50 = 1.5 M;  IC50 = 19 M), and 16-fold for 4'-Br substituted (±)1.40 ( IC50 = 1.4 M;  IC50 = 23 M).
In conclusion, the best balance of potency for DA and NE uptake inhibition, along with
nAChR subtype antagonism, was displayed by the 3'-chloro-4'-methyl derivative (±)-1.44, the 3'bromo derivative (±)-1.37, and 4'-bromo compound (±)-1.40. These compounds were also more
potent than bupropion in blocking nicotine induced locomotor activity as well as antinociception
in a tail-flick test. Several of these compounds showed potential as leads for further drug
development for better smoking cessation therapy. In particular, extended side chain analog (±)1.53 with 41- and 7.5-fold greater DA and NE uptake potency, and 3-fold higher potency in
 inhibition than bupropion, was the most interesting compound in the series as it
demonstrated that replacing the -methyl group in 3,4-dichloro substituted (±)-1.43 with a larger
alkyl chain produced a compound with better overall efficacy. Consequently, this compound
also displayed 9-fold greater potency when compared to bupropion in antagonizing nicotineinduced antinociception effects in a mouse tail-flick experiment. These results support the
hypothesis that targeting compounds with higher inhibitory potency at multiple targets (i.e.,
DAT, NET, and nAChRs) can lead to new pharmacotherapies potentially with higher efficacy as
aids to smoking cessation (Carroll et al., 2010).
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1.6.4. Hydroxybupropion. Several in vivo pharmacokinetic studies on bupropion in humans
have consequently revealed that only 10% of orally administered bupropion is excreted in the
urine as the parent compound and a majority of it is systemically metabolized by cytochrome
P450

2B6

oxidation

to

its

metabolites,

(i.e.,

(2S,3S)-hydroxybupropion,

(2R,3R)-

hydroxybupropion, threo-hydrobupropion and erythro-hydrobupropion) (Figure 1.18; Laizure et
al., 1985; Benowitz et al., 2013; Zhu et al., 2014).

Figure 1.18. Chemical structures of bupropion metabolites.

Among these metabolites, the hydroxylated form, (2S,3S)-hydroxybupropion ((2S,3S)1.54) is the main pharmacologically active metabolite. In a recent randomized clinical study of
bupropion for its smoking cessation activity, Zhu and coworkers demonstrated that the smoking
cessation effect in patients increased with an increase in bupropion metabolism and subsequent
increase in hydroxybupropion concentration (Zhu et al., 2012). This irrefutably established that
bupropion’s efficacy as a smoking cessation aid is mainly associated with this active metabolite.
In particular, it has been observed that the (2S,3S)-hydroxybupropion isomer is significantly
more pharmacologically active and displays the highest steady state plasma levels versus other
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metabolites in a number of behavioral-, monoamine-, and nAChR-based pharmacological assays
(Damaj et al., 2004 and 2010; Benowitz et al., 2013). Furthermore, (2S,3S)-hydroxybupropion
displays higher potency and a longer elimination half-life than bupropion (Yeniceli et al., 2011;
Parekh et al., 2012; Laib et al., 2014). In addition, (2S,3S)-hydroxybupropion is 3-10 times more
potent that BP in antagonizing nicotine-induced hypomobility and hypothermia, plus analgesia in
the tail-flick and hot plate tests in mice.

As a result, (2S,3S)-hydroxybupropion has been

suggested to represent a better drug candidate for developing smoking cessation therapeutics
versus bupropion.
In this regard, Lukas and coworkers in 2010 synthesized and pharmacologically
evaluated several analogs of (2S,3S)-hydroxybupropion in the search for better drugs for the
treatment of nicotine addiction (Lukas et al., 2010) (Table 1.4).
Analogous to the structure-activity relationship studies of bupropion analogs,
hydroxybupropion analogs were also tested for potency against nAChR subtypes as well as
DA/NE reuptake inhibition. In terms of monoamine reuptake inhibition potency, (2S,3S)-1.54
([3H]NE IC50 = 241 ± 60 nM) showed 9-fold greater NE reuptake inhibition versus BP ([3H]NE
IC50 = 1850 ± 300 nM), while the DA reuptake inhibition potency remained unchanged.
Moreover, (2S,3S)-hydroxybupropion is more potent than bupropion towards inhibiting nAChR over -nAChR (-nAChR IC50 = 3.3 M for (2S,3S)-1.54 versus IC50 = 12 M
for BP; whereas -nAChR IC50 = 11 M for (2S,3S)-1.54 versus IC50 = 1.8 M for BP).
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1

Values for mean ± standard error of three independent experiments conducted with triplicate determination.
Mean micromolar IC50 values from three independent experiments for inhibition of functional responses to an EC80EC90 concentration of carbamylcholine mediated by nAChR subtypes composed of the indicated subunits (where the
asterisk (*) indicates that additional subunits are or may be additional assembly partners with the subunits specified.
3
Racemic.
2

Table 1.4. Structure-activity relationship studies of (2S,3S)-hydroxybupropion and some of its analogs: monoamine
reuptake and nAChR inhibition as reported by Lucas et al., 2010.

Likewise, hydroxybupropion analogs also showed more selectivity for -nAChR
versus -nAChRs. Changes in the 3'-chlorophenyl group in (2S, 3S)-1.54 to 3'-bromo (2S,
3S)-1.56 or 3'-fluoro (2S, 3S)-1.57 substituents afforded analogs with improved affinity and
selectivity for -nAChRs while significantly losing monoamine inhibition potency. The
racemic threo-3',4'-dichlorophenyl derivative (±)-threo-1.62 (DA uptake inhibition IC50 = 70 ±
20 nM; [3H]NE IC50 = 114 ± 43 nM) and 4'-chloro (2S,3S)-1.59 ([3H]DA IC50 = 285 ± 70 nM;
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[3H]NE IC50 = 830 ± 90 nM) had higher DA and NE inhibitory potency than (2S,3S)hydroxybupropion ([3H]DA IC50 = 630 ± 50 nM; [3H]NE IC50 = 241 ± 60 nM) and bupropion
([3H]DA IC50 = 658 ± 178 nM; [3H]NE IC50 = 1850 ± 300 nM) with significant loss in nAChR potency. Compound (2S,3S)-1.61 (3',5'-difluoro) displayed the highest selectivity for
NE uptake inhibition ([3H]NE IC50 = 151 ± 43 nM) over DA uptake inhibition ([3H]DA IC50 =
1020 ± 190 nM). The bromo-analog (2S,3S)-1.57 (inhibition IC50 = 0.55 M) and 3-F'
analog (2S,3S)-1.56 (inhibition IC50 = 1.3 M) were the most potent  nAChR
antagonists in the series.
Concomitantly, hydroxybupropion and its analogs were also tested in in vivo models of
nicotine and smoking dependence, such as nicotine-induced effects in tail-flick, hot-plate,
locomotor activity, and hypothermia assays (Carroll et al., 2010). The results indicated that
(2S,3S)-hydroxybupropion was more potent than its analogs, as well as bupropion, in blocking
nicotine-induced effects in hot-plate, locomotor activity and hypothermia assays. However, in
contrast, almost all of the hydroxybupropion analogs (except 3,4-dicloro analog (±)-threo-1.62)
were more potent in blocking the nicotine-induced antinociception effects in tail-flick assay than
(2S,3S)-hydroxybupropion.
Despite the development of several analogs, currently there are no hydroxybupropionrelated compounds in clinical trial specifically for smoking cessation. This is principally due to
the observation that the behavioral response of these compounds do not correlate with their in
vitro nAChR and DA/NE uptake inhibition data (Carroll et al., 2014).

Furthermore, the

mechanistic rationale behind the smoking cessation property of these compounds, and the
importance of nAChR inhibition versus DA/NE reuptake inhibition, is still unclear.
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1.7. The Glutamatergic System

Figure 1.19. The chemical structure of L-glutamate (1.68) as a neurotransmitter.

Glutamate (L-glutamic acid; 1.68, Figure 1.19) is the major excitatory neurotransmitter in
the central nervous system (CNS) of mammals. Glutamate plays a critical role in regulating
various brain functions by activating the glutamate family of receptor distributed abundantly in
the CNS. The two classes of glutamate receptors are ionotropic and metabotropic glutamate
receptors (Figure 1.20) (Kew and Kemp, 2005).

Figure 1.20. A general pictorial representation of location, distribution, and function of glutamate receptors in
neurons (Benarroch, 2008. Reprinted with permission from Neurology 2008, 70, 964-968. Copyright 2008, AAN
Enterprises, Inc.).

Ionotropic glutamate receptors (iGluRs) are ligand-gated cation channels that mediate
fast excitatory neurotransmission and are divided into three major types, named according to the
agonists that activate them selectively: N-methyl-D-aspartate (NMDA), -amino-3-hydroxy-5-
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methyl-4-isoazolepropionic

acid

(AMPA),

and

2-carboxy-3-carboxymethyl-4-

isopropenylpyrrolidine (kainate) receptors.
In contrast, metabotropic glutamate receptors (mGluRs) are G-protein coupled glutamate
receptors that regulate neuronal excitability, synaptic transmission, and plasticity by activating
slow excitatory synaptic potentials (Pin and Duvoisin, 1995). mGluRs are broadly classified into
three groups (I to III) based on their sequence homology, second messenger coupling, and
pharmacology (Figure 1.20) (Niswender and Conn, 2010). Group I receptors comprises mGlu1
and mGlu5, which are located on post-synaptic neurons and are positively linked to
phospholipase C via Gq/G11.

Therefore, direct activation of mGlu1/5 results in increased

phosphoinositide turnover resulting in an increase of intracellular Ca2+. In contrast, Group II
(mGlu2 and mGlu3) and III (mGlu4, mGlu6, mGlu7, and mGlu8) receptors inhibit adenylyl
cyclase activity via Gi/Go. Their activation leads to inhibition of forskolin-stimulated cyclic
AMP formation.

Group II mGlu receptors are located presynptically and are primarily

distributed in forebrain regions.

These receptors represent classic autoreceptors that upon

agonist binding inhibit the release of glutamate into the synapse. In contrast, group III mGlu2
receptors are expressed both presynaptically and postsynaptically, and are localized in the
cerebellum, striatum and hippocampus regions (Vinson and Jeffrey, 2012).

1.7.1. The Role of mGlu2 in Drug Addiction
The abundunce of mGlu receptors located throughout the limbic and cortical brain
regions, which are implicated in drug addiction, has led to the emerging role of mGlus in
regulating the behavioral and physiological effects of psychostimulants (Kenny and Markou,
2004; Knackstedt et al., 2009; Cleva and Olive et al., 2012; Pomierny-Chamiolo et al., 2014).
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Glutamatergic neuronal projections originate from the prefrontal cortex (PFC) and reach up to
the nucleus accumbens (NAc) and ventral tegmental area (VTA).

Increased glutamate

transmission innervates the dopaminergic system in the VTA leading to reward and responseinitiating effects of drugs of abuse. Moreover, repeated use of addictive drugs causes long term
cellular adaptations in the glutamatergic system, leading to the characteristic behaviors of
addiction (Cornish and Kalivas, 2000; Gass and Olive, 2008; Kalivas, et al., 2009; Schmidt and
Pierce, 2010; Uys and Reissner, 2011). Extensive preclinical studies employing animal models
of addiction for drug self-administration, reinstatement, and conditioned place preference have
strongly suggested the potential of various mGlu ligands as anti-addiction therapeutics (reviewed
in Pomierny-Chamioło et al., 2014). Furthermore, changes in the function of mGlu2 under the
influence of drugs of abuse have been observed that contribute towards the progression of drug
dependence and the occurrence of withdrawal symptoms (Moussawi and Kalivas, 2010). In
particular, studies have shown that functional downregulation of mGlu2 occurs during
withdrawal from chronic abuse of morphine and cocaine (Vandergriff and Rasmussen, 1999;
Rasmussen et al., 2004; Xie and Steketee, 2008 and 2009). In addition, receptor mediated
neuroplasticity and coupling to G-protein is significantly impaired after chronic drug abuse
(Neugebauer et al., 2000; Martin et al., 2006; Huang et al., 2007; Moussawi et al., 2009;
Beveridge et al., 2011; Lu et al., 2012). This dysfunctional neurotransmission could also explain
the failure of drug addicts to control compulsive urges of drug seeking behavior. To support this,
it has been shown that self-administration of drugs of abuse such as cocaine and nicotine, as well
as the reinstatement of drug seeking behavior in animals, was suppressed with administration of
mGlu2/3 agonists LY379268 and LY404039 (Figure 1.22) (Fundytus and Coderre, 1997;
Baptista et al., 2004; Greenslade and Mitchell, 2004; Adewale et al., 2006; Peters and Kalivas,
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2006; Kufahl et al., 2013). Additionally, Morishima and coworkers found that mGlu2-knockout
mice show greater locomotor sensitization as well as conditioned placed preference, in response
to cocaine (Morishima et al., 2005).
In conclusion, increasing evidence suggests that mGlu2 is strongly implicated in
regulating drug seeking and reward processes during chronic drug addiction. This corroborates
the importance of developing ligands that efficiently enhance mGlu2 function for anti-addiction
therapy.

1.7.2. Structural and Functional Features of mGlu2
All the existing Class C GPCRs, including the mGlu receptor family, are known to share
common structural features consisting of seven transmembrane structures, an extracellular Nterminus, and an intracellular C-terminus (Rosenbaum et al., 2009).

The extracellular N-

terminus of mGluRs form a bi-lobed clam shell-shaped structure called the Venus Flytrap
Domain (VFD) (Figure 1.21). This domain contains a highly conserved orthosteric agonist (i.e.,
glutamate) binding site that has been validated by x-ray crystallography (Kunishima et al., 2000),
ligand-binding studies (Tsuchiya et al., 2002; Pin et al., 2003), and mutagenesis reports (Sato et
al., 2003; Muto et al., 2007). The 7-transmembrane domain is connected to the VFD via a
conserved cystein-rich domain, which transmits conformation changes between the two domains
and promotes subsequent signal transduction. Allosteric binding sites for these GPCRs are
proposed to be embedded within the 7-transmembrane structure (Kunishima et al., 2000).
Once glutamate binds to the orthosteric site of mGlu2, it stabilizes the closed
conformation of the extracellular domain, which then activates the G-protein coupling
mechanism, thereby initiating second messenger pathways. More specifically, upon activation of
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mGlu2, Gi/o proteins get activated, which inhibit the activity of adenylyl cyclase (AC), thereby
decreasing intracellular concentrations of cAMP (Kenny and Markou, 2004).

Figure 1.21. Structural and functional representation of mGlu2 as a family C G-protein coupled receptor (Kenny
and Markou, 2004. Reprinted with permission from Trends in Pharmacol. Sc. 2004, 25, 265-272. Copyright 2004,
Elsevier Ltd.)

1.8. mGlu2 Ligands
1.8.1. Orthosteric Ligands
A majority of mGlu2 orthosteric agonists and antagonists have been designed based on
structural modifications to the endogenous ligand, L-glutamate (Figure 1.22) (e.g., see Monn et
al., 1997; Kingston et al., 1999; Monn et al., 1999; Wright et al., 2001; Chaki et al., 2004;
Rorick-Kehn, Johnson, Burkey, et al., 2007; Rorick-Kehn, Johnson, Knitowski, et al., 2007).
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Such orthosteric ligands have helped in understanding the functional role of these receptors and
their implication in a corresponding disease state. However, given that these compounds are
amino acid derivatives that have a high polar surface area, they lack appropriate hydrophobicity
to cross the blood-brain barrier and reach the CNS where the majority of mGlu2 receptors are
located. Additionally, since the glutamate-binding site is highly conserved structurally amongst
the entire mGluR family, orthosteric ligands frequently lack appropriate receptor subtype
selectivity (Conn and Pin, 1997; Schoepp et al., 1999; Cartmell and Schoepp, 2000).

Figure 1.22. Structural examples of mGlu2 agonists targeting the orthosteric- / glutamate-binding site of mGlu2.

1.8.2. Allosteric Modulators
In order to overcome the drawbacks associated with the traditional approach of targeting
the orthosteric site, studies have now focused on exploring allosteric mechanisms to control
glutamate neurotransmission by modulating the activity of mGlu2 receptors.

Allosteric

modulators exert a range of pharmacological responses, such as positive allosteric modulation
(PAM), negative allosteric modulation (NAM), and silent allosteric modulation (SAM)
(Langmead and Christopoulos, 2014). PAMs bind to an allosteric site and enhance receptor
function by increasing the affinity or efficacy of the orthosteric ligand. NAMs, on the other
hand, decreases the affinity or efficacy of the orthosteric ligand upon binding to an allosteric site.
Ligands that have no effect on the binding or function of the orthosteric ligand when bound to
the allosteric site are the SAMs which, in turn, sterically block the binding of other allosteric
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modulators. Allosteric ligands provide several advantages over the orthosteric ligands, namely
1.) Since the allosteric site is topographically distinct from the orthosteric site, receptor subtype
selectivity can be better achieved with allosteric ligands, 2.) an allosteric modulator can exert its
effect only in the presence of the endogenous ligand, (e.g., L-glutamate), and 3.) allosteric
modulators frequently show better chemical tractability and more ligands can be designed with
greater drug-like properties (Jensen and Spalding, 2004; Lewis et al., 2008; Conn et al., 2009;
Rocheville and Garland, 2010; Smith et al., 2011).
Despite these advantages, small molecule drug discovery programs of allosteric
modulators are associated with several challenges. mGlu allosteric modulators routinely display
“flat” SAR, wherein a minimal change to the structure can result in a significant loss in
pharmacological activity (Zhao et al., 2007).

Furthermore, the SAR studies of allosteric

modulators are complicated by the phenomenon of “molecular switches”, whereby a subtle or
minimal structural change to an allosteric ligand can completely change the mode of
pharmacology or selectivity of a ligand for a given receptor subtype (Wood et al., 2011). This
problem of molecular switches poses a serious challenge towards developing SAR based on a
single mode of pharmacology. Additionally, allosteric ligands can also display ligand-biased
pharmacology in which a single modulator can exert different pharmacological responses
(Kenakin, 2012). In addition, the problem of probe-dependent allosteric interactions exists
wherein the same allosteric modulator can enhance the efficacy of one orthosteric ligand, while
acting as a NAM or SAM for another. Moreover, structure-based lead optimization of allosteric
modulators towards developing clinically-relevant candidates is currently impossible due to the
lack of accurate and reliable mGlu2 3-D structural information. In contrast to the extracellular
N-terminal, an x-ray crystal structure of the transmembrane domain is yet to be determined for
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mGlu2.

Though computer-aided homology models of mGlu1 (Malherbe, Pari, Kratochwil,

Knoflach, et al., 2003) and mGlu5 (Malherbe, Pari, Kratochwil, Zenner, et al., 2003) using Class
A GPCRs as templates, and their subsequent crystal structures (Doré et al., 2014; Wu et al.,
2014) have provided insights into the structure of allosteric binding sites of these subtypes,
currently only a single low-resolution homology model of the TM domain of mGlu2 exists in the
literature (Radchenko et al., 2014). Nevertheless, site-directed mutagenesis and the construction
of chimeric receptors of mGlu2 have provided, to some extent, information on the molecular
determinants of allosteric modulator-binding site interactions within the mGlu2 TM domain
(Malherbe, et al., 2001; Schaffhauser et al., 2003; Hemstapat et al., 2007). In particular, Rowe
and coworkers prepared a series of mutant receptors by exchanging various single or multiple
amino acids between hmGlu2 and hmGlu3 residues (Rowe et al., 2008). The results showed that
replacing hmGlu2 amino acid residues between Leu656 and Arg750 in TM3-4 region with
homologous hmGlu3 segments resulted in a complete loss of the potentiator activity of mGlu2specific PAMs.

On the other hand, substitution of hmGlu2 residues Ser688, Gly689, and

Asn735 into the homologous region of hmGlu3 created an active hmGlu2 allosteric modulation
site within mGlu3 which was potentiated by mGlu2-specific PAMs, suggesting the importance
of these three residues in the potentiation effect.

1.8.2.1. Positive Allosteric Modulators of mGlu2
Regardless of the complexities associated with optimizing the activity of allosteric
modulators, discovery efforts towards selective PAMs of mGlu2 are still gaining tremendous
momentum as they represent promising drug candidates for a number of disease states including
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schizophrenia (Fell et al., 2012), drug abuse (Moussawi and Kalivas, 2010), impaired cognition,
and depression (Goeldner et al., 2013).

1.8.2.1.2. SAR of Biphenyl-Carboxylic Acid-Indanone-Based mGlu2 PAMs
The study of mGlu2 PAMs as anti-addiction therapeutics has been principally aided by
the

discovery

of

3’-[[(2-cyclopentyl-2,3-dihydro-6,7-dimethyl-1-oxo-1H-inden-5-

yl)oxy]methyl]-[1,1’-biphenyl]-4-carboxylic acid (BINA (±)-1.71; hmGluR2 GTP-S EC50 =
111 nM). BINA ((±)-1.71, Table 1.5), which originated from extensive SAR efforts by Merck in
an attempt to improve the physicochemical properties of an initial hit compound discovered via
mGlu2 high-throughput screening (Pinkerton et al., 2005). BINA is a selective, brain-penetrant,
and potent mGlu2 PAM that produces long-lasting antipsychotic and anxiolytic effects in various
behavioral animal models (Galici et al., 2006).

Furthermore, BINA has been shown to

consistently reduce the reinforcing properties of cocaine, amphetamine, and alcohol in squirrel
monkeys and rats (Adewale et al., 2006; Jin et al., 2010). Moreover, animals addicted to
cocaine, amphetamine, and alcohol showed reduced drug-seeking behavior and relapse upon
treatment with BINA (Kim et al., 2005; Zhao et al., 2006). Additionally, since BINA noncompetitively potentiates the function of mGlu2, it did not show off-site actions such as
attenuation of response to food which is a natural reward stimulant often seen in the case of nonselective orthosteric agonists (Jin et al., 2010). However, despite promising results from BINA,
this compound significantly lacked in vivo and in vitro potency as well as possessed low oral
bioavailability. Therefore, in an effort to improve the efficacy, potency and drug-like properties
of BINA, several structural modifications of BINA were further reported (Bonnefous et al.,
2005; Pinkerton et al., 2005; Galici et al., 2006; Pinkerton et al., 2006; Dhanya et al., 2011).
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Table 1.5. SAR of a biphenyl-indanones: mGlu2 PAM potencies reported by Bonnefous et al., 2005.

The pharmacological evaluation of all analogs for their mGlu2 PAM activity was
reported in terms of their functional efficacy in glutamate potentiation (i.e., IC50 values) rather
than their binding affinity (i.e., Ki values) at mGlu2 due to the absence of a suitable radiolabelled
ligand for mGlu2 allosteric sites. The effects of substitutions on the indanone and the terminal
phenyl ring are briefly summarized as follows: the acid at C3 ((±)-1.70; hmGluR2 GTP-S EC50
= 69 nM, glutamate potentiation 118%) was slightly more preferred over C4 (BINA, (±)-1.71;
hmGluR2 GTP-S EC50 = 111 nM, glutamate potentiation 114%) when X = Y = CH3. Further
exploration of SAR at the terminal phenyl ring revealed that the 2'-position of the phenyl ring
was not tolerable to methyl substitutions wherein both (±)-1.72 and (±)-1.73 displayed 4-fold
(hmGluR2 GTP-S EC50 = 252 nM, glutamate potentiation 94%) and 5-fold (hmGluR2 EC50 =
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353 nM, glutamate potentiation 103%) reduced potency respectively when compared to (±)-1.70
(hmGluR2 GTP-S EC50 = 69 nM). In contrast, 6'-methoxy analog (±)-1.74 (hmGluR2 GTP-S
EC50 = 36 nM, % glutamate potentiation = 114) and 4'-chloro analog (±)-1.75 (hmGluR2 GTPS EC50 = 24 nM, % glutamate potentiation = 109) displayed 2-fold and 3-fold higher mGlu2
potency, respectively, relative to parent compound (±)-1.70 (hmGluR2 GTP-S EC50 = 69 nM, %
glutamate potentiation = 118), while their glutamate potentiation ability remained unchanged.
Position Y on the indanone ring, when substituted with a -Cl group, consistently increased the
potency of the compounds irrespective of the position of the carboxylic acid group ((±)-1.76 to
(±)-1.79). Though the potency was not affected when the 4'-position of the phenyl ring was
substituted with 4'-Cl ((±)-1.78, hmGluR2 GTP-S EC50 = 67 nM, glutamate potentiation 121%)
when compared to (±)-1.76 (hmGluR2 GTP-S EC50 = 64 nM, glutamate potentiation 122%),
there was a large boost in the potency when the substituent on position X was replaced with a Cl
atom ((±)-1.79, hmGluR2 GTP-S EC50 = 5 nM, glutamate potentiation 117%).

Racemic

compound (±)-1.79 was the most potent mGlu2 PAM synthesized in this biphenyl-indanone
series.

1.8.2.1.3. SAR of Pyridone-Based mGlu2 PAMs
Another series of mGlu2 PAMs identified through high throughput screening (HTS) were
1,5-disubstituted 2-pyridones 1.82 and 1.83 (Cid et al., 2010). In particular, 1,5-substituted
pyridones emerged as a promising class of potent and selective mGlu2 PAMs via high
throughput screening (HTS) efforts at Addex Pharmaceuticals using a mGluR2 PAM FLIPR
(fluorometric imaging plate reader) assay (Cid et al., 2010). Though the mGlu2 PAM activity of
the two initial hits was low (hmGlu2 GTP-S binding EC50 = 6.29 M, glutamate potentiation
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Emax = 138% for 1.82 and EC50 = 4.47 M, Emax = 133 % for 1.83), these compounds were
reasonable starting points for lead optimization efforts.

Table 1.6. SAR of some 1,5-substituted pyridones: mGlu2 PAMs reported by Cid et al., 2010.

Initial efforts focused on examining the effect of introducing halogen substitutions on the
benzyl ring of 1.82.

Although the 2'-F substitution in 1.84 increased mGlu2 potency as

compared to the lead 1.82 by 6-fold, this substitution resulted in a marked decrease in glutamate
potentiation ability (hmGlu2 GTP-S binding EC50 = 1.00 M, glutamate potentiation = 44% for
1.84 versus hmGlu2 GTP-S EC50 = 6.29 M, glutamate potentiation = 138% for 1.82).
Subsequently, compounds 1.85 (3'-F), 1.86 (4'-Cl), 1.87 (2',3'-di-F), and 1.90 (2'-F-4'-CF3)
showed significant improvements in the percentage potentiation of glutamate versus 1.84 (2'-F).
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Notably, a ten-fold increase in mGlu2 potency was observed with 2'-F-4'-Cl- substituted 1.89
(hmGlu2 GTP-S EC50 = 0.53 M, glutamate potentiation = 194%) versus 2',4'-difluoro
substituted 1.88 (hmGlu2 GTP-S EC50 = 4.79 M, glutamate potentiation = 128%) suggesting
the preference for larger groups at the para-position. Furthermore, slight improvements in the
mGlu2 potency were observed with the 3'-F-4'-MeO containing 1.91 (hmGlu2 GTP-S EC50 =
0.71 M, glutamate potentiation 241% ). The unsubstituted phenyl analog (1.92) of the second
HTS hit 1.83 resulted in the same level of in vitro mGlu2 potency as compared to 1.83 (hmGlu2
GTP-S EC50 = 6.31 M, glutamate potentiation = 139% for 1.92 versus hmGlu2 GTP-S EC50 =
4.47 M, glutamate potentiation = 133% for 1.83). Exploration of other alkyl chains with Hbond acceptor groups at the para-position of the phenyl ring slightly improved the mGlu2
potency (1.93 hmGlu2 GTP-S EC50 = 1.26 M, glutamate potentiation = 196%; 1.94 hmGlu2
GTP-S EC50 = 3.39 M, glutamate potentiation = 184%).
Among all 2-pyridone derivatives, compound 1.89 displayed the most promising results
during in vivo evaluation in mice. Upon intraperitoneal administration, 1.89 markedly attenuated
the increase in phencyclidine-induced locomotor activity in animal models of psychosis. Such
results were similar to other previously known mGlu2 PAMs. Furthermore, 1.89 also displaced
appreciable bioavailability and brain penetration upon iv administration. However, despite the
promising results of 1.89, further studies with this compound were discontinued due to its poor
metabolic stability (Cid et al., 2010). As a result, since the poor pharmacokinetic properties of
this compound precluded its further development, more advanced leads with improved potency
and drug-like properties were later pursued (Cid et al., 2012).
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CHAPTER TWO
2. Determination of Drug-Target Interactions via Small-Molecule Photoaffinity Labeling:
a Concise Literature Review
2.1. Introduction
In order to vertically advance the DAT, mGlu2, and nAChR fields towards rational
structure-based drug design, it is imperative to obtain detailed 3-D structural information
regarding ligand-binding sites within these therapeutically significant proteins. In this regard,
the most common experimental methods towards acquiring detailed 3-D structural information
of proteins are x-ray crystallography (Garman, 2014), site-directed mutagenesis (Shortle et al.,
1981), computational modeling (Rodrigues and Bonvin, 2014), and photoaffinity labeling
(Sumranjit and Chung, 2013).
Currently, x-ray crystal structures of human forms of the DAT, mGlu2, and nAChRs are
not available. In particular, procuring 3-D structural information regarding membrane-bound
proteins such as the DAT, mGlu2, and nAChRs by x-ray crystallography and NMR analysis is
very challenging due to their complex heterogeneity and insolubility in water (Bill et al., 2011).
Most recently, multiple research groups have computationally built human DAT molecular
models (e.g., Stockner et al., 2013; Huang and Chang-Guo, 2007) based on 3-D structural
information obtained from several available bacterial LeuTAa leucine transporter crystal
structures (e.g., Singh et al., 2007; Yamashita et al., 2005; Zhou et al., 2007 and 2009). In turn,
these computer homology models have aided in characterizing ligand-binding sites within the
DAT (e.g., Beuming et al., 2006 and 2008; Bisgaard et al., 2011; Indarte et al., 2008). Likewise,
homology models of human nAChRs are known (e.g., Hu et al., 2009; Bisson et al., 2008;
Saladino et al., 2005; Law and Lightstone, 2009) based on crystallographic structures of Torpedo
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nAChRs (e.g., Unwin, 2005) and several AChBPs (e.g., Brejc et al., 2001). However, due to
significant differences between the human DAT, nAChRs, and their corresponding protein
templates for computational homology modeling, careful experimental validation and critical
refinement of these molecular models is necessary in order to understand the structure, function,
and pharmacological properties of these proteins. In a similar light, structure-function studies of
allosteric binding sites within mGlu2 are minimal (Lundstrom et al., 2011; Schaffhauser et al.,
2003), and only one research group has recently disclosed a molecular modeling study of the
transmembrane domain of mGlu2 featuring a proposed binding site for positive allosteric
modulators (Radchenko et al., 2014). As a result, there is a critical need for direct mapping of
ligand-binding sites within the DAT, nAChRs, and mGlu2 in order to rationally develop
therapeutics for numerous disease states associated with these proteins.
To date, the status quo towards gaining insight into DAT, nAChR, and mGlu2 regions
where ligands bind and confer pharmacology has been provided by mutagenesis-based studies
coupled with homology modeling (e.g. for the DAT: Severinsen et al., 2014, Stockner et al.,
2013, Guptaroy et al., 2011, Bisgaard et al., 2011; Schmitt et al., 2008; e.g. for nAChRs: Marotta
et al., 2014; Grishin et al., 2013; Pavlovicz et al., 2011). However, in the absence of detailed 3D structural information it is difficult to confirm if the impact of certain amino acid mutations
are due to disruptions of specific ligand-protein binding sites, or to alterations of protein
structure that indirectly impact binding sites. These shortcomings have prevented advancement
of the fields involving these target proteins and bring into question the validity of the 3-D
structures of ligand-protein complexes generated by coupling site-directed mutagenesis with
homology modeling. In contrast, what objectively sets affinity and photoaffinity labeling apart
from this status quo is that these experimental approaches allow direct identification of binding
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sites and poses of ligands when coupled with homology modeling, thus allowing one to
understand the structural basis for a particular ligand’s pharmacology at the molecular level.

2.2. The Concept of Photoaffinity Labeling
The concept of photoaffinity labeling was first proposed in 1962 (Singh et al., 1962). In
turn, Chakrabarti and Khorana were the first to implement this method in order to directly
investigate sites of lipid−protein interactions at the molecular level in biomembranes
(Chakrabarti and Khorana, 1975).

Scheme 2.1. An overview of identification levels possible via photoaffinity labeling (Dorman and Prestwich, 2000.
Reprinted with permission from Trends in biotech. 2000, 18, 64-77. Copyright 2000, Elsevier).

Photoaffinity labeling represents one of the most direct approaches towards elucidating
ligand-binding sites within target proteins.

Although this experimental approach has been

employed extensively with the DAT (e.g., Agoston et al., 1997; Lever et al., 2005; Newman et
al., 2006; Parnas et al., 2008; Vaughan et al., 1999, 2005, and 2007; Vaughan and Kuhar, 1996;
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Zou et al., 2001; Lapinsky et al., 2009, 2011, and 2012) and select nAChRs (e.g., Hamouda et
al., 2009, 2011, and 2013; Srivastava et al., 2009; Chiara et al., 2009; Tantama et al., 2008;
Sanghvi et al., 2008; Garcia et al., 2007; Nirthanan et al., 2008), this dissertation has contributed
the first ever probes to conduct photoaffinity labeling experiments with mGlu2.
In photoaffinity labeling, known ligands are typically derivatized with a reporter tag and
a photoreactive group, which is capable of forming an irreversible, covalent bond with a target
protein after initial reversible target binding and subsequent exposure to UV light (Scheme 2.1).
Under normal ambient light conditions, photoreactive groups tend to remain inert and chemically
unreactive.

However, upon irradiation with an appropriate wavelength of UV light,

photoreactive groups can be converted into highly reactive, radical-based intermediates. When
such reactive intermediates are formed within the binding site of a target protein, they can react
irreversibly with proximal amino acid residues found within their vicinity. Photo-crosslinking
products are then traditionally identified and analyzed using methods such as SDS-PAGE and
HPLC coupled with MS (Robinette et al., 2006). In particular, proper photoaffinity experiments
can be used to identify the targets of biologically active compounds, determine the affinity and
selectivity of ligand-target complexes, interrogate the structure and function of target biological
macromolecules, investigate ligand-receptor interactions, identify amino acids at biological
macromolecule interfaces (e.g., protein-protein interactions, lipid-protein interactions), and also
isolate and identify unknown enzymes or receptors (Lapinsky, 2012).
A set of criteria has been disclosed regarding ideal photoprobes, namely: (1) they utilize a
wavelength-selective activation that does not damage other components in the testing system; (2)
they possess high stability in the dark under various pH conditions; (3) they form a stable adduct
with their target biological macromolecule(s) and survive subsequent characterization and
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detection methodology; (4) they bear a structural resemblance to the parent ligand with similar
binding affinity and pharmacology; (5) they have the ability to react with any type of bond or
residue without any preference; (6) they are sterically non-congested; and (7) they generate
highly reactive, short-lived photo-intermediates upon irradiation with UV light (Das, 2011;
Vodovozova, 2007). Despite being employed for decades in biochemical research, so far there
have been no reports of photoprobes that possess all of the previously mentioned characteristics.
Arguably the most important component of a photoaffinity probe is the photoreactive
functional group.

The most widely used photoreactive functional groups in photoaffinity

labeling are aromatic azides, benzophenones and acetophenones, and aliphatic (Das, 2011) and
aromatic diazirines (e.g., Dubinsky et al., 2012; Hashimoto and Hatanaka, 2011).

These

functional groups can also be classified according to their photochemically-generated reactive
species, principally nitrenes, diradicals, and carbenes, respectively (Fleming, 1995). Given that
this dissertation features chemical probes containing an aromatic azide, benzophenone, or
acetophenone photoreactive group, only these functional groups in terms of photoaffinity
labeling are reviewed below.

2.2.1. Discussion of Select Photoreactive Groups Employed in This Dissertation
2.2.1.1. Aryl Azides as Photoreactive Groups in Photoaffinity Labeling
Aryl azides represent the most frequently employed photoreactive group in photoaffinity
probes, mainly because of their small size and straightforward synthetic routes for incorporation
into parent ligands via conventional aniline diazotization and azide displacement. Aryl azides
remain chemically inert in the dark and are relatively stable to multiple synthetic transformation
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conditions. These functional groups possess high reactivity upon photoirradiation, wherein they
generate reactive nitrene species with presumably longer lifetimes than carbenes.
The photochemistry of aryl azides (e.g., 2.1) is well established and proceeds after
photoirradiation under UV light (Morris et al., 2013) (Scheme 2.2). Once activated, a singlet
nitrene (2.2) is generated upon the release of nitrogen. The in situ generated reactive singlet
nitrene (2.2) undergoes bond insertion into proximal carbon-hydrogen or heteroatom-hydrogen
bonds (pathway A) of amino acids within the binding pocket resulting in photolabeling to form a
covalent complex (2.3). Apart from this desired reaction pathway, the nitrene can also undergo
other side reactions, namely ring expansion to form a ketenimine (2.7) (pathway B) or
intersystem conversion (pathway C) to form a triplet intermediate (2.4). These latter pathways
are generally less desirable and tend to account for non-specific protein labeling and lower yields
during photoaffinity labeling experiments. In particular, the resulting ketenimine from pathway
B is an electrophile that can react with nucleophiles to form azepines (2.8) in either a desirable
(i.e., specific) or undesirable (i.e., non-specific) manner. In order to increase the stability of the
desired singlet nitrene (2.2) to favor the insertion reaction pathway (pathway A) while avoiding
side reactions (pathways B and C), electron-withdrawing groups (e.g., one or more fluorine
atoms) have traditionally been incorporated into the aromatic ring bearing the photoreactive aryl
azide. In particular, it has been experimentally shown that fluorinated aryl azides impede ring
expansion reactions and favor bond insertion reactions in a desirable manner (Schnapp et al.,
1993).
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Scheme 2.2. The photochemistry of aryl azides as photoreactive groups in photoaffinity labeling.

Photoactivation of phenylazides is achieved at their maximal absorption wavelength of
around 260 nm. This amount of energy can be highly unfavorable to biomacromolecules such as
proteins and nucleic acids given they have an absorption maxima around 260-280 nm. As a
result, it is possible that the photoactivation of aryl azides can cause considerable damage to the
biological system being studied during photoaffinity labeling.

In order to overcome this

potential problem, several groups have successfully shifted the absorption wavelength of
photoreactive aryl azides beyond 300 nm, principally by substituting the phenyl ring with
electron-withdrawing groups such as a nitro functional group (Mohr, 2004).
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2.2.1.2.

Benzophenones and Acetophenones as Photoreactive Groups in Photoaffinity

Labeling
Benzophenones (2.9), as well as their more conformationally flexible counterparts,
acetophenones (2.10), are common precursors to reactive free radicals generated during
photoaffinity labeling (Scheme 2.3). Benzophenone and acetophenone moieties get converted
into a triplet biradical (2.11) upon photoactivation. This triplet biradical can subsequently
abstract a hydrogen atom from a nearby amino acid to form two free radicals (2.12 and ·CProt).
These two radicals can then combine to result in the formation of a photoadduct (2.13).

Scheme 2.3. The photochemistry of benzophenone and acetophenone as photoreactive functional groups in
photoaffinity labeling.

Despite their large size, which could potentially adversely affect reversible formation of
the photoprobe-protein complex prior to irradiation, benzophenones offer several advantages
over other photoaffinity labeling groups (Dorman and Prestwich, 1994).

The maximal

absorption of a benzophenone functional group for photoactivation is 350-360 nm, which in
sharp contrast to aryl azides, lies well outside the energy range that causes damaging effects to
living cells. As a result, benzophenone-containing photoprobes routinely show success in cell
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cultures or other living systems. Additionally, a number of benzophenone-containing building
blocks are commercially available for photoprobe synthesis, and this functional group is stable in
most organic solvents and compatible with multiple synthetic strategies. Benzophenones also
tend to possess much higher chemical stability when compared to other nitrene and carbene
precursors. In particular, the reversible nature of the biradical species 2.11 generated during
acetophenone and benzophenone photochemistry also increases the labeling efficiency for probes
that contain these particular photoreactive groups. In addition, benzophenones can preferentially
react with inactive C-H bonds in the presence of water. Besides their bulkiness that could hinder
reversible binding to a biological target, another principal disadvantage associated with
benzophenone-containing photoprobes is that they normally require longer irradiation times
versus aryl azide-containing probes, thus potentially resulting in higher amounts of non-specific
labeling.
Similar to benzophenones, the acetophenone moiety (2.10) has long been known to
undergo photochemical reactions upon photoactivation (Berger and Steel, 1975; Huix-Rotllant et
al., 2013).

However, its use as a photoreactive group in photoaffinity labeling (e.g., van

Scherpenzeel et al., 2010) is significantly less when compared to aryl azides, benzophenones,
and diazirines.

2.2.1.3. Pyrimidones as Photo-masked Electrophiles for Affinity Labeling
In contrast to photoaffinity labeling, affinity labeling features a compound that is
designed to be structurally similar to a ligand that is known to bind to a target biological
macromolecule of interest, but already inherently contains an electrophilic functional group
capable of covalently reacting with proximal nucleophilic amino acids (Miller and Cornish,
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2005) (Scheme 2.4). The expectation is that the affinity label will initially form a reversible
probe-target complex and, once bound at a specific site, will react in a proximal, irreversible
manner with a nearby nucleophilic amino acid within the binding site. Application of this
technique can result in tagging of a particular ligand-binding site within a specific protein or in
the labeling of one protein within a complex mixture of proteins.

AFFINITY LABELING

PHOTOAFFINITY LABELING
Scheme 2.4. Schematic representation of affinity labeling versus photoaffinity labeling towards determining the
binding site of a ligand within a drug target (Lapinsky et al., 2012. Adapted with permission from Bioorg. Med.
Chem. 2012, 20, 6237-6247. Copyright 2012, Elsevier).

In contrast to aryl azides, benzophenones, and acetophenones, pyrimidones (2.15,
Scheme 2.5) are unique chemical structures that upon irradiation are known to photochemically
generate isocyanate-based electrophiles (2.17), which can then covalently react with proximal
nucleophiles in ligand-binding sites via affinity labeling (Battenberg et al., 2011).

Since

pyrimidones are present in many natural products (e.g., bufadienolides, zebularine, and
citreoviridin), this moiety can be potentially exploited as an intrinsic photoreactive group
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naturally present within a lead compound. As a result, this circumvents the need to incorporate
non-natural functional groups (e.g., photoreactive azide and diazirine functional groups) into a
lead compound that could potentially negatively disrupt protein-ligand interactions prior to
photo-unmasking affinity labeling.
The photochemistry of pyrimidones is induced by UV irradiation ranging between 290320 nm and proceeds via a Norrish type 1 reaction to form a reactive isocyanate (2.17) or a
bicyclic intermediate (2.20) (Scheme 2.5). In turn, the electrophilic carbon of the isocyanate
moiety is susceptible to nucleophilic attack by proximal alcohol- or amine-containing derivatives
(e.g., the amino acid side chains serine and lysine, respectively) to give rise to a stable covalent
adduct (2.19).

Scheme 2.5. Photochemistry of pyrimidones as photomasked electrophiles for affinity labeling.
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2.3. Select Reporter Groups Traditionally Employed in Affinity and Photoaffinity Probes
In addition to a functional group that can eventually form a covalent bond to a ligandbinding site within a target biological macromolecule, affinity and photoaffinity chemical probes
also traditionally require incorporation of a reporter group within the probe structure (Sadaghiani
et al., 2007). Examples include radioactive isotopes (e.g.,
fluorophores.

125

I), affinity tags (e.g., biotin), or

These reporter groups function to facilitate visualization, identification,

enrichment, or isolation of probe-labeled covalent adducts associated with irreversible labeling
experiments.

2.3.1. Radioactive Isotopes as a Reporter Group in Chemical Probes
Radioactive isotopes are commonly used in biological applications for the detection of a
wide variety of biological molecules. In particular, I125 represents one of the most frequently
used radioactive isotope tags in biochemistry owing to its ease of incorporation via simple
synthetic steps, relatively small size, and highly sensitive signal for easy detection and
quantification (Gevaert et al., 2008). However, the relatively short half-life associated with I125
prevents storage of probes and reagents containing this radioisotope for prolonged periods of
time. In addition, the synthesis of probes labeled with I125 requires a special laboratory setting
wherein extra care during handling is necessary given as I125 is a harmful radioactive health
hazard.
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2.3.2.

‘Clickable’ Handles as Chemical Reporters in Tandem Photoaffinity Labeling-

Bioorthogonal Conjugation
In order to facilitate complete proteomic analysis following photoaffinity labeling and
address the shortcomings associated with radioactive isotopes as reporter groups, alternatives
such as biotin (Tomohiro et al., 2012), epitope tags (e.g., FLAG peptide), or fluorophores can be
directly incorporated into the structure of photoaffinity probes. These moieties frequently allow
easy enrichment, detection, and/or isolation of photolabeled products after photoaffinity labeling.
However, biotin, epitope tags, and fluorophores are somewhat notoriously large in size, cell
impermeable, and may adversely affect pharmacological activity relative to a parent compound
by sterically disrupting key interactions between the photoprobe and the target biological
macromolecule.

Scheme 2.6. Tandem photoaffinity labeling-bioorthogonal conjugation chemical proteomics strategy. (Lapinsky,
2012. Reprinted with permission from Bioorg. Med. Chem. 2012, 20, 6237-6247. Copyright 2012, Elsevier).

In order to overcome the disadvantages previously noted, tandem photoaffinity labelingbioorthogonal conjugation has emerged as a powerful chemical proteomics strategy within the
past decade (Lapinsky, 2012) (Scheme 2.6). In this strategy, a terminal alkyne or an aliphatic
azide is incorporated into the structure of photoprobes to serve as a ‘clickable’ handle / chemical
reporter. Following the formation of a covalent probe-target complex after photoirradiation
(Step 1, Scheme 2.6), a variety of tags such as biotin, fluorophores, or FLAG peptide can be
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subsequently attached specifically to the terminal alkyne or aliphatic azide functional group
within the photoprobe via bioorthogonal conjugation reactions, e.g., copper-catalyzed Huisgen
1,3-dipolar cycloaddition (Rostovtsev et al., 2002) (‘click’ reaction) or Staudinger-Bertozzi
ligation (Saxon and Bertozzi, 2000) (Scheme 2.7). Due to their relatively small size, biological
compatibility, and easy incorporation, terminal alkynes and aliphatic azides as bioorthogonal
chemistry handles (Sletten and Bertozzi, 2009) have proven to be highly advantageous given
they are less likely to potentially disrupt key ligand-target interactions during irreversible
labeling experiments.

Scheme 2.7. Bioorthogonal conjugation chemistries traditionally employed during tandem photoaffinity labelingbioorthogonal conjugation.

It should be noted that the only apparent disadvantage associated with tandem
photoaffinity labeling-bioorthogonal conjugation is that yields of the bioorthogonal conjugation
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step (Step 2, Scheme 2.6) can vary in different systems. In particular, it has been reported that
higher yields are frequently observed when copper-catalyzed Huisgen 1,3-dipolar cycloaddition
is employed in the bioorthogonal conjugation step during protein labeling experiments versus
Staudinger-Bertozzi ligation (Speers et al. 2003).

Despite this variability in bioorthogonal

conjugation yield, the noteworthy advantages of tag flexibility, high-throughput analysis, and in
vivo use makes this strategy the current method of choice for analysis of probe-labeled products
after photoaffinity labeling.

2.4. Binding Ensemble Profiling with (f)Photoaffinity Labeling (BEProFL)
It is well established that the basis of medicinal chemistry, pharmacophore research,
structure-activity relationships, and drug development is fundamentally linked to understanding
how a ligand interacts in a 3-D manner with its biological macromolecular target(s) at the
molecular level (Keiser et al., 2010; Leach et al., 2010; Nicholls et al., 2010). In particular,
combining tandem photoaffinity labeling-bioorthogonal conjugation with LC-MS and molecular
modeling studies represents a powerful experimental approach towards determining the 3-D
structure of a ligand-target complex. This approach features a synergism of chemical biology,
proteomics, and computational chemistry in order to determine key ligand-target binding
interactions and conformational preferences for both the biological target and the ligand being
analyzed. In turn, high quality 3-D information from this combined experimental approach aids
in validation or refinement of biological target molecular models to be used for computer-aided
drug discovery and development (e.g., virtual / in silico screening, structure-based drug design)
(Sliwoski et al., 2013). In particular, this merged experimental approach was coined “BEProFL
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(binding ensemble profiling with (f)photoaffinity labeling)” in the late 2000s by the Petukhov
group (He et al., 2009).
In BEProFL, a ligand-target covalent complex formed via photoaffinity labeling is
subjected to traditional proteomic experiments in order to determine the biological target’s amino
acid(s) directly attached to the photoprobe (Scheme 2.8). Such results are then coupled with
computational studies of the probe-target complex in order to unambiguously map the binding
pose(s) and site(s) of probe compounds within the biological target.

Scheme 2.8. Binding ensemble profiling with (f)photoaffinity labeling (BEProFL) towards mapping the binding
sites and poses of drug candidates within the DAT, nAChRs, and mGlu2.

With the aim of gaining 3-D structural information on how promising drug candidates
interact with either the DAT, nAChRs, or mGlu2 at the molecular level, the Lapinsky lab has a
history of pursuing the BEProFL strategy towards understanding the binding modes and poses of
promising CNS therapeutics, particularly anti-addiction lead compounds (Lapinsky et al., 2009,
2011, and 2012). In particular, the work described in this dissertation features derivatization of
known DAT inhibitors, nAChR antagonists, and mGlu2 PAMs as lead compounds for BEPRoFL
studies via modifying the synthesis of these compounds to include a photoreactive group and a
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chemical reporter. Following pharmacological evaluation in order to identify suitable probe
candidates for irreversible labeling experiments via collaboration, photoprobes are then subjected
to traditional photoaffinity labeling with a biological target of interest.

Analysis of the

photoprobe-target covalent adduct then proceeds via a multi-step sequential protocol of
bioorthogonal conjugation, fragmentation, LC-MS/MS, and coupling with computational
modeling in order to specifically determine the binding sites and poses of DAT/nAChR/mGlu2
lead compounds within their corresponding biological target.

Continued utilization of this

innovative and collaborative research approach is expected to experimentally validate and refine
current DAT, nAChR, and mGlu2 homology models, thus aiding in the discovery and
development of therapeutics associated with these proteins.
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CHAPTER THREE
3. Known Synthetic Approaches to Lead Compounds
3.1. Review of Synthetic Approaches for Pyrovalerone as a Lead Compound for DAT
Photoprobe Design
Heffe developed the first chemical synthesis of racemic pyrovalerone ((±)-1.19) in 1962
via Stevens rearrangement of an unsymmetrical olefin (Heffe, 1964) (Scheme 3.1).

This

approach begins with displacement of 2-bromo-4’-methylacetophenone (3.1) with pyrrolidine,
followed by formation of the hydrobromide salt of 2-pyrrolidino-4’-methylacetophenone (3.2).
This salt was then converted to the free base and subsequently reacted with allylbromide to
provide N-allyl-N-(p-methylphenacyl)-pyrrolidinium bromide (3.3) in 85% yield. Subsequent
Stevens rearrangement using basic conditions resulted in key migration of the allyl group alpha
to the ketone to provide unsaturated pyrovalerone analog (±)-3.4 in 89% yield.

Final

hydrogenation of the alkene analog then provided racemic pyrovalerone (±)-1.19 in 91% yield.

Scheme 3.1. Synthesis of racemic pyrovalerone ((±)-1.19) according to Heffe, 1962.
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Lancelot and coworkers reported a short, simple three-step route for accessing thiophene
analogs of pyrovalerone in 1992 (Lancelot et al., 1992) (Scheme 3.2). In their approach, 2,5disubstituted thiophene ketones (3.6) were first obtained by Friedel-Crafts acylation of 2substituted thiophenes (3.5) with a mixed anhydride of valeric acid. Subsequent -bromination
and nucleophilic displacement with a variety of cycloaliphatic amines (e.g., pyrrolidine,
piperidine, morpholine) readily provided substituted thiophene analogs of pyrovalerone ((±)-3.7)
in yields between 60 to 80%.

Scheme 3.2. Synthesis of racemic thiophene analogs of pyrovalerone ((±)-3.7) reported by Lancelot and coworkers
(Lancelot et al., 1992).

Meltzer and coworkers described a synthesis of pyrovalerone analogs for their evaluation
as potential drug candidates to treat cocaine abuse (Meltzer et al., 2006). In particular, their
synthesis of pyrovalerone was accomplished analogous to the strategy previously reported by
Lancelot for thiophene analogs (see Scheme 3.2). Beginning with 1-(4-methylphenyl)pentan-1one (3.8), which was synthesized by Friedel-Craft’s acylation of toluene with valeryl chloride, bromination followed by nucleophilic displacement with pyrrolidine provided racemic
pyrovalerone ((±)-1.19) in 68% yield (Scheme 3.3).

Enantiomerically pure forms of

pyrovalerone ((2R)-1.19) and (2S)-1.19) were then accessed via diastereomeric salt resolution of
racemic pyrovalerone using either dibenzoyl-D- or L-tartaric acid and multiple recrystallizations
in ethanol.

In particular, assignment of the stereochemistry associated with the resolved
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enantiomers of pyrovalerone was achieved by x-ray crystallography of the tartarate-based
diastereomeric salts.

Scheme 3.3. Synthesis of optically pure (2R) and (2S)-pyrovalerone via diastereomeric salt formation (Meltzer et
al., 2006).

As a precursor to accessing pyrovalerone analogs for pharmacological evaluation via the
established synthetic methodology, Meltzer and colleagues also reported the synthesis of a
variety of substituted aryl ketones (3.10) by reacting n-BuMgCl with a variety of substituted aryl
nitriles (3.9), followed by acidic hydrolysis (Scheme 3.4) (Meltzer et al., 2006).

Scheme 3.4. Synthesis of some pyrovalerone analogs stemming from substituted aryl nitriles (Meltzer et al., 2006).
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3.2. Review of Synthetic Approaches for Bupropion as a Lead Compound for DAT and
nAChR Photoprobe Design
The first reported preparation of racemic bupropion ((±)-1.20) was described by Mehta in
1975 (Mehta, 1975) (Scheme 3.5). This work began with reaction of m-chlorobenzonitrile (3.15)
with ethylmagnesium bromide, followed by imine hydrolysis, to give m-chloropropiophenone
(3.16),

which

upon

-chlorination

with

sulfuryl

chloride

provided

m-chloro--

chloropropiophenone ((±)-3.17) in 90% yield. Subsequent nucleophilic displacement of the iodo group (generated in situ from (±)-3.17) with t-butylamine in acetonitrile, followed by
treatment with HCl, in turn provided racemic bupropion hydrochloride ((±)-1.20). Alternatively,
the synthesis of racemic bupropion hydrochloride could also be achieved through m-chloro-bromopropiophenone ((±)-3.18) in an analogous manner; however, in situ-generation of an iodo
leaving group was not needed in this case.

Scheme 3.5. Synthesis of racemic bupropion hydrochloride ((±)-1.20) reported by Mehta, 1975.

In order to address problems associated with long displacement reaction times of tbutylamine with -bromo intermediate (±)-3.18, further modifications to the Mehta route were
made by Perrine and co-workers, who employed N-methyl-2-pyrrolidine (NMP) as a solvent
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during the N-alkylation step instead of acetonitrile (Scheme 3.6). This slight change in solvents
during displacement of -bromo leaving group significantly reduced the reaction time to 10
minutes and increased the overall yield to 80% (Perrine et al., 2000). Additionally, Hamad and
coworkers used a similar method with slightly different reaction conditions to synthesize
bupropion for the generation of tripartate codrugs of naltrexone and 6-naltrexol with
hydroxybupropion as potential alcohol abuse and smoking cessation agents (Hamad et al., 2006).

Scheme 3.6. Racemic bupropion hydrochloride ((±)-1.20) synthesis reported by Perrine et al., 2000.

Slight improvements were made to Scheme 3.6 in order to avoid evaporation of CH2Cl2
after bromination and NMP after N-alkylation. As a result, Dabak and coworkers accomplished
a much safer, one-pot synthesis of bupropion by using excess tert-butylamine as a solvent and a
reactant in the bromination and N-alkylation steps, respectively, thus circumventing the need to
evaporate additional solvents (Dabak et al., 2004) (Scheme 3.7).

In this process, 3’-

chloropropiophenone (3.16) was first dissolved in excess tert-butylamine as a solvent, and then
bromine was added dropwise in order to directly isolate the desired free base of bupropion. The
HCl salt of racemic bupropion ((±)-1.20) was then obtained by treating the free base with 1N
HCl and isopropyl alcohol (yields were not disclosed).
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Scheme 3.7. One-pot synthesis of racemic bupropion hydrochloride ((±)-1.20) according to Dabak et al., 2004.

Deshpande and colleagues reported additional changes in bupropion synthesis reaction
conditions that were much simpler, economical, and applicable in an industrial setting
(Deshpande et al., 2008). In this work, the -bromination of m-chloropropiophenone (3.16) was
carried out using liquid bromine in water, instead of DCM. In particular, the entrapment of HBr
gas released during the bromination step required special equipment when the reaction was
carried out in dichloromethane, thus making the process inconvenient at an industrial level.
However, when the reaction was carried out in water, the HBr side-product remained in water,
thus allowing the resulting product to be easily isolated via simply partitioning with an organic
solvent.
In order to avoid using toxic liquid bromine during a scalable synthesis of racemic
bupropion, Reddy and co-workers reported N-bromosuccinimide (NBS) as an efficient
brominating agent by carrying out the halogenation reaction in the presence of p-toluenesulfonic
acid (p-TSA) as a catalyst (Scheme 3.8) (Reddy et al., 2010). m-Chloro--bromopropiophenone
(3.18) was then reacted with t-butylamine in a mixture of N-methyl-2-pyrrolidine (NMP) and
toluene to obtain the free base of bupropion, which was subsequently converted to the HCl salt
((±)-1.20) in 75% overall yield and 100% purity.
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Scheme 3.8. Commercially scalable synthesis of racemic bupropion ((±)-1.20) reported by Reddy et al., 2010.

As a logical application to this known chemistry, Carroll and coworkers synthesized a
number of racemic bupropion analogs as fumarate salts ((±)-1.35 - (±)-1.43) for investigation as
potential pharmacotherapies for cocaine addiction and smoking cessation (Carroll et al., 2009
and 2010). In particular, the general reaction scheme for synthesizing these analogs is outlined
in the Scheme 3.9 and utilizes strategies and reactions conditions previously discussed in this
chapter.

Scheme 3.9. General synthetic scheme reported by Carroll and coworkers (Carroll et al., 2009 and 2010) for the
synthesis of bupropion analogs ((±)-1.35 - (±)-1.43).

In a lengthy, but rather unique process as ‘proof-of-principle’, Amarante and coworkers
reported a seven-step synthesis of racemic bupropion in 27% overall yield using Morita-Baylis83

Hillman (MBH) adducts (Scheme 3.10) (Amarante et al., 2008 and 2011). This method began
with MBH acid (±)-3.28, derived in almost quantitative yield using 3 steps starting from 3chlorobenzaldehyde (3.25). MBH acid (±)-3.28 was then treated with ethyl chloroformate to
form a carbonate derivative, which was converted to an acyl azide intermediate by reaction with
sodium azide. The acylazide intermediate was then subjected to Curtius rearrangement by
refluxing in toluene for 2 hours, followed by 12 hr reflux in water to obtain acyloin (±)-3.29 in
45% yield. In turn, acyloin (±)-3.29 was subjected to keto-reduction, deprotection, and selective
-oxidation to provide -hydroxyketone derivative (±)-3.32, which was treated with triflic
anhydride and 2,6-lutidine at -78oC to form the corresponding -ketotriflate derivative in situ,
which upon stirring at -40oC followed by t-butylamine addition provided racemic bupropion
((±)-1.20) in 75% yield.

Scheme 3.10. Synthesis of racemic bupropion ((±)-1.20) from Morita-Baylis-Hillman adduct 3.26 (Amarante et al.,
2008 and 2011).
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Synthesis of the optically pure enantiomers of bupropion has been accomplished via
several methods. Musso and colleagues attempted to resolve racemic bupropion ((±)-1.20) via
recrystallization of the corresponding diastereomeric salts by employing chiral acids such as (+)and (-)-tartaric acid (Musso et al., 1993). However, this conventional resolution method was
unsuccessful because of the ability of chiral aminoketones to racemize in the absence of strong
acids (Berrang et al., 1982). In order to overcome this problem, these researchers first reduced
the aminoketone moiety of racemic bupropion to the corresponding chiral amino alcohols ((±)threo-1.55 and (±)-erythro-1.55) using BH3-THF (Scheme 3.11) (Musso et al., 1993 and 1997).

Scheme 3.11. Synthesis of optically-pure bupropion enantiomers via aminoalcohol derivative 1.55 (Musso et al.,
1993).

Racemic amino alcohols (±)-1.55 (R,R; threo) and (±)-1.55 (R,S; erythro) were then
separated via preparative liquid chromatography (Musso and Mehta, 1981).

Subsequent

resolution of (±)-1.55 (R,R; threo) was accomplished via distereomeric salt formation with (+)85

and (-)-tartaric acid, followed by recrystallization.

Swern oxidation of the corresponding

enantiomeric amino alcohols then successfully provided both enantiomers of bupropion in
approximately 50% yield each.
However, the most efficient route for obtaining the enantiomers of bupropion is via
asymmetric synthesis employing readily accessible enantiopure -hydroxy ketones (S)-3.32 and
(R)-3.32 as key intermediates, which are synthesized via Sharpless’s asymmetric dihydroxylation
of silyl enol ether 3.35 (Scheme 3.12) (Fang et al., 2000). During this work, 3’-chlorophenyl
propanone (3.16) was first converted to its corresponding enolate by treatment with LDA and
trapped by reaction with TBSCl. The resulting enantiopure -hydroxyphenylketones (S)-3.32
and (R)-3.32 were then obtained via Sharpless’s asymmetric dihydroxylation in 82% overall
yield

with

98%

and

99%

ee,

respectively.

Subsequently,

enantiopure

(R)--

hydroxyphenylketone (R)-3.32 was converted to ketotriflate intermediate (R)-3.36, which was
then subjected to nucleophilic attack by t-butylamine, proceeding with complete inversion of
chemistry to provide (S)-bupropion in 98% ee (Scheme 3.13). In turn, (R)-bupropion was
obtained in an analogous manner starting with (S)-3.32.

Scheme 3.12. Asymmetric synthesis of enantiomerically pure keto alcohols (S)-3.32 and (R)-3.32 via Sharpless
dihydroxylation (Fang et al., 2000).
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Scheme 3.13. Asymmetric synthesis of bupropion enantiomer (S)-1.19 according to Fang et al., 2000.

3.3. Review of Synthetic Approaches for (2S,3S)-Hydroxybupropion as a Lead Compound
for DAT and nAChR Photoprobe Design
Since the free base and HCl salt of bupropion are prone to undergo racemization readily,
considerable attention has been focused on the synthesis of bupropion’s most active and
conformationally stable metabolite, (2S,3S)-hydroxybupropion (1.54). In particular, treatment of
(R)--hydroxyketone (R)-3.32 with trifluoroacetic anhydride, followed by reaction with 2amino-2-methyl-1-propanol, gives (2S,3S)-hydroxybupropion 1.54 in 98% ee (Scheme 3.14)
(Fang et al., 2000). Additionally, attempts to isolate optically pure (2S,3S)-hydroxybupropion
((2S,3S)-1.54) via resolution of diastereomeric salts employing chiral acids have been reported.
However, asymmetric synthesis remains the most widely used route for accessing pure (2S,3S)hydroxybupropion (Fang et al., 2001 and 2002; Jerussi et al., 2000). Furthermore, Lukas and
other groups have reported a wide range of (2S,3S)-hydroxybupropion analogs following a
similar synthetic strategy (Carroll, Blough, et al., 2011; Carroll, Muresan, et al., 2011; Lukas et
al., 2010).

Scheme 3.14. Asymmetric synthesis of (2S,2S)-hydroxybupropion (1.54) reported by Fang et al., 2000.
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3.4. Review of Synthetic Approaches for Racemic BINA as a Lead Compound for mGlu2
Photoprobe Design
Biphenyl-carboxylic acid indanone (±)-1.71 and several of its analogs emerged from
SAR efforts based on a combination of compounds identified from high throughput screening
(Bonnefous et al., 2005; Pinkerton et al., 2005). These compounds were synthesized following
the synthetic route outlined in Scheme 3.15 (Pinkerton et al., 2006; Sidique et al., 2012).

Scheme 3.15. Synthesis of BINA ((±)-1.71) and some of its analogs (Bonnefous et al., 2005).

As depicted, Bonnefous and coworkers (Bonnefous et al., 2005) first synthesized boronic
ester intermediate (±)-3.41 via O-alkylation of known hydroxy indanone (±)-3.40 (Woltersdorf et
al., 1977; DeSolms et al., 1978) with 2-[3-(bromomethyl)phenyl]-5,5-dimethyl-1,3,2dioxaborinane (3.39) (Scheme 3.15). Subsequent Suzuki coupling of benzyl ether (±)-3.41 with
substituted aryl bromides (3.47) then gave ester derivatives (±)-3.42 – (±)-3.44. The final
products ((±)-1.71, (±)-1.74, (±)-1.75) were then obtained by ester hydrolysis using aqueous
LiOH.
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In an alternate scheme, Galici and colleagues synthesized BINA in 9 steps with 16%
overall yield (Galici et al., 2006). This approach featured initial synthesis of 3-toluoyl zinc
bromide 3.49 by treating 3-bromotoluene with n-butyl lithium and zinc chloride (Scheme 3.16).
Simultaneously,

4-ethoxycarbonylphenyl-bis(triphenylphosphine)

palladium

(3.52)

was

synthesized from ethyl 4-iodobenzoate and bis(triphenylphosphine)palladium dichloride.
According to conditions in a previous report (Klein et al., 1998), compounds 3.49 and 3.52 were
then combined to form key building block 3.50 (Scheme 3.16).

Scheme 3.16. Synthesis of intermediate 3.50 for the preparation of BINA (Galici et al., 2006).

Free radical bromination of biphenyl 3.50 using N-bromosuccinimide in the presence of
AIBN produced benzyl bromide 3.53 in 86% yield (Scheme 3.17). Subsequent O-alkylation of
known hydroxy-indanone (±)-3.40 (Bonnefous et al., 2005; DeSolms et al., 1978; Woltersdorf et
al., 1977) with benzyl bromide 3.53 then provided ether (±)-3.42, whose ester was hydrolyzed
with 2N NaOH to provide BINA ((±)-1.71) in 63% yield.
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Scheme 3.17. Synthesis of BINA ((±)-1.71) according to Galici et al., 2006.

3.5. Review of Synthetic Approaches for 1,5-Substituted Pyridones as Lead Compounds
for mGlu2 Photoprobe Design
Using a high throughput screening FLIPR (fluorimetric image plate reader) assay, Addex
Pharmaceuticals discovered several 1,5-substituted pyridones as moderately potent and selective
mGlu2 PAMs (Cid et al., 2010). Further SAR was developed by sequential modification of
substituents at positions 1 and 5 of the pyridone ring, from which compound 1.89 emerged as the
most potent mGlu2 PAM from their studies (Cid et al., 2010; Imogai et al., 2006). Compound
1.89 was synthesized via a simple 3-step synthetic route depicted in Scheme 3.18.

First,

bromohydroxy pyridine 3.55 was N-alkylated with benzyl bromide 3.56 to provide pyridone 3.57
in 79% yield. Subsequent Suzuki coupling with the para boronic acid derivative of anisole
(3.58) then provided mGlu2 PAM 1.89 in 30% yield.
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Scheme 3.18. Synthesis of pyridone lead compound 1.89 by Cid et al., 2010.

Several compounds with modifications at the 5-phenyl substituent could then be
synthesized as shown in Scheme 3.19. For example, deprotection of methyl ether 1.89 using
BBr3 provided phenol analog 3.59 in 83%.

Subsequent O-alkylation under microwave

conditions then provided acetophenone 1.93 in 34% yield.

Scheme 3.19. Synthesis of an acetophenone-containing pyridone (1.93) reported by Cid et al., 2010.
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CHAPTER FOUR
4. Statement of Research Problems
4.1. Current Knowledge Gaps
4.1.1. DAT Structure-Function Knowledge Gap
Despite the emergence of several LeuT-based DAT homology models (e.g., Koldsoe et
al., 2013; Stockner et al., 2013; Seddik et al., 2013; Gedeon et al., 2010; Huang and Zhan, 2007;
Huang et al., 2009; Indarte et al., 2008) and the identification of a plethora of DAT-interactive
compounds (reviewed in Runyon and Carroll, 2006), details regarding the transport inhibition
mechanism, structural elements, conformational states, and ligand-binding sites associated with
the DAT remain poorly understood. In particular, it is still not clear how the DAT discriminates
substrates (e.g., dopamine, amphetamines), inhibitors (e.g., cocaine, bupropion, methylphenidate,
GBR-12909, pyrovalerone), highly abused compounds (e.g., cocaine, amphetamines,
cathinones), and therapeutic compounds (e.g., bupropion, methylphenidate) at the molecular
level. Furthermore, establishment of the non-covalent interactions that dictate a given DAT
ligand’s pharmacological profile (e.g., affinity, selectivity, potency, behavioral phenotype, etc.)
have yet to be achieved. Answers to these research questions remain unknown principally due to
the absence of human DAT x-ray crystal structures and incomplete structure-function
characterization of proposed ligand-binding sites within the DAT. In turn, this lack of 3-D DAT
structural knowledge significantly compromises our understanding of the neuronal mechanisms
underlying numerous disease states associated with the DAT (reviewed in Vaughan and Foster,
2013 and Mash, 2008), which include Parkinson’s disease, Alzheimer’s disease, normal aging,
schizophrenia, Tourette’s syndrome, Lesch-Nyhan disease, attention deficit hyperactivity
disorder (ADHD), obesity, depression, and stimulant abuse.
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4.1.2. mGlu2 Structure-Function Knowledge Gap
Analogous to DAT ligands, positive allosteric modulators of mGlu2 represent promising
drug candidates for a number of disease states including schizophrenia (Fell et al., 2012), drug
abuse (Moussawi and Kalivas, 2010), impaired cognition, and depression (Goeldner et al., 2013).
Likewise, there are a multitude of compounds known to modulate mGlu2 in a positive allosteric
manner (reviewed in Trabanco et al., 2011; Trabanco and Cid, 2013). However, very few
studies have been disclosed with respect to structure-function characterization of allosteric sites
within mGlu2 (Lundstrom et al., 2011; Schaffhauser et al., 2003). Furthermore, and in very
sharp contrast to the DAT field where homology modeling is well established, currently there is
only one recently disclosed low-resolution homology model of the transmembrane domain of
mGlu2 (Radchenko et al., 2014).
Collectively, challenges associated with developing mGlu2 PAMs for clinical use (e.g.,
biased signaling (Kenakin, 2012), molecular switches (Wood et al., 2011), desired higher
selectivity with durable pharmacological effects under repeated dosing (Trabanco and Cid, 2013)
can be attributed to the affinity and / or cooperativity of mGlu2 PAMs, which are dictated by
specific non-covalent interactions within distinct mGlu2 binding sites.

However, our

understanding of mechanistic and / or conformational mGlu2 structure-function relationships is
grossly lacking when compared to other well-studied mGlu receptor subtypes such as mGlu5
(Dalton et al., 2014). Additionally, experimental strategies that further refine and validate the
recently disclosed mGlu2 homology model are sorely needed. In short, elucidation of the
molecular determinants for mGlu2 allosteric modulator affinity, selectivity, potency, and
cooperativity represents a key knowledge gap that must be resolved if we are to understand the
inherent complexities of these compounds that hinder their rational development into
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therapeutics. Furthermore, and much like the DAT inhibitor field, transition of the design and
development of mGlu2 PAMs from a ligand- to a structure-based perspective would represent a
major advance and no doubt spur further research.

4.1.3. nAChR Structure-Function Knowledge Gap
The implication of neuronal nAChRs in mediating reward, tolerance, dependence, and
sensitization-producing effects associated with drugs of abuse (De Biasi and Dani, 2011;
Hendrickson et al., 2013; Rahman, 2013) has led to multiple drug discovery efforts in finding
ligands targeting nAChRs for smoking cessation (Crooks et al., 2014), alcohol abuse (Rhaman
and Prendergast, 2012), and psychostimulant addiction (Pubill et al., 2011). Bupropion’s antidepressant and smoking-cessation effects have been mainly attributed to its inhibition of the
DAT and NET; however, there is increasing evidence that bupropion non-competitively inhibits
several nAChR subtypes, particularly 42 and 34, and modulation of these targets may also
contribute to the drug’s therapeutic efficacy (Arias, 2009 and 2010; Carroll et al., 2014).
Additionally, varenicline (Chantix) is a 42 nAChR partial agonist FDA approved for smoking
cessation, thus providing additional substantial evidence of involvement of this receptor subtype
in nicotine addiction (Coe et al., 2005; Crunelle et al., 2010). Despite its status as an FDAapproved drug for major depressive disorder, seasonal affective disorder, and aid to help people
stop smoking by reducing cravings and other withdrawal effects, the molecular determinants of
how bupropion interacts with its major drug targets, including the DAT and select nAChR
subtypes, remains unknown. As a result, in order to identify improved therapeutics targeting
these proteins, it is important to understand, in detail, how clinically approved ligands like
bupropion interact with binding sites within the DAT and select nAChR subtypes.
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This

information is currently lacking in the nAChR field due to the unavailability of high-resolution
x-ray crystal structures of human 42 and 34 nAChR subtypes. Despite predictions that
bupropion binds near the middle of the nAChR ion channel between M2-6 and M2-13 from
molecular dynamics and docking simulations (Arias et al., 2009; Arias, 2010), currently there is
a dearth of direct experimental evidence regarding the location of bupropion-binding sites within
the DAT and select nAChR subtypes.

4.2. Long-Term Goal of This Research
The long-term goal of this research is to understand how the pharmacology profile (i.e.,
affinity, selectivity, potency, behavioral phenotype, etc.) of clinically relevant lead compounds
(e.g., bupropion, BINA) is dictated by the three-dimensional interactions that occur when these
compounds non-covalently interact with their major drug targets (e.g., the DAT, mGlu2, and
select nAChR subtypes) at the molecular level.

This information is expected to facilitate

improved rational, structure-based manipulation and discovery of lead compounds in order to
obtain improved therapeutics for numerous disease states associated with these proteins,
including drug abuse and addiction.

4.3. Overall Objective of This Research Dissertation
The overall objective of this research dissertation was to rationally design and chemically
synthesize irreversible chemical probes based on promising anti-addiction lead compounds (e.g.,
pyrovalerone, bupropion, BINA) in order to map the binding sites and poses of these compounds
within their proposed major drug targets (i.e., the DAT, α4β2 nAChR, α3β4 nAChR, or mGlu2).
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4.4. Central Hypothesis of This Research Dissertation
The central hypothesis of this research dissertation was that appropriate anti-addiction
lead compounds (i.e., pyrovalerone, bupropion and BINA) could be rationally derivatized
without significant alteration in their pharmacological activity to contain both a photoreactive
group (PRG) and a tag for application of a “Binding Ensemble Profiling with (f)Photoaffinity
Labeling (BEProFL)” experimental approach (He et al., 2009).

In particular, BEProFL

sequentially and rationally couples photoaffinity labeling, chemical proteomics, and
computational molecular modeling in order to map the binding poses and sites of lead
compounds within a target protein (Scheme 4.1).

Scheme 4.1. Schematic representation of the BEProFL experimental approach in order to map the ligand-binding
poses and sites of anti-addiction lead compounds within the human DAT, mGlu2, or a select nAChR subtype.

BEProFL has been successfully used to understand the binding modes of histone
deacetylase (HDAC) inhibitors as epigenetic modulators (Abdelkarim et al., 2013; Vaidya et al.,
2012; Neelarapu et al., 2011, He et al., 2009) and to probe the microenvironment of fatty acid
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amide hydrolase (FAAH) as a drug target implicated for the development of pain therapeutics
(Saario et al., 2012). In general, the coupling of photoaffinity labeling, chemical proteomics, and
computational molecular modeling via BEProFL has been proposed as a unique and powerful
way to analyze the binding of ligands to their macromolecular drug targets (He et al., 2009). In
particular, BEProFL expands the data typically obtained in protein x-ray crystallography.
Furthermore, this experimental approach serves as a viable alternative towards understanding
protein structure-function relationships at the molecular level when co-crystallization of a target
protein with a ligand of interest has failed, as is frequently the case with membrane-bound
proteins such as transporters and GPCRs. Importantly, the ligand-binding poses determined by
BEProFL are determined in solution, thus the “snapshots” generated by this experimental
approach arguably reflect the dynamic nature of ligand-macromolecular drug target
conformations in a more accurate manner. Finally, BEProFL has the potential to guide future
ligand optimization and is poised to contribute to multiple disciplines including molecular
modeling, validation, development, and application of computer-aided drug design methods,
especially those for rapid prediction of ligand-protein interactions such as scoring and docking.

4.5. Rationale of This Research Dissertation
The rationale that underlies this research dissertation is that, once it is known how
promising anti-addiction lead compounds (e.g., pyrovalerone, bupropion, BINA) interact with
their major drug targets (i.e., the DAT, α4β2 nAChR, α3β4 nAChR, or mGlu2) in a threedimensional manner at the molecular level, this information can then be rationally exploited to
manipulate lead compounds into drug candidates via structure-based drug design in order to
improve therapeutic outcomes associated with disease states linked to these proteins.
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Additionally, detailed, 3-D structural information generated by application of the BEProFL
approach to the DAT, α4β2 nAChR, α3β4 nAChR, or mGlu2 is also expected to aid in the
building, refinement, and experimental validation of reliable computer-generated molecular
models of these proteins, thus providing an improved template for powerful, structure-based in
silico / virtual screening of millions of candidate therapeutic compounds for drug discovery and
development (e.g., see Nolan et al., 2011; Indarte et al., 2010; Mahasenan et al., 2011).

4.6. Rational Design of Pyrovalerone-Based Photoprobes for DAT Structure-Function
Studies
As previously introduced in Section 1.4.2.2.3., pyrovalerone ((±)-1.19; PV; Scheme 4.2)
is a high affinity and potent DAT inhibitor (DAT Ki = 21.4 ± 4.6 nM; DA uptake IC50 = 52.0 ±
20 nM) and NET inhibitor (NET Ki = 195 ± 26 nM; NE uptake IC50 = 28.3 ± 8.1 nM) with little
effect on serotonin trafficking (SERT Ki = 3770 ± 560 nM; SER uptake IC50 = 2780 ± 590 nM)
(pharmacology data from Meltzer et al., 2006). Additionally, being structurally similar to
rapidly emerging, highly abusive designer cathinones (also called “bath salts”; Simmler et al.,
2013; Zawilska and Wojcieszak, 2013; Bonano et al., 2014; Glennon, 2014), pyrovalerone
possesses significant abuse and addiction liability. In particular, pyrovalerone is known to
produce psychostimulant effects similar to amphetamine in humans (Holliday et al., 1964) and is
a schedule V controlled substance in the United States.
As previously mentioned, the binding site(s) and conformational preference(s) for
pyrovalerone in its major drug target, the DAT, are largely unknown, thus representing a
significant knowledge gap in terms of understanding the molecular basis of addiction and abuse
associated with this compound and related cathinones. This prompted rational design and
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synthesis of photoprobes based on PV (Lapinsky et al., 2009) in order to address this important
knowledge gap via DAT structure-function studies.
It should be noted that the overwhelming majority of DAT irreversible ligands prior to
this dissertation were designed such that the photoreactive aryl azide group was some distance
away from the inhibitor pharmacophore via the employment of conformationally flexible,
variable-length methylene linkers (e.g., see [125I]-MFZ-2-24, 4.7 in Figure 4.1 where the azide
functional group is predicted to be 10.5 Angstroms from the tropane pharmacophore nitrogen as
calculated by molecular modeling (Zhou et al., 2001; Parnas et al., 2008). In particular, the
covalent point of photoprobe attachment to a protein is directly dictated by the location of the
photoreactive functional group with respect to a ligand pharmacophore. As a result, when a
photoreactive functional group is somewhat removed from a ligand’s pharmacophore by means
of a conformationally flexible, variable-length methylene linker, adduction to a target protein
may occur at a residue near, but not at, a direct ligand pharmacophore-protein contact point. As
a result, employment of conformationally flexible, variable-length methylene linkers in
irreversible chemical probe design strategy creates distinct disadvantages when trying to
definitively map the amino acids of a ligand-binding pocket or optimally model a photoprobeprotein complex via BEProFL. Furthermore, prior to this dissertation the overwhelming majority
of known DAT irreversible ligands (see Figure 4.1 for examples) were based on tropanecontaining compounds (e.g., see Carroll et al., 1992; Agoston et al., 1997; Lever et al., 2005;
Newman et al., 2006; Vaughan et al., 2007; Murthy et al., 2008; Dahal et al., 2014) or their
conformationally flexible piperidine- or piperazine-based analogues (e.g, see Grigoriadis et al.,
1989; Sallee et al., 1989; Dutta, et al., 2001; Cao et al., 2004), whereas non-tropane DAT
irreversible ligands had yet to be examined.
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Figure 4.1. Photoaffinity probes based on tropane-, piperidine- and piperizine-containing DAT inhibitors featuring
aromatic 4-azido-3-iodo ring substituted motif.

Given these previous literature observations, this research dissertation features the design
and synthesis of three compact photoprobes ((±)-4.16 – (±)-4.18) based on PV as a non-tropane
DAT inhibitor (Scheme 4.2). These novel photoprobes were significantly unique at the time of
their design and chemical synthesis given they represented the very first examples of compact
non-tropane photoaffinity ligands for DAT structure-function studies wherein the photoreactive
group was placed directly on the inhibitor pharmacophore (i.e., bearing no linker functionality).
Such photoprobes are expected to covalently attach to an amino acid residue directly within the
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pyrovalerone-binding pocket of the DAT and also result in a more conformationally restricted
photoprobe-DAT complex in 3-D hDAT molecular modeling studies.

In particular, PV

photoprobes (±)-4.16 – (±)-4.18 in Scheme 4.2 were rationally designed based on known DAT
binding affinity data for a host of pyrovalerone analogs previously reported in the chemical
literature.

Scheme 4.2. Rational design of azido-iodo-PV photoprobes (±)-4.16 – (±)-4.18 as photoaffinity ligands for DAT
structure-function studies via isosteric replacement.

According to the DAT binding affinity SAR reported (Meltzer et al., 2006), the 3- and 4positions of the phenyl ring of PV appeared tolerable to a variety of functional groups in terms
maintaining significant DAT binding affinity for potential photoprobe design (see Section
1.4.2.2.3 for more pyrovalerone SAR details). Initially, dichloro-substituted pyrovalerone analog
(±)-1.28 (Scheme 4.2) was chosen as an appropriate lead compound for DAT photoprobe design
given this compound displayed the highest DAT binding affinity within a series of aromatic ring101

substituted analogs pharmacologically tested by Meltzer and coworkers (DAT Ki for (±)-1.28 =
11.5 ± 1.4 nM; Meltzer et al., 2006). Target DAT photoprobes (±)-4.16 to (±)-4.18 were then
rationally designed by systematic replacement of the chlorine atoms within lead compound (±)1.28 with a photoreactive azide and iodine atom at the 3- and 4-positions (Scheme 4.2). The
iodine atom was viewed as a classical bioisostere of the chlorine atom (Brown, 2014) given both
atoms are halogens and lipophilic. Additionally, the location of the iodine atoms within the
target photoprobes were also viewed as natural positions for potential substitution with an
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radiotracer for detection during proteomic experiments. Furthermore, the photoreactive aryl
azide functional group has been suggested as an isostere for aryl chlorine atoms given both
functional groups display similar hydrophobic properties (He et al., 2009).
Additionally, target

pyrovalerone-based DAT photoprobe

(±)-4.16 features

a

photoreactive aryl azide functional group at the 4-position of the aromatic ring and an iodine
atom at the 3-position, whereas these functional groups are flip-flopped in target photoprobe (±)4.17 (Scheme 4.2). The rational design behind these particular photoprobes is that each probe
could potentially covalently react with a different amino acid within the DAT pyrovaleronebinding site given their aryl azides are located at different positions on the pyrovalerone scaffold.
In turn, such photoprobes would then be expected to give finer details of the DAT pyrovaleronebinding site upon microlevel characterization. In particular, target DAT pyrovalerone-based
photoprobe (±)-4.18 was pursued as a potential higher DAT binding affinity, branched-side chain
analog of target photoprobe (±)-4.16 (Scheme 4.2) given the observation that branched-side
chain PV analog (±)-4.15 displays ~1.6-fold higher DAT binding affinity than pyrovalerone,
which contains an n-propyl side chain (DAT Ki for (±)-4.15 = 13.7 ± 3 nM versus DAT Ki for
PV = 21.4 ± 4.6 nM; Meltzer et al., 2006).
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Target pyrovalerone-based DAT photoprobes (±)-4.16 to (±)-4.18 were synthesized as
described in Section 5.1 and sent for pharmacological determination of their DAT binding
affinities in N2A neuroblastoma cells. In particular, photoprobe (±)-4.16 was characterized as a
promising compound for DAT photoaffinity labeling studies given the DAT binding affinity of
this compound was <100 nM and within 10-fold of parent compound (±)-1.19 (DAT Ki = 78 ±
18 nM for (±)-4.16 versus DAT Ki = 8 ± 2 nM for (±)-1.19 represents an ~9.8-fold loss in DAT
binding affinity; Lapinsky et al., 2009). Finally, an
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I version of compound (±)-4.16 was

synthesized and shown to bind specifically and irreversibly to rDAT and hDAT upon UV
irradiation in the absence or presence of cocaine as a competitor (Lapinsky et al., 2009) (see
Appendix, Section A.1).

4.7. Rational Design of Bupropion-Based Photoprobes for DAT and nAChR StructureFunction Studies

Figure 4.2. The chemical structure of bupropion ((±)-1.20, Wellbutrin, Zyban), a DAT, NET, and nAChR inhibitor.

Bupropion ((±)-1.20, Figure 4.2) is a well-known, FDA approved drug for the treatment
of major depressive disorder and seasonal affective disorder (marketed as Wellbutrin; Dhillon et
al., 2008), and is also used to help people stop smoking by reducing cravings and other
withdrawal effects (marketed as Zyban).

It is well established that bupropion exerts its

therapeutic effects mainly by binding to and inhibiting the DAT and NET as neurotransmitter
reuptake transporters, thus increasing the synaptic concentrations of dopamine (DA) and
103

norepinephrine (NE), respectively, in key areas of the brain associated with these disease states
(Sasse et al., 2008). In addition, another widely accepted mechanism of action of bupropion is
noncompetitive antagonism of select nAChR subtypes, mainly 42 and 34 (Arias, 2009).
It should be noted that at the initiation of this dissertation research, bupropion was
disclosed as a clinically promising lead compound for potential development into a
pharmacotherapeutic for cocaine and methamphetamine dependence (Elkashef et al., 2008;
Reichel et al., 2009; Heinzerling et al., 2014). As a result and concomitant to this dissertation
research, a number of bupropion analogs were chemically synthesized and pharmacologically
evaluated as potential treatments for cocaine and methamphetamine dependence in addition to
smoking cessation (Carroll et al., 2009, 2010, and 2014). However, despite its clinical success
as a routinely prescribed antidepressant and smoking cessation agent, plus its significant promise
as a lead compound for the development of cocaine and methamphetamine dependence
therapeutics, the specific non-covalent interactions bupropion has with its major drug targets
remain poorly understood. As a result, it is imperative to elucidate the high-resolution structural
features of bupropion’s binding sites within its major target proteins in order to improve health
outcomes. In particular with respect to the DAT, high quality structure-function information
would be expected to help our understanding of the molecular basis of how this protein
discriminates high addiction liability compounds (e.g., methamphetamine, pyrovalerone, and
cocaine) from therapeutic compounds (e.g., bupropion), despite these compounds having several
shared structural features. With these thoughts in mind, bupropion-based photoprobes were
rationally designed and chemically synthesized for mapping the binding sites and poses of
bupropion within the DAT, the 42 nAChR, and the 34 nAChR (as the drug’s major targets)
via BEProFL.
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4.7.1. Rational Design of 4-Azido-3-Iodo-Bupropion as a Photoprobe for DAT and nAChR
Structure-Function Studies
As previously mentioned, Carroll and coworkers have prepared numerous bupropion
analogs with various substituents on the phenyl ring, as well as side chain analogs (for detailed
SAR studies of bupropion, see Section 1.4.2.2.4) (Carroll et al., 2009, 2010, and 2014). Given
dichloro-substituted compound (±)-1.43 (Scheme 4.3) displayed 1.8-fold higher DAT binding
affinity than bupropion, this particular bupropion analog was chosen as a lead compound for
rational photoprobe design (hDAT Ki = 472 ± 81 nM for (±)-1.43; hDAT Ki = 871 ± 126 nM for
bupropion; Carroll et al., 2009). Once again and now based on previous DAT labeling success
of structurally similar 4-azido-3-iodo-PV photoprobe (±)-4.16 (Scheme 4.2) (Lapinsky et al.,
2009), which features an n-propyl side chain instead of a methyl side chain and a tertiary cyclic
amine instead of secondary tert-butyl amine (when structurally compared to bupropion), target
bupropion photoprobe (±)-4.20 was rationally designed by isosteric replacement of chlorine
atoms in lead compound (±)-1.43 with a hydrophobic iodine at the 3-position and a hydrophobic,
photoreactive azide at the 4-position of the aromatic ring (Scheme 4.3).

Scheme 4.3. Rational design of target bupropion-based photoprobe (±)-4.20 for DAT and nAChR structurefunction studies based on known analog (±)-1.43 (Carroll et al., 2009).
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Target bupropion-based photoprobe (±)-4.20 was synthesized as described in Section
5.2.1 and its hDAT and 42 nAChR binding affinity were determined (Lapinsky et al., 2012).
In particular, the DAT binding affinity of target compound (±)-4.20 was found to be 7-fold lower
than bupropion (hDAT Ki = 3071 ± 497 nM for (±)-4.20; hDAT Ki = 441 ± 174 nM for
bupropion).

Furthermore, (±)-bupropion inhibited (±)-[125I]-4.20 binding to human 42

nAChRs with an IC50 value of 8.3 M (Lapinsky et al., 2012). Additionally, photoreactive
bupropion analog (±)-4.20 was characterized at different muscle nicotinic acetylcholine receptors
and subjected to molecular docking studies (Arias et al., 2012). In short, collected results from
this work were consistent with a model where bupropion, photoreactive analog (±)-4.20, and
thienycyclohexylpiperidine bind to overlapping sites within the lumen of muscle AChR ion
channels. Furthermore, it was suggested that (±)-4.20 represents a promising photoprobe for
mapping the bupropion-binding site, especially within the resting AChR ion channel.
Even though target photoprobe (±)-4.20 displayed modest DAT and 42 nAChR
binding affinity when compared to bupropion, this compound still met one of our criteria for
identifying candidates for preliminary photoaffinity labeling experiments; namely, no more than
10-fold lower binding affinity when compared to an appropriate parent compound. As a result,
photoprobe (±)-4.20 was advanced to preliminary DAT and nAChR photoaffinity labeling
experiments. Photoprobe (±)-[125I]-4.20 was shown to bind covalently to hDAT expressed in
cultured cells and affinity-purified, lipid-reincorporated human 42 neuronal nAChRs
(Lapinsky et al., 2012).

Additionally, fragmentation studies of the (±)-[125I]-4.20-nAChR

binding site complex subsequently led to the identification of the exact point of covalent probe
attachment to the Torpedo nAChR transmembrane domain (Pandhare et al., 2012) (see
Appendix, Section A.2 for more details).
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4.7.2. Rational Design of 3-Iodo-Bupropion as a Potentially Photoreactive AcetophenoneBased Probe
Despite successful photoaffinity labeling results achieved with bupropion-based
photoprobe (±)-[125I]-4.20 (Lapinsky et al., 2012; Pandhare et al., 2012), this compound raised a
potential issue of concern.

In particular, photoprobe (±)-[125I]-4.20 not only contains a

photoreactive aryl azide group, but also is an example of an acetophenone derivative, which
represents another potential photoreactive functional group (Lukac et al., 2009). As a result,
discrepancy could potentially arise in terms of discerning the exact point of covalent attachment
of (±)-[125I]-4.20 to a protein after photoaffinity labeling. Therefore, in order to experimentally
investigate this potential discrepancy, target compound (±)-4.21 (Figure 4.3) was rationally
designed to remove any ambiguity during proteomics after photoaffinity labeling, and also to test
whether the iodo isostere of bupropion could function as a natural acetophenone-based
photoprobe. Additionally, a tri-n-butyl stannyl version (±)-4.22 was synthesized as described in
Section 5.2.2 as a precursor to the 125I analog of (±)-4.21 via radio-iodo destannylation. In short,
(±)-[125I]-4.21 was unable to covalently label the Torpedo nAChR using identical photoreaction
conditions to that previously described for (±)-[125I]-4.20 (Pandhare et al., 2012), thus suggesting
the aryl azide in (±)-[125I]-4.20 was the functional group responsible for covalent attachment of
this probe to the Torpedo nAChR, not the acetophenone moiety (see Appendix, Section A.3).

Figure 4.3. Compound (±)-4.21 contains a potentially photoreactive acetophenone moiety and is the iodo isostere
of bupropion.
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4.7.3.

Rational Design of 4-Azido-3-Iodo-Hydroxybupropion as a Potential DAT and

nAChR Photoprobe for Structure-Function Studies
Hydroxybupropion, a major metabolite of bupropion, is believed to contribute to the
antidepressant and smoking cessation activity of bupropion. In particular, it has been observed
that the (2S,3S)-hydroxy enantiomer is significantly more pharmacologically active than other
hydroxybupropion enantiomers in a number of behavioral-, monoamine-, and nAChR-based
pharmacological assays (Damaj et al., 2004 and 2010). Furthermore, hydroxybupropion displays
higher potency and a longer elimination half-life than bupropion (Yeniceli et al., 2011; Parekh et
al., 2012; Laib et al., 2014). Due to its clinical significance, a number of hydroxybupropion
analogs have also been pursued in the search for better drugs for treatment of nicotine addiction
(Lukas et al., 2010; Carroll et al., 2011) (for detailed SAR studies of hydroxybupropion, see
Section 1.6.4). As a result and given the previous photolabeling successes with pyrovalerone
probe (±)-[125I]-4.16 (Lapinsky et al., 2009) and bupropion probe (±)-[125I]-4.20 (Lapinsky et al.,
2012; Pandhare et al., 2012), hydroxybupropion represented an additional logical scaffold for
photoprobe development. In particular, it is known that racemic dichlorohydroxybupropion
analog

(±)-(2S,3S)-1.62

(Scheme

4.4)

is

significantly

more

potent

than

(2S,3S)-

hydroxybupropion in terms of dopamine uptake inhibition (IC50 = 70 ± 20 nM for racemic (±)(2S,3S)-1.62; IC50 = 630 ± 50 nM for (2S,3S)-hydroxybupropion; binding affinities for these
compounds, which are traditionally used for photoprobe design, were not reported; Lukas et al.,
2010) and inhibition of 34 nAChR function (IC50 = 2.6 M for racemic (±)-(2S,3S)-1.62; IC50
= 11 M for (2S,3S)-hydroxybupropion; once again, binding affinities for these compounds,
which are traditionally used for photoprobe design, were not reported; Lukas et al., 2010).
Therefore, analogous to that previously described for rational design of pyrovalerone probe (±)-
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[125I]-4.16 (Section 4.6) and bupropion probe (±)-[125I]-4.20 (Section 4.7.1), target bupropion
metabolite photoprobe (2S,3S)-4.23 was rationally designed using dichlorohydroxybupropion
analog (±)-(2S,3S)-1.62 as a lead compound and azido-iodo isosteric replacement (Scheme 4.4).
The synthesis of target bupropion metabolite photoprobe (2S,3S)-4.23 is described in Section
5.2.3.

Scheme 4.4. Design of target photoaffinity probe (2S, 3S)-4.23 based on known bupropion metabolites.

4.8. Rational Design of BINA-Based PAM Photoprobes for mGlu2 Structure-Function
Studies
BINA ((±)-1.71, Figure 4.4) originated from extensive SAR efforts by Merck in an
attempt to improve the physicochemical properties of an initial hit compound discovered via
mGlu2 high-throughput screening (Pinkerton et al., 2005). In particular, BINA is a selective,
brain-penetrant, and potent mGlu2 PAM that produces long-lasting antipsychotic and anxiolytic
effects in various behavioral animal models (Galici et al., 2006). Furthermore, BINA has
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garnered significant attention as a cocaine abuse therapeutic, wherein in vivo studies in rats
showed that the reinforcing and rewarding effects of cocaine were inhibited by BINA (Jin et al.,
2010), and the compound also decreased cue-induced cocaine-seeking behavior without affecting
food-seeking behavior (Dhanya et al., 2011). These initial in vivo results strengthen BINA as a
lead compound for potential development into a therapeutic entity.

Figure 4.4. The chemical structure of BINA ((±)-1.71), a selective mGlu2 PAM (GTPS binding EC50 = 111 nM;
% glutamate potentiation = 114; Bonnefous et al. 2005)

4.8.1. Rational Design of a Clickable BINA-Based mGlu2 PAM Photoprobe for StructureFunction Studies Containing an Inherent Acetophenone Photoreactive Group
In an effort to improve BINA’s physicochemical properties, including bioavailability, a
series of BINA analogs were reported featuring numerous substitutions on the terminal phenyl
ring (Bonnefous et al., 2005) (for a detailed discussion of BINA mGlu2 SAR studies, see Section
1.8.2.1.2).

Analogous to bupropion, BINA contains an acetophenone moiety that could

potentially represent a natural photoreactive compound analogous to other acetophenones (e.g.,
4.26; Scheme 4.5; van Scherpenzeel et al., 2009 and 2010). As a result, we hypothesized that
inclusion of a bioorthogonal / click chemistry handle into an appropriate BINA analog would
result in a compact photoprobe for potential use in mGlu2 BEProFL studies. In this regard,
BINA analog (±)-1.74 (Scheme 4.5; mGlu2 PAM EC50 = 111 nM) bearing a methyl ether at the
6-position was chosen as a lead compound for photoprobe design given the observation that this
compound is 3-fold more potent than BINA as a mGlu2 PAM (hmGluR2 GTP-S EC50 = 111
nM with 114% potentiation for BINA; hmGluR2 GTP-S EC50 = 36 nM with 114% potentiation
110

for (±)-1.74; Bonnefous et al., 2005). As a result and with the aim of retaining high mGlu2
functional potency (note: mGlu2 binding affinities are not reported for mGlu2 PAMs for rational
photoprobe design, given the absence of an appropriate radioligand for competitive
displacement), target photoprobe (±)-4.25 was designed by slight extension of the 6-methoxy
group within BINA analog (±)-1.74 to a clickable propargyl ether terminal alkyne as a click
chemistry handle (Scheme 4.5).

In particular, target compound (±)-4.25 bears a natural

photoreactive acetophenone moiety and represents a compact photoprobe potentially capable of
covalently reacting with an amino acid directly within the mGlu2 BINA-binding site. Target
BINA photoprobe (±)-4.25 was chemically synthesized as described in Section 5.3.2 and sent for
pharmacological evaluation in a mGlu2 functional assay via the Gregory group. In turn, the
mGlu2 PAM functional potency of target photprobe (±)-4.25 measured via Ca2+ mobilization
assay (mGlu2 PAM pEC50 = 6, % glutamate potentiation = 135) proved comparable to the lead
compound (±)-1.74 (mGlu2 PAM pEC50 = 6, % glutamate potentiation = 114) in the
pharmacological assay, thus representing a justifiable candidate for future photoaffinity labeling
studies involving mGlu2 (for further pharmacological details, see Appendix Section A.4).

In

case if it is observed during photoaffinity labeling studies that the acetophenone moeity is not
capable of crosslinking to the mGlu2 binding site due to steric hindrance, as an alternative, the
ketone will be synthetically converted to a diazirine photoactivatable labeling group (Vervacke et
al., 2014) which forms a more reactive carbene intermediate upon photoactivation by UV light.
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Scheme 4.5. Rational design of target BINA-based photoprobe (±)-4.25 for mGlu2 structure-function studies based
on known BINA analog (±)-1.74 (Bonnefous et al., 2005) and known acetophenone-alkyne clickable photoprobe
4.26 (van Scherpenzeel et al., 2010).

4.8.2. Rational Design of a BINA-Based PAM Photoprobe for mGlu2 Structure-Function
Studies That Contains an Aryl Azide as a Photoreactive Group
In an attempt to access an additional clickable compound featuring a photoreactive group
at a different position on the BINA scaffold, target photoprobe (±)-4.27 was rationally designed
as a potential photoaffinity probe for mGlu2 structure-function studies (Scheme 4.6). Target
photoprobe (±)-4.27 features isosteric replacement of the hydrophobic chlorine atom in
functionally potent BINA analog (±)-1.75 with a hydrophobic aryl azide (He et al., 2009). In
particular, support for the design of target photoprobe (±)-4.27 stems from the observation that
BINA analog (±)-1.75 is 4.6-fold more potent than BINA as a mGlu2 PAM (hmGluR2 GTP-S
EC50 = 24 nM with 109% potentiation for compound (±)-1.75; hmGluR2 GTP-S EC50 = 111
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nM with 114% potentiation for BINA; Bonnefous et al., 2005). Furthermore, the underlying
rationale for pursuit of target photoprobe (±)-4.27 is two-fold: 1.) the aryl azide is expected to
have higher probability for successful covalent attachment to mGlu2 versus the acetophenone
based on previous work with bupropion-based photoprobes (see Section 4.7.1); 2.) the aryl azide
photoreactive group is present at the opposite end of the molecule versus alkyne compound (±)4.25, thus allowing one to potentially obtain additional information regarding the BINA-binding
site in mGlu2 when these compounds are used in photoaffinity labeling studies (i.e., given the
anticipated different points of covalent attachment to mGlu2 with compounds (±)-4.25 and (±)4.27). Last but not least, another unique feature in the rational design of (±)-4.27 is the potential
utilization of the ketone in the probe as a chemical reporter for attachment of detection and
purification tags via bioorthogonal chemistry. In particular, Kiyonaka and coworkers have
successfully demonstrated the use of a ketone as a bioorthogonal chemistry handle within a
diazirine-based photoprobe, wherein attachment of a biotin tag to the probe was accomplished by
oxime formation after photoaffinity labeling (Kiyonaka et al., 2009). However, in case the
ketone in (±)-4.27, due to steric hindrance, is inaccessible for attachment of a biotin tag during
the tandem photoaffinity labeling experiment, an alternative strategy will be employed. The
ketone will be converted to a diazirine photoreactive group via known synthetic methodology
(Vervacke et al., 2014) and the aryl azide will instead be used as a clickable handle for
attachment of a tag. The synthesis of target photoprobe (±)-4.27 is described in Section 5.3.2.

113

Scheme 4.6. Rational design of target photoaffinity probe (±)-4.27 for mGlu2 structure-function studies based on
known BINA-analog (±)-1.75 (Bonnefous et al., 2005).

4.9. Rational Design of Clickable Pyridone-Based PAM Photoprobes for mGlu2 StructureFunction Studies
1,5-Substituted pyridones emerged as a promising class of potent and selective mGlu2
PAMs via high throughput screening (HTS) efforts at Addex Pharmaceuticals using a mGluR2
PAM FLIPR (fluorometric imaging plate reader) assay (Cid et al., 2010). The initial hits from
screening of the Addex compound collection were selected as lead compounds for further
exploration of SAR (for discussion, see Section 1.8.2.1.3). In particular, a variety of substituents
explored on the N-benzyl ring suggested that this ring is tolerable to hydrophobic substituents at
positions 2 and 4. From this series of analogs, compound 1.89 (Scheme 4.7) emerged as a lead
compound for photoprobe design given its high mGlu2 potency and selectivity.
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Scheme 4.7. Chemical structures of target clickable photoprobes for mGlu2 structure-function studies based on
mGlu2 PAM 1.89 (Cid et al., 2010).

The rationally designed photoprobes in Scheme 4.7 (discussed in detail vide infra) feature
incorporation of different photoreactive functional groups at different parts on the 1,5-pyridone
mGlu2 PAM scaffold, thus allowing potential systematic mapping of the PAM-binding site
within mGlu2 via BEProFL. Furthermore, the absence of a stereocenter in the 1,5-pyridone
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series represents a distinct advantage in terms of chemical simplification versus the BINA-based
photoprobes previously discussed in Section 4.8.

4.9.1.

Rational Design of a Pyridone-Based PAM Photoprobe for mGlu2 Structure-

Function Studies Featuring an Aryl Azide as a Photoreactive Group
Target pyridone-based mGlu2 PAM photoprobe 4.29 was rationally designed by isosteric
replacement of the chlorine atom in lead compound 1.89 with a hydrophobic, photoreactive aryl
azide and extension of the methoxy ether into a clickable propargyl ether (Scheme 4.8). Support
for the tolerability of these proposed structural changes stems from lead compounds 1.90 and
1.94, which retain appreciable mGlu2 PAM selectivity and potency by containing a 4-trifluoro
methyl group and a 4-methylnitrile group, respectively. In addition, target photoprobe 4.29
features a fluorine atom meta to the photoreactive aryl azide group, which as an electronwithdrawing group that could potentially stabilize the in situ generated highly reactive nitrene
formed during photoirradation.

In turn, this chemical strategy could potentially prevent

undesirable 7-membered ketenimine ring formation, which is traditionally associated with nonspecific protein labeling (Schrock and Schuster, 1984; Poe et al., 1992; Schnapp et al., 1993; see
Section 2.2.1.1. for discussion). The synthesis of target photoprobe (±)-4.29 is described in
Section 5.3.6.
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Scheme 4.8. Rational design of target mGlu2 PAM photoaffinity probe 4.29 based on known pyridone-containing
mGlu2 PAMs (Cid et al., 2010).

4.9.2. Rational Design of a Pyridone-Based PAM Photoprobe for mGlu2 StructureFunction Studies That Contains a Diazido Structural Motif Common to Clickable
Photoprobes
A number of clickable photoprobes have been disclosed featuring a parent ligand
conjugated to a phenyl ring bearing an aryl azide photoreactive group and an aliphatic alkyl
azide chemical reporter that survives photolysis (e.g., see 4.33 in Figure 4.5; Hosoya et al., 2004,
2005, and 2009; He et al., 2009; Neelarapu et al., 2011; Gandy et al., 2011). In particular, these
probes tend to possess a common structural motif wherein the three substituents are spatially
oriented in a 1,3,5-fashion around an aromatic phenyl ring. Additionally, parameters for this
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routinely employed diazido structural motif have been reported for application of designed
photoaffinity ligands in molecular dynamics studies (Pieffet and Petukhov, 2009). Given the Nbenzyl ring of lead mGlu2 PAM 1.89 is tolerable to a wide variety of hydrophobic groups at
different positions (see Section 1.8.2.1.3 for discussion of detailed SAR), target photoprobe 4.30
was rationally designed to include the common diazido structural motif as an N-benzyl
substituent (Figure 4.5). The synthesis of target photoprobe 4.30 is described in Section 5.3.7.

Figure 4.5. Structure of target mGlu2 PAM pyridone-based photoprobe 4.30, that contains a common diazido
structural motif common to many clickable photoprobes.

4.9.3.

Rational Design of a Pyridone-Based Clickable PAM Photoprobe for mGlu2

Structure-Function Studies That Contains an Acetophenone Photoreactive Group
Lead compound 1.93 (Scheme 4.9) represents another potent and selective mGlu2 PAM
from the 1,5-pyridone series (Cid et al., 2010). In particular, this lead compound contains an
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acetophenone as a potential photoreactive functional group. As a result, target photoprobe 4.31
was rationally designed by adding a propargyl ether para to the photoreactive carbonyl in order
to enable click chemistry proteomic applications after photoaffinity labeling.

Scheme 4.9. Rational design of target PAM photoprobe 4.31 for mGlu2 structure-function studies based on mGlu2
PAM lead pyridone 1.93 (Cid et al., 2010) and known acetophenone-alkyne clickable photoprobe 4.34 (van
Scherpenzeel et al., 2010).

In particular, support for the rational design of target photoprobe 4.31 stems from
compound 4.34, which possesses a similar acetophenone-para-propargyl ether structural motif.
Compound 4.34 was shown to label a glycosidase enzyme after UV irradiation and click
chemistry visualization with a fluoroscein-azide (van Scherpenzeel et al., 2010). Furthermore,
the presence of the labeling moiety two-carbon atoms removed from the substituted pyridone
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scaffold could potentially lead to better labeling efficiency due to less steric hindrance from the
surrounding aromatic groups and conformational flexibility. The synthesis of target photoprobe
4.31 is described in Section 5.3.8.

4.9.4. Rational Design of a Photo-masked mGlu2 PAM Affinity Labeling Probe for mGlu2
Structure-Function Studies
Pyrimidones are common moieties found in numerous bioactive compounds and natural
products.

In particular, pyrimidones display photochemistry capable of generating latent

electrophiles that can react with nucleophilic amino acids in proteins via photo-masked affinity
labeling. For example, pyrimidone 4.37 (Scheme 4.10) was successfully employed by the
Battenberg group for protein profiling in crude cell lysates (Battenberg et al., 2011). Specifically
upon UV irradiation, pyrimidones undergo a Norrish type 1 reaction leading to the formation
reactive intermediates capable of forming covalent bonds with proximal nucleophiles in the
ligand-binding site (see Section 2.2.1.3). During this work, labeled proteins were visualized by
click chemistry attachment of a rhodamine-azide dye to the heteroaryl alkyne moiety.
Furthermore, labeling results of a vancomycin-based probe containing a pyrimidone were
compared with a vancomycin-based probe containing a benzophenone as a photoreactive group.
In particular, the labeling patterns of both probes were identical and indicated selective labeling
of autolysin (ATLam) and an ABC transporter protein (pABC) in S. aureus and E. faecalis,
respectively. These results have provided proof-of-concept that pyrimidones are capable of
acting as efficient photo-masked affinity labeling groups similar to benzophenones traditionally
employed in photoaffinity labeling.
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Scheme 4.10. Rational design of pyrimidone-containing lead compound 4.36 and target photo-masked affinity
probe 4.32 from mGlu2 PAM 1.89 and known affinity probe 4.37.

With this acquired knowledge in hand, target probe 4.32 (Scheme 4.10), which features a
photoreactive pyrimidone moiety instead of a pyridone moiety found in lead mGlu2 PAM
compound 1.89, was rationally designed for future mGlu2 structure-function studies. This target
probes also features slight extension of the methyl ether in lead mGlu2 PAM compound 1.89 to a
propargyl ether for click chemistry applications after photo-unmasking affinity labeling.
Furthermore, in order to compare the mGlu2 pharmacology profile of target probe 4.32 versus an
appropriate analog, compound 4.36 was also synthesized featuring a –CH versus –N= isosteric
replacement when structurally compared to lead mGlu2 PAM compound 1.89. In particular,
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compounds 4.32 and 4.36 were synthesized as described in Section 5.3.9 and are currently the
subject of mGlu2 pharmacology and photoaffinity labeling studies via an established research
collaboration with Dr. Karen Gregory.
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CHAPTER FIVE
5. Chemical Discussion
5.1. Synthesis of Pyrovalerone-Based Photoprobes for DAT Structure-Function Studies
As previously discussed in Section 4.6., our interest in pyrovalerone-based photoaffinity
probes for DAT structure-function studies emerged from its structural resemblance to the
marketed antidepressant and smoking cessation agent, bupropion (Wellbutrin, Zyban), as well as
highly abused designer cathinones (e.g., MDPV). Additionally, high DAT binding affinities
were reported for a number of pyrovalerone analogs as a promising class of monoamine uptake
inhibitors (Meltzer et al., 2006), thus aiding in rational photoprobe design from a ligand-based
perspective.

5.1.1. Synthesis of Racemic 1-(4-Azido-3-Iodophenyl)-2-(Pyrrolidin-1-yl)Pentan-1-one as a
Photoaffinity Ligand for DAT Structure-Function Studies
As previously described in Section 4.6, racemic p-azido-m-iodo pyrovalerone ((±)-4.16)
was desired as a compact photoaffinity labeling probe featuring a photoreactive aryl azide placed
directly on the pyrovalerone pharmacophore.

The synthesis of target probe (±)-4.16 was

envisioned from known acetamide pyrovalerone analog (±)-1.32 (Meltzer et al., 2006) utilizing
three steps: amide hydrolysis, electrophilic aromatic iodination of the resulting aniline, then
conversion of the aniline to the azide via diazotization and azide displacement (Scheme 5.1). In
turn, acetamide pyrovalerone analog (±)-1.32 was envisioned from commercially available
acetanilide (5.1) using methodology previously reported (i.e., Friedel-Crafts acylation, bromination, and pyrrolidine N-alkylation; Meltzer et al., 2006). In particular, the vision behind
this proposed retrosynthesis features incorporation of the photoreactive aryl azide as the last step

123

in the synthesis given the potential inherent instability traditionally associated with this
functional group over multiple synthetic steps.

Scheme 5.1. Proposed retrosynthesis of target pyrovalerone-based photoprobe (±)-4.16 from acetanilide (5.1).

For the forward synthesis, acetanilide (5.1) was initially subjected to Friedel-Craft’s
acylation using 1,2-dichloroethane (1,2-DCE), AlCl3, and valeryl chloride (5.2) (reaction
conditions adapted from Ogawa et al., 1988 and Ianni and Waldvogel, 2006) in order to obtain
known ketone 5.3 (Meltzer et al., 2006) in bulk quantities. However, this particular FriedelCraft’s acylation suffered from several practical problems in the lab (Table 5.1). Initially, the
reaction resulted in no product formation due to the insolubility of acetanilide in 1,2-DCE (Entry
1, Table 5.1).

Even though changing the solvent to dichloromethane (DCM) resulted in

improved solubility of the starting materials, monitoring of the reaction for completion via TLC
was difficult because acetanilide 5.1 and ketone 5.3 have the same Rf values (Rf = 0.42 in
hexanes:EtOAc, 1:1) (Entry 2, Table 5.1). As a result, target ketone 5.3 was obtained alongside
acetanilide as a major impurity because separation by silica gel flash column chromatography
could not be readily achieved. Even with increasing equivalents of valeryl chloride and AlCl 3,
complete consumption of acetanilide was not observed (Entry 3, Table 5.1).
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Valeryl

Entry

Acetanilide

1

1 eq.

2 eq.

2

1 eq.

1.8 eq.

3

1 eq.

5 eq.

Chloride

AlCl3
2.5
eq.
1.8
eq.
5 eq.

Solvent
1,2-DCE

Reaction
Conditions
0˚C to rt,

No reaction; solubility

2 hr

problems

0˚C to rt,

DCM

3 hr
0˚C to reflux,

DCM

Result

O/N

Incomplete reaction
Incomplete reaction

Table 5.1. Optimization efforts with respect to Friedel-Craft’s acylation of acetanilide with valeryl chloride.

In order to overcome this previously noted problem, the inseparable mixture of target
ketone 5.3 and acetanilide (5.1) (after silica gel chromatography) was subjected to reduction with
NaBH4 in MeOH (Scheme 5.2).

Scheme 5.2. Synthesis of target ketone 5.3 via a Friedel-Crafts acylation, ketone reduction, alcohol oxidation
sequence.
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This reaction selectively reduced ketone 5.3 to benzyl alcohol derivative (±)-5.4 and did
not reduce the amide in acetanilide. As a result, benzyl alcohol (±)-5.4 could then be readily
separated from acetanilide via silica gel flash chromatography due to the significant difference in
Rf values for the two compounds. In turn, benzyl alcohol (±)-5.4 was then oxidized back to pure
target ketone 5.3 in 70% yield using PCC in dichloromethane. With ketone 5.3 in hand, the next
synthetic step, -bromination of the ketone, was optimized using the conditions listed in Table
5.2. When ketone 5.3 was treated with liquid bromine and AlCl3 in a mixture of Et2O and
dichloromethane, incomplete formation of target product (±)-5.5 was observed (Entry 1, Table
5.2). Changing the solvent to chloroform resulted in no product formation (Entry 2, Table 5.2).
However, subsequent increase in the number of equivalents of AlCl3 provided better yields of
target bromide (±)-5.5. In particular, the best reaction conditions that provided quantitative yield
of alkyl bromide (±)-5.5 were utilization of 0.5 equivalents of AlCl3 and CHCl3 as the reaction
solvent (Entry 5, Table 5.2).

Entry

AlCl3

Br2

Solvent

Conditions

Result

1

0.05 eq.

1 eq.

Et2O, DCM

0°C, O/N

Target Bromide + Starting material

2

0.05 eq.

1 eq.

CHCl3

0˚C, O/N

No reaction

3

0.2 eq.

1 eq.

CHCl3

4

0.2 eq.

1 eq.

CHCl3

5

0.5 eq.

1 eq.

CHCl3

0˚C, 1 hr then rt,
1.5 hr
0˚C, 30 min then
rt, O/N
0˚C, 1 hr then rt,
O/N

73% yield of (±)-5.5
96% yield of (±)-5.5
100% yield of (±)-5.5

Table 5.2. Optimization of bromination of ketone 5.3 to provide -bromide (±)-5.5.
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Using Entry 5 from Table 5.2, -bromoketone (±)-5.5 was then taken ahead without
purification to nucleophilic displacement with pyrrolidine to provide known pyrovalerone
acetamide analog (±)-1.32 (Meltzer et al., 2006) in 59% yield (Scheme 5.3). The amide in
compound (±)-1.32 was then subjected to acid hydrolysis (conditions adapated from Ianni and
Waldvogel, 2006) followed by basification with aqueous K2CO3 to provide aniline (±)-5.6 in
58% yield. Subsequently, electrophilic iodination of aniline (±)-5.6 (conditions adapted from
Newman et al., 2006), followed by aniline diazotization and displacement with NaN3 provided
target pyrovalerone-based probe (±)-4.16 for DAT photoaffinity labeling (Lapinsky et al., 2009).

Scheme 5.3. Synthesis of target pyrovalerone-based photoprobe (±)-4.16 for DAT structure-function studies
starting from acetamide 5.3.

5.1.2. Synthesis of Racemic 1-(4-Azido-3-Iodophenyl)-4-Methyl-2-(Pyrrolidin-1-yl)Pentan1-one as a Potential Photoaffinity Ligand for DAT Structure-Function Studies
According to pyrovalerone SAR reported by Meltzer and coworkers (Meltzer et al.,
2006), branched side chain analogs of pyrovalerone possess higher DAT binding affinity than
pyrovalerone (see Section 4.6). As a result, target photoprobe (±)-4.18 (Scheme 5.4) was
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envisioned as a DAT photoaffinity ligand with potentially higher DAT binding affinity than
previously described successful pyrovalerone DAT photoprobe [125I]-(±)-4.16 (Lapinsky et al.,
2009). In particular, a proposed retrosynthesis (Scheme 5.4) of branched side chain target probe
(±)-4.18 was naturally envisioned similar to straight chain analog (±)-4.16 in Scheme 5.1. Once
again, incorporation of the photoreactive aryl azide was envisioned as the last step in the
synthesis given the potential inherent instability traditionally associated with this functional
group over multiple synthetic steps.

Scheme 5.4. Proposed retrosynthesis of target branched side chain pyrovalerone-based photoprobe (±)-4.18 for
DAT structure-function studies.

The synthesis of target pyrovalerone-based photoprobe (±)-4.18 was initiated by FriedelCraft’s acylation of acetanilide (5.1) with 4-methylvaleryl chloride (5.8). However, once again,
this Friedel-Craft’s acylation provided an inseparable mixture of acetanilide (5.1) and target
ketone N-(4-(4-methylpentanoyl)phenyl)acetamide (5.9). As a result, access to target ketone 5.9
was instead anticipated via its aniline precursor 5.11 via N-acetylation (Scheme 5.5). Aniline
precursor 5.11 could then be obtained from commercially available 4-(trifluoromethyl)aniline
(5.10) via a known synthetic route (Lin et al., 1997).

Scheme 5.5. An alternative synthetic strategy to access the target branched side chain ketone 5.9.
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This work began with the synthesis of isopentylmagnesium bromide from isopentyl
bromide and magnesium turnings (Scheme 5.6). In particular, Grignard reagent formation was
accelerated by adding a few drops of dibromoethane at 0˚C. After the mixture was stirred for 1
hour, the reaction was cooled to -78˚C and 4-(trifluoromethyl)aniline (5.10) was added followed
by refluxing the reaction for 4 hours at 80˚C. Subsequent hydrolysis of the intermediate imine
with 10% H2SO4 provided the branched side chain ketone 5.11 in 10% yield (Lin et al., 1997).
The low yield of target ketone formation was reflective of the incomplete formation of the in situ
Grignard reagent.

Scheme 5.6. Synthesis of branched side chain pyrovalerone-based photoprobe (±)-4.18 for DAT structure-function
studies.

Subsequently, aniline 5.11 was N-acetylated, followed by -bromination and
displacement with pyrrolidine to provide 4-acetamide-branched chain intermediate (±)-5.12
(25% yield, 3 steps). The amide of compound (±)-5.12 was then subjected to acid hydrolysis and
electrophilic aromatic iodination to provide p-amino-m-iodo branched chain pyrovalerone analog
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(±)-5.14. Finally, aniline (±)-5.14 was subjected to diazotization and displacement with NaN3 to
provide the target photoprobe (±)-4.18 in 74% yield. In turn, the free base of pyrovalerone
analog (±)-4.18 was converted to its hydrochloride salt by treatment with 2M HCl-ether solution
to provide the HCl salt of target photoprobe (±)-4.18 as a yellow solid.

5.1.3. Synthesis of Racemic 1-(3-Azido-4-Iodophenyl)-2-(Pyrrolidin-1-yl)Pentan-1-one as a
Potential Photoaffinity Ligand for DAT Structure-Function Studies
Alongside branched side chain pyrovalerone-based photoprobe (±)-4.18, the synthesis of
meta-azido-para-iodo pyrovalerone probe (±)-4.17 was pursued simultaneously.

From a

retrosynthesis perspective (Scheme 5.7), target azide (±)-4.17 was envisioned from acetamide
derivative (±)-5.20 via acid hydrolysis and conversion of the requisite aniline to the azide via the
corresponding diazonium salt. In turn, the synthesis of acetamide (±)-5.20 was anticipated by
subjecting p-iodo valerophenone (5.16; Meltzer et al., 2006) to a sequence of electrophilic
aromatic nitration, nitro reduction, and aniline acylation, then -bromination and pyrrolidine Nalkylation. Once again, incorporation of the photoreactive aryl azide was envisioned as the last
step in the synthesis given the potential inherent instability traditionally associated with this
functional group over multiple synthetic steps.
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Scheme 5.7. Proposed retrosynthesis of target pyrovalerone-based photoprobe (±)-4.17 featuring the azide and iodo
functional groups reversed versus the traditional 3-iodo-4-azido photoaffinity labeling motif.

Therefore, according to this proposed retrosynthesis, p-iodovalerophenone (5.16),
obtained from p-aminovalerophenone via aprotic diazotization and iodide displacement (see
Krasnokutskaya et al., 2007), was subjected to electrophilic aromatic nitration (conditions
adapted from Chang et al., 1995) by treatment with fuming nitric acid to yield p-iodo-m-nitro
valerophenone (5.17) in 58% yield (Scheme 5.8). It was observed that valerophenone derivative
5.17 was rather unstable at room temperature and completely degraded within 24 hours
according to TLC experiments.

As a result, nitro valerophenone derivative 5.17 was

immediately reduced (Fe powder and sonication; conditions adapted from Gamble et al., 2007)
after chromatography to provide aniline 5.18 in 83% yield and requiring no purification. Aniline
5.18 was then subjected to N-acetylation, -bromination, and displacement with pyrrolidine to
provide pyrovalerone analog (±)-5.20 in 43% yield from (±)-5.19. However, subsequent acid
hydrolysis of amide (±)-5.20 proved unsuccessful. In particular, refluxing amide (±)-5.20 in
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aqueous HCl resulted in a mixture of several inseparable compounds. The only compound
isolated from this reaction in a very small amount was the des-iodo derivative of the target ((±)5.21) (confirmed from 1H-NMR and HRMS results), which was formed via an unidentified
mechanism.

Scheme 5.8. Attempted synthesis of pyrovalerone aniline analog (±)-5.22 towards generation of target
pyrovalerone-based probe (±)-4.17 for DAT structure-function studies.

In order to overcome the roadblock encountered upon amide hydrolysis, a new strategy
towards target photoprobe (±)-4.17 was envisioned featuring incorporation of the photoreactive
azide moiety earlier in the synthesis (Scheme 5.9). In particular, target photoprobe (±)-4.17 was
now envisioned from m-azido-p-iodo valerophenone (5.23) via -bromination and displacement
with pyrrolidine, and the synthesis of ketone 5.23 was envisioned from previously mentioned mamino-p-iodo valerophenone (5.18) via diazotization and displacement with NaN3.
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Scheme 5.9. Alternative retrosynthesis of target pyrovalerone-based photoprobe (±)-4.17 for DAT structurefunction studies via incorporation of the azide moiety earlier in the synthesis.

With this strategy in mind, m-amino-p-iodovalerophenone (5.18) was converted to its
corresponding diazonium salt then treated with NaN3 to provide target azide 5.23 in nearly
quantitative yield (conditions adapted from Kym et al., 1993) (Scheme 5.10). Azide 5.23 was
found to degrade upon storage for prolonged periods, thus -bromination was pursued
immediately (using conditions adapted from Habeeb et al., 2001). Finally, displacement of bromide (±)-5.24 with pyrrolidine provided target pyrovalerone-based photoprobe (±)-4.17 in
20% yield from ketone 5.23. In particular, the success of the chemistry in Scheme 5.10 indicates
pyrovalerone-based photoprobes for DAT structure-function studies can be accessed by
introducing the photoreactive aryl azide group either earlier in the synthesis, or as the last step
(e.g., see Scheme 5.6).

Scheme 5.10. Synthesis of target photoprobe (±)-4.17 for DAT structure-function studies featuring the azide and
iodo groups reversed versus the traditional 4-azido-3-iodo photoaffinity labeling motif.

133

5.2. Synthesis of Bupropion-Based Photoprobes for DAT and Select nAChR Subtypes
Structure-Function Studies
5.2.1. Synthesis of Racemic 1-(4-Azido-3-Iodophenyl)-2-(tert-Butylamino)Propan-1-one as
a Potential Photoaffinity Ligand for DAT and nAChR Structure-Function Studies
As previously described in Section 4.7.1 and given the DAT labeling success of
structurally similar 4-azido-3-iodo-PV photoprobe (±)-4.16 (Section 4.6), racemic p-azido-miodo bupropion ((±)-4.20) was desired as a compact photoaffinity labeling probe featuring a
photoreactive aryl azide placed directly on the bupropion pharmacophore. In this regard, a
proposed retrosynthesis of target probe (±)-4.20 (Scheme 5.11) was envisioned using similar
methodology employed earlier to synthesize pyrovalerone-based photoprobe (±)-4.16 (in Scheme
5.3) featuring incorporation of the photoreactive aryl azide as the last step in the synthesis. This
strategy was pursued in order to also allow the formation of aniline intermediate (±)-5.31
(Scheme 5.12) as a synthetic precursor to access the radio-iodinated version of (±)-4.20 by our
collaborator, Dr. John Lever (see Appendix, Section A.2).

Scheme 5.11. Proposed retrosynthesis of bupropion-based photoprobe (±)-4.20 featuring the traditional 4-azido-3iodo photoaffinity labeling motif starting from 4-aminopropiophenone (5.27).

The synthesis of target bupropion-based photoprobe (±)-4.20 was initiated by N-acylation
of

commercially

available

4-aminophenylpropanone

(5.27)

to

obtain

p-

acetamidephenylpropanone (5.28) in quantitative yield (Scheme 5.12). Acetamide 5.28 was then
subjected to -bromination and displacement with t-butylamine to provide amide analog (±)134

5.30, which upon acid hydrolysis provided aniline (±)-5.31 in 20% yield over 4 steps.
Subsequently, electrophilic iodination of aniline (±)-5.31 with iodine monochloride in the
presence of glacial acetic acid provided p-amino-m-iodo (±)-5.32 in low yield (23%). The low
yield of (±)-5.32 was a result of difficult monitoring of the reaction for completion via TLC
because the aniline and its p-amino-m-iodo derivative (±)-5.32 have the same Rf values (Rf =
0.27 in hexanes:EtOAc:Et3N, 10:88:2). As a result, p-amino-m-iodo derivative (±)-5.32 was
obtained alongside aniline (±)-5.31 as a major impurity and separation by silica gel flash column
chromatography could not be achieved efficiently.

Furthermore, increasing the number of

equivalents of ICl to facilitate the completion of the reaction resulted in a mixture of aniline (±)5.31, target (±)-5.32 and di-iodinated side product (±)-5.33, all having the same Rf value and
proved practically inseparable by silica gel flash column chromatography (Scheme 5.12).
The resulting small quantities of p-amino-m-iodo derivative (±)-5.32, due to the
previously mentioned problems of incomplete reaction and poor chromatographic separation,
was subsequently subjected to diazotization conditions and displacement with NaN3 to provide
the target photoprobe (±)-4.20. However, this final reaction resulted in multiple spots on TLC.
The isolation of clean p-azido-m-iodo derivative (±)-4.20 proved unsuccessful due to
decomposition of the labile azide functional group during the silica gel flash column
chromatography upon elution with CHCl3:MeOH:Et3N mobile phase. Furthermore, attempted
purification of target (±)-4.20 via HCl salt formation by treatment with 1N HCl in diethyl ether
solution, followed by trituration of the salt in diethyl ether did not provide sufficiently clean
product.
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Scheme 5.12. Attempted synthesis of bupropion-based photoprobe (±)-4.20 starting from 4-aminopropiophenone
(5.27).

As a result, an alternative strategy towards target photoprobe (±)-4.20 was envisioned
featuring incorporation of the photoreactive azide moiety earlier in the synthesis (Scheme 5.13).
According to this strategy, target photoprobe (±)-4.20 was now envisioned from p-azido-miodopropiophenone (5.36) via -bromination and displacement with tert-butylamine, and the
synthesis of ketone 5.36 was envisioned from previously mentioned p-aminopropiophenone
(5.27) in two steps via iodination followed by diazotization and displacement with NaN3
(Scheme 5.13).
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Scheme 5.13. Alternate retrosynthesis of target bupropion-based photoprobe (±)-4.20 for DAT and nAChR
structure-function studies via incorporation of the azide moiety earlier in the synthesis.

With this strategy in mind, commercially available p-aminopropiophenone (5.27) was
subjected to electrophilic iodination with ICl in presence of CaCO3, MeOH, and water to obtain
p-amino-m-iodo ketone 5.35 in 47% yield (Scheme 5.14).

p-Amino-m-iodopropiophenone

(5.35) was then converted to its corresponding diazonium salt, and treated with NaN3 to provide
azide 5.36 in nearly quantitative yield. With p-azido-m-iodopropiophenone (5.36) in hand, bromination was carried out with liquid bromine in the presence of CHCl3. The reaction was
concentrated and the -bromo ketone (±)-5.37, without isolation, was directly subjected to
displacement with t-butylamine. The resulting crude product was treated directly with 2M HCl
in diethyl ether solution to obtain the HCl salt of target (±)-4.20 (11% yield over 3 steps) (see
Lapinsky et al., 2012).

Scheme 5.14. Synthesis of target bupropion-based photoprobe (±)-4.20 for DAT and nAChR structure-function
studies featuring the traditional 4-azido-3-iodo photoaffinity labeling motif (Lapinsky et al., 2012).
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5.2.2.

Synthesis of Racemic 2-(tert-Butylamino)-1-(3-Iodophenyl)Propan-1-one as a

Photoaffinity Ligand Featuring an Intrinsic Acetophenone Moeity for DAT and nAChR
Structure-Function Studies
Bupropion-based photoprobe (±)-4.20 (Section 5.2.1) not only contains a photoreactive
aryl azide group, but also is an example of an acetophenone derivative, which represents another
potential photoreactive functional group (Lukac et al., 2009). As a result, discrepancy could
potentially arise in terms of discerning the exact point of covalent attachment of (±)-4.20 to a
protein after photoaffinity labeling. In order to experimentally investigate whether the nitrene
from the azide or the diradical from the intrinsic acetophenone was acting as the photoreactive
center, the des-azido probe (±)-4.21 was rationally designed to remove any ambiguity during
proteomics after photoaffinity labeling.

Scheme 5.15. Synthesis of des-azido probe (±)-4.21 featuring an intrinsic acetophenone as a potential photoreactive
moiety, and tri-n-butyl stannyl analog (±)-4.22 as a precursor to radio-iodinated photoprobe (±)-[125I]-4.21 for DAT
and nAChR structure-function studies.
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Target (±)-4.21 was obtained in 47% overall yield starting with -bromination of 3iodophenylpropiophenone (5.38) with bromine, followed by displacement of the -bromide with
tert-butylamine, and subsequent isolation of the target as the hydrochloride salt by stirring in 1M
HCl in diethyl ether (Scheme 5.15). Tri-n-butyl stannyl analog (±)-4.22 was also synthesized as
a precursor to the
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I analog of (±)-4.21. In this regard, the HCl salt of (±)-4.21 was basified

using aqueous K2CO3, then subjected to Pd-catalyzed Stille coupling with bis(tributyltin) to
provide tri-n-butyl stannyl derivative (±)-4.22 in 35% yield. Synthesis of the

125

I analog of (±)-

4.21 via radio-iodo destannylation was subsequently performed by Dr. John Lever to enable
photoaffinity labeling studies with nAChRs by Dr. Michael Blanton’s group (see Appendix,
Section A.3).

5.2.3. Synthesis of (2S,3S)-2-(4-Azido-3-Iodophenyl)-3,5,5-Trimethylmorpholin-2-ol as a
Photoaffinity Ligand for DAT and nAChR Structure-Function Studies

Scheme 5.16. Synthesis of hydroxybupropion-based photoaffinity probe (+)-4.23 featuring the classical azido-iodo
motif.
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As previously described in Section 4.7.3, synthesis of target azido-iodo probe (2S,3S)4.23 based on bupropion’s active metabolite, (2S,3S)-hydroxybupropion ((2S,3S)-1.54), was
desired for DAT and nAChR structure-function studies. In particular, the synthesis of target
photoprobe (2S,3S)-1.54 was adapted using the synthetic strategy reported by Lukas and
coworkers (Lukas et al., 2010) to prepare several analogs of (2S,3S)-hydroxybupropion. Briefly,
p-azido-m-iodophenyl propanone (5.36) (prepared in Scheme 5.14) was treated with Et3N and
TBSOTf to provide silyl enol ether 5.40 in 68% yield after silica gel flash column
chromatography (Scheme 5.16).

-Hydroxylation of silyl enol ether 5.40 under Sharpless

asymmetric dihydroxylation conditions using AD-mix-and CH3SO2NH2 in t-BuOH and H2O
(conditions adapted from Lukas et al., 2010) subsequently provided -hydroxyphenylketone (+)5.41 in 73% yield.

Treatment of alcohol (+)-5.41 with triflic anhydride, followed by

displacement of the in situ formed -OTf group with 2-amino-2-methylpropanol and subsequent
intramolecular cyclization, provided photoprobe (+)-4.23, which was isolated as an oxalate salt
in 20% yield.

The absolute stereochemistry of (+)-4.23 was not determined via x-ray

crystallography.

5.3. Synthesis of mGlu2 PAM Control Compounds and Irreversible Chemical Probes
Suitable for mGlu2 Structure-Function Studies
5.3.1. Synthesis of a Lead Biphenylindanone-Based mGlu2 PAM as a Control Compound
for mGlu2 Pharmacological Evaluation
Given known lead mGlu2 PAM (±)-1.71 was required as a positive control for
pharmacological comparison to our novel BINA-based photoprobes, (±)-1.71 was synthesized
according to the known chemical literature (Bonnefous et al., 2005). In this regard, synthesis of
140

required intermediate phenol (±)-3.40 was initiated (Scheme 5.17) according to conditions
reported in the literature (Woltersdorf et al., 1977; DeSolms et al., 1978).
As shown in Scheme 5.17, Friedel-Craft’s acylation of 5.45 with acetyl chloride
derivative 5.46 first provided ketone 5.47 in 82% yield. Next, the synthesis of -unstaurated
ketone 5.48 via Mannich base formation (following previously reported conditions; i.e.,
paraformaldehyde, dimethylamine, AcOH, 80 ºC; DeSolms et al., 1978) provided 5.48 in only
30% yield. Reducing the number of equivalents of dimethylamine hydrochloride from 4.5 to 3
equivalents, and stirring the reaction at 100 ºC in DMF with paraformaldehyde and AcOH, led to
significant improvements in product yield of the reaction (69% from modified procedure versus
30% from the literature procedure). Subsequent intra-molecular cyclization of the resulting ,unsaturated ketone 5.48 under strong acidic conditions (i.e. conc. H2SO4) provided with cyclized
ketone (±)-5.49 in 81% yield without the need for chromatography.

For methyl ether

deprotection of (±)-5.49, BBr3 was employed instead of stirring in hot 30-48% HBr as reported
in the literature. This BBr3 deprotection proceeded with excellent yield (90%) to directly
provide known hydroxyl indanone (±)-3.40 as a white solid.

Scheme 5.17. Synthesis of intermediate hydroxyl indanone (±)-3.40 with reaction conditions modified from
DeSolms et al., 1978 and Woltersdorf et al., 1977.
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For the forward synthesis, biphenyl 5.52 (Scheme 5.18) was obtained in 90% yield via
Suzuki coupling (conditions adapted from Bonnefous et al., 2005; Pinkerton et al., 2006) of 3bromo-4-methoxyphenyl methyl ester (5.50) with 3-boronic acid benzyl alcohol (5.51). The
resulting biphenyl 5.52 was then subjected to Mitsunobu coupling (conditions adapted from
Pinkerton et al., 2006) with phenol (±)-3.40 to provide the ester (±)-3.44. This ester (±)-3.44
was obtained in extremely low yield (16%) with the majority of starting phenol recovered back
via chromatography. Hydrolysis of ester (±)-3.44 under basic conditions (LiOH) then provided
target acid (±)-1.74 (Bonnefous et al., 2005) in 65% yield. With control compound (±)-1.74 in
hand, synthesis of novel mGlu2 irreversible PAMs as chemical probes for mGlu2 structurefunction studies were subsequently initiated.

Scheme 5.18. Synthesis of lead biphenylindanone-based mGlu2 PAM (±)-1.74 as a control for mGlu2
pharmacological evaluation (Bonnefous et al., 2005).
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5.3.2. Synthesis of a Racemic Clickable BINA-based mGlu2 PAM Photoprobe for mGlu2
Structure-Function Studies Containing an Inherent Acetophenone Photoreactive Group
As previously described in Section 4.8.1, we desired clickable mGlu2 PAM (±)-4.25 as a
potential photoprobe suitable for mGlu2 structure-function studies. The synthesis of target
photoprobe (±)-4.25 was envisioned via Mitsunobu coupling of benzyl alcohol 5.58 with phenol
(±)-3.40 (synthesized in Section 5.3.1.1.) followed by ester hydrolysis. Benzyl alcohol 5.58, in
turn, could then be potentially accessed via Suzuki coupling between boronic acid 5.51 and aryl
bromide 5.54, followed by subsequent terminal alkyne deprotection of the silyl-protected
propargyl ether (Scheme 5.19).

Scheme 5.19. Proposed retrosynthesis of clickable alkyne-acetophenone mGlu2 PAM photoprobe (±)-4.25 for
mGlu2 structure-function studies.

With this retrosynthesis in mind, Suzuki coupling of TMS-protected propargyl ether 5.54
(synthesized via O-alkylation of phenol 5.53 with TMS-protected propargyl bromide) with
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commercially available boronic acid 5.51 proved unsuccessful due to the in situ deprotection of
the TMS-protected propargyl group (Scheme 5.20).

Scheme 5.20. Attempted synthesis of biphenyl intermediate 5.55 via O-alkylation and Suzuki coupling sequence.

In order to overcome this problem, the Suzuki coupling was instead carried out directly
with commercially available phenol 5.53 to obtain biphenyl compound 5.57 in moderate yield
(60%). Subsequent O-alkylation of phenol 5.57 with propargyl bromide then provided benzyl
alcohol 5.58, which was subjected to Mitsunobu coupling conditions with phenol (±)-3.40 to
obtain ester (±)-5.59 in 46% yield. Final ester hydrolysis in aqueous LiOH then provided target
acid (±)-4.25 in 90% yield (Scheme 5.21).

Scheme 5.21. Synthesis of clickable alkynyl-acetophenone mGlu2 PAM photoprobe (±)-4.25 suitable for mGlu2
structure-function studies.
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5.3.3. Synthesis of a Racemic BINA-Based mGlu2 PAM Photoprobe for mGlu2 StructureFunction Studies That Contains an Aryl Azide as a Photoreactive Group
As previously described in Section 4.8.2, mGlu2 PAM (±)-4.27 was desired as a
photoprobe for mGlu2 structure-function studies. The synthesis of aryl azido photoprobe (±)4.27 was envisioned in 3 steps via O-alkylation, Suzuki coupling and ester hydrolysis, starting
with commercially available 3-bromomethylphenyl boronic acid (5.61) and previously
synthesized phenol (±)-3.40. This retrosynthesis strategy (Scheme 5.22) was adapted from the
existing chemical literature known for BINA-based analogs (Bonnefous et al., 2005).

Scheme 5.22. Proposed retrosynthesis of racemic mGlu2 PAM photoprobe (±)-4.27 featuring an aryl azide as a
photoreactive group and an acetophenone as a chemical handle for the attachment of reporter tags.

With this synthetic strategy in mind, O-alkylation of phenol (±)-3.40 with commercially
available benzyl bromide 5.61 (under previously reported conditions; Cs2CO3, DMF; Van de
Bittner et al., 2013) provided ether (±)-5.62 in only 10% yield after chromatography. In order to
improve the yields of this transformation, conditions were modified by increasing the number of
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equivalents of K2CO3 (from 3 to 4.5) and further addition of KI (0.2 equivalents) to the reaction
mixture.

The final outcome of the reaction improved drastically with aryl boronic acid

derivative (±)-5.62 obtained in nearly quantitative yields with sufficient purity without any need
for purification via chromatography (Scheme 5.23). Boronic acid intermediate (±)-5.62 was
subsequently subjected to Suzuki coupling (conditions adapted from Pudlo et al., 2007) with
known methyl 2-azido-5-bromobenzoate 5.63 (Pokhodylo and Matiychuk, 2010), which
provided ester (±)-5.65 in 55% yield. Final ester hydrolysis with aqueous LiOH successfully
gave target photoprobe (±)-4.27 in 90% yield.

Scheme 5.23. Synthesis of racemic mGlu2 PAM photoprobe (±)-4.27 for mGlu2 structure-function studies via Oalkylation, Suzuki coupling, ester hydrolysis sequence.
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5.3.4. Synthesis of a Lead Pyridone-Based mGlu2 PAM as a Control Compound for mGlu2
Pharmacological Evaluation
Given known lead mGlu2 PAM 1.89 was required as positive control for
pharmacological comparison to novel probe compounds, 1.89 was synthesized according to the
known chemical literature (Imogai et al., 2006).

Scheme 5.24. Synthesis of lead pyridone-based mGlu2 PAM 1.89 as a control for mGlu2 pharmacological studies
via N-alkylation and Suzuki coupling (Cid et al., 2010).

In this regard, N-alkylation of commercially available 5-bromo-2-pyridone (3.55) with 2-fluoro4-chlorobenzyl bromide (3.56) first provided N-benzylated pyridone 3.57 in 79 % yield (Scheme
5.24). Subsequent Suzuki coupling of bromide 3.57 with 4-methoxy phenylboronic acid (3.58)
under bench-top refluxing conditions instead of microwave-assisted heating (reported in Cid et
al., 2010), provided lead mGlu2 PAM 1.89 in 62% yield. Lead compound 1.89 was used as a
standard control compound in the pharmacological evaluations of pyridone-based probes.

5.3.5. Synthesis of a Lead Pyridone-Based Acetophenone-Containing mGlu2 PAM as a
Control Compound for mGlu2 Pharmacological Evaluation
The synthesis of known pyridone-based acetophenone-containing lead 1.93 was initially
attempted via synthetic methodology reported in the literature (Cid et al., 2010; Section 3.5).
When phenol 3.59 was heated in a microwave with alkyl chloride 5.67 and K2CO3 in THF at
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100ºC, no product (i.e., ether 1.93) formation was observed (Entry 1, Table 5.3). Even with an
increase in the number of equivalents of chloride 5.67 and addition of catalytic amounts of KI,
no product was observed (Entry 2, Table 5.3). Furthermore, heating the reaction with traditional
bench-top conditions upon changing the solvent to DMF (Entry 3, Table 5.3) or replacing K2CO3
with Cs2CO3 as the base still resulted in no reaction (Entry 4, Table 5.3). TLC of the reaction
indicated the presence of only the starting phenol 3.59 with no spots indicative of target ether
1.93 upon separation via flash column chromatography and 1H NMR analysis.

Entry

Phenol
3.59

Alkyl
chloride

Base

KI

Solvent

0 eq.

THF

5.67

1

1 eq.

1.1 eq.

K2CO3

2

1 eq.

1.5 eq.

K2CO3

3

1 eq.

2 eq.

K2CO3

4

1 eq.

2 eq.

Cs2CO3

0.02
eq.
0.5
eq.
0.5
eq.

THF
DMF
DMF

Reaction
conditions

Result

Microwave,

No observed target ether

80ºC, 10 min

1.93 formed

Microwave,

No observed target ether

100ºC, 10 min

1.93 formed

Bench-top,

No observed target ether

100ºC, overnight

1.93 formed

Bench-top, 80ºC,

No observed target ether

overnight

1.93 formed

Table 5.3. Optimization efforts with respect to O-alkylation of phenol 3.59 with alkyl chloride 5.67 to provide
mGlu2 PAM 1.93 as a control compound.

The previously noted problem of unsuccessful O-alkylation of phenol 3.59 was attributed
mainly to the possibility that phenol 3.59 facilitated elimination of alkyl chloride 5.67 rather than
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nucleophilic substitution. As a result, instead of using phenol 3.59, synthesis of the target
acetophenone 1.93 was attempted via an alternate strategy shown in Scheme 5.25 starting with
commercially available 4-hydroxyphenyl pinacol boronate ester 5.70.

Scheme 5.25. Proposed alternate retrosynthesis for synthesis of lead mGlu2 PAM 1.93 starting with O-alkylation of
commercially available phenol 5.70.

As previously noted, attempts to N-alkylate 4-hydroxyphenyl boronate ester 5.70 with
alkyl chloride 5.67 failed (Scheme 5.26). In particular, 1H NMR analysis of isolated reaction
components indicated that -chloroketone 5.67 converted to an unidentified side product, as the
major product isolated from the reaction was the starting phenol 5.70. Due to the susceptibility
of -haloketones to undergo -elimination under basic conditions at high temperature, benzyl
alcohol 5.72 (Onishi et al., 2011; Park et al., 2011; Coric et al., 2013) was instead used as the
more stable alkylating agent (Scheme 5.26).
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Scheme 5.26. Synthesis of lead mGlu2 PAM 1.93 as a control compound for mGlu2 pharmacological evaluations
via O-alkylation of phenol 5.70 with thermally stable alkyl chloride 5.72.

The phenoxide of 4-hydroxyphenyl boronate (5.70), generated in situ by treatment with NaH
(conditions adapted from Mahale et al., 2012 and Kolkhof et al., 2009), was trapped with 3chloro-1-phenylpropan-1-ol ((±)-5.72) to successfully provide ether 5.73 in 40% yield. Benzyl
alcohol (±)-5.73 was then subjected to Dess-Martin Periodinane oxidation (conditions adapted
from Jin et al., 2005) to provide ketone 5.71 in 81% yield. However, the reaction of boronate
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ester 5.71 with bromide 3.57, by implementing traditional Suzuki coupling conditions, did not
result in the desired acetophenone 1.93. Instead, phenol 3.59 was isolated from this reaction,
which indicated that the -substituted phenyl ketones could not be subjected to high temperature
during basic reaction conditions due to competing -elimination. In order to circumvent this
problem, Suzuki reaction between the benzyl alcohol 5.73 and aryl bromide 3.57 was employed
first to obtain benzyl alcohol 5.74 in 42% yield, followed by DMP-oxidation conditions at room
temperature for 2 hours to obtain target ketone 1.93 in 72% yield (Scheme 5.26).
With pyridone based mGlu2 PAM control compounds 1.89 and 1.93 in hand, synthesis of
novel mGlu2 irreversible PAMs as chemical probes for mGlu2 structure-function studies were
subsequently initiated.

5.3.6.

Synthesis of a Clickable Pyridone-Based mGlu2 PAM Photoprobe for mGlu2

Structure-Function Studies Featuring an Aryl Azide as a Photoreactive Group
The synthesis of azido-alkyne pyridone-based mGlu2 PAM photoprobe 4.29 was
envisioned in 5 steps starting with known 2-fluoro-4-nitro benzyl bromide (5.77) (Scheme 5.27).
Briefly, N-alkylation of 5-bromo-(1H)-N-pyridone with 2-fluoro-4-nitro benzyl bromide (5.77),
followed by Suzuki coupling of N-benzyl pyridone derivative 5.78, O-propargylation, nitroreduction to aniline 5.81, and aniline to azide conversion via diazotization and azide
displacement was envisioned to efficiently provide target photoprobe 4.29.
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Scheme 5.27. Proposed retrosynthesis of clickable azide-alkyne mGlu2 photoprobe 4.29 for mGlu2 structurefunction studies.

For the forward synthesis, 2-fluoro-4-nitro toluene (5.76) was initially subjected to
radical-mediated benzyl bromination conditions (using N-bromosuccinamide (NBS) as a
brominating agent and AIBN as a radical initiator; reaction conditions adapted from Ortuno et
al., 2011 and Frank et al., 2013) in order to obtain 2-fluoro-4-nitrobenzyl bromide (5.77) in bulk
quantities. However, this benzyl bromination reaction provided extremely low yields due to
incomplete formation of target product 5.77 (Entry 1 and 2, Table 5.4). Even with an increase in
the equivalents of NBS and using benzoyl peroxide as the radical initiator, a majority of target
5.77 was lost due to the formation of a mixture of target 5.77, starting material 5.76, and a
possible dibromominated side product. All the three components appeared as close spots on
TLC and were practically inseparable by silica gel flash column chromatography. In addition,
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benzyl bromide 5.77 appeared to be a highly reactive compound that degraded when stored for a
prolonged period.

2-Fluoro-4Entry

nitrotoluene
(5.76)

1

1 eq.

2

1 eq.

3

1 eq.

Br

Radical

source

initiator

NBS

AIBN

(1.1 eq.)

(0.1 eq.)

NBS

AIBN

(1.05 eq.)

(0.02 eq.)

NBS

(PhCO2)2

(3 eq.)

(0.3 eq.)

Solvent

Reaction
conditions

Result

Benzene

80 ºC, 4 hrs

8% yield of 5.77

CCl4

85 ºC, 7 hrs

15% yield of 5.77

Chlorobenzene

140 ºC, 2 hrs

Target Bromide + Starting
material + Dibromination

Table 5.4. Optimization efforts of radical bromination of 5.76 to provide benzyl bromide 5.77.

Nevertheless, obtained benzyl bromide 5.77 (from Entry 2, Table 5.4) was sequentially
subjected to N-alkylation with 5-bromo-2-pyridone, Suzuki coupling with 4-methoxy phenyl
boronic acid, then methyl ether cleavage using BBr3 to obtain phenol 5.80 in 5% yield over 4
steps (Scheme 5.28). The obtained phenol 5.80, a highly polar compound, was practically
insoluble in most organic solvents and required long, tedious silica gel flash column
chromatography for its purification.

Phenol 5.80 was subsequently treated with propargyl

bromide followed by reduction of the p-nitro group to provide aniline 5.81. The final conversion
of aniline 5.81 to azide 4.29 via diazotization and displacement with azide completely failed and
did not result in the formation of desired azide target 4.29.
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Scheme 5.28. Attempted synthesis of clickable mGlu2 PAM photoprobe 4.29 via a radical bromination, Nalkylation, Suzuki coupling, methyl ether deprotection, O-alkylation, nitro reduction, diazotization and azide
displacement sequence.

Given the problems encountered in the previous synthetic scheme, this chemical strategy
towards the target probe 4.29 was dropped in favor of pursuit of alternative synthetic routes. In
particular, target 4.29 was envisioned via N-alkylation of key intermediate 2-methoxy pyridine
(5.85) with 4-azido-2-fluoro benzyl chloride (5.89) (Scheme 5.29).

The key synthetic

intermediate 2-methoxypyridine 5.85 could potentially be accessed in three steps from
commercially available 4-hydroxyphenyl boronate pinacol ester (5.70). Briefly, sequential Opropargylation of phenol 5.70 with propargyl bromide followed by Suzuki coupling with 2methoxy-5-bromo pyridine (5.83) and then terminal alkyne deprotection of the protected
propargyl ether was envisioned to provide pyridine derivative 5.85.
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The synthesis of key

intermediate 4-azide-2-fluoro benzyl chloride (5.89) was envisioned starting with aniline to azide
conversion of 4-amino-2-fluorobenzoic acid (5.86) via diazotization and azide displacement.
Subsequent carboxylic acid (5.87) to benzyl alcohol (5.88) conversion was envisioned via mixed
anhydride formation and then reduction, followed by the conversion of the resulting benzyl
alcohol (5.88) to benzyl chloride 5.89.

Scheme 5.29. Proposed alternate retrosynthesis of clickable azide-alkynyl mGlu2 PAM photoprobe 4.29 via Nalkylation reaction between synthetic intermediates 5.85 and 5.89.

With this retrosynthesis in mind, commercially available 4-hydroxy boronate pinacol
ester (5.70) was first treated with TIPS-protected propargyl bromide (Hoogboom and Swager,
2006) to obtain the O-alkylated phenyl boronate ester 5.82 in 62% yield (Scheme 5.30). The
boronate ester 5.82 was then subsequently subjected to palladium-catalyzed Suzuki coupling
conditions with 5-bromo-2-methoxypyridine (5.83) to provide biaryl 5.84 in excellent yield
(99%). Subsequent TIPS-group deprotection of the terminal alkyne using tert-butyl ammonium
fluoride (TBAF) provided pyridine intermediate 5.85 in 45% yield.
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Scheme 5.30. Synthesis of pyridine derivative 5.85 via O-alkylation, Suzuki coupling, and silyl-group deprotection.

The synthesis of 4-azido-2-fluoro benzyl chloride (5.89) for N-alkylation of pyridone
5.85 was initiated by conversion of aniline 5.86 to azide 5.87 via diazotization and azide
displacement (Scheme 5.31). Acid 5.87 was then subsequently converted into a mixed anhydride
in situ by treatment with isopropyl chloroformate, followed by reduction with NaBH4 in EtOH to
form benzyl alcohol 5.88 in 30% yield. To convert primary alcohol 5.88 into a methanesulfonyl
leaving group, benzyl alcohol 5.88 was treated with 1.5 equivalents of methane sulfonylchloride
in the presence of Et3N at 0 oC for 1 hour. However, instead of the mesylate derivative, only
benzyl chloride 5.89 was obtained in 15% yield via displacement of in situ generated benzylic
mesylate by chloride ion. Nevertheless, the obtained benzyl chloride 5.89 was taken ahead for
N-alkylation of 5.85 (Scheme 5.31) to obtain the final target 4.29 in 30% yield.
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Scheme 5.31. Synthesis of clickable mGlu2 PAM photoprobe 4.29 featuring an azide and a propargyl ether for
mGlu2 structure-function studies.

5.3.7.

Synthesis of a Clickable Pyridone-Based mGlu2 PAM Photoprobe for mGlu2

Structure-Function Studies That Contains a Diazido Structural Motif Common to
Clickable Photoprobes
The synthesis of probe 4.30 was accomplished by N-alkylation of known pyridone 5.90
with diazido benzyl mesylate 5.91 (Hosoya et al., 2005) (provided by Dr. Ranganadh Velagaleti)
to provide di-azido photoprobe 4.30 in 25% yield (Scheme 5.32).
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Scheme 5.32. Synthesis of diazido clickable mGlu2 PAM photoprobe 4.30 for mGlu2 structure-function studies.

5.3.8.

Synthesis of a Clickable Pyridone-Based mGlu2 PAM Photoprobe for mGlu2

Structure-Function Studies That Contains an Acetophenone Photoreactive Group

Scheme 5.33. Proposed retrosynthesis of clickable mGlu2 PAM photoprobe 4.31 featuring acetophenone and
propargyl ether group for mGlu2 structure-function studies.
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The synthesis of target photoprobe 4.31 was envisioned via direct alkylation of phenol
3.59 with alkyl bromide (±)-5.99 followed by oxidation of resulting benzyl alcohol (±)-5.100 to
provide the target phenyl ketone 4.31 (Scheme 5.33).
With this plan in mind, the forward synthesis was initiated via Friedel-Craft’s acylation
of propargyl phenol (5.95) with 3-bromopropionyl chloride (5.96) (conditions adapted from
Rueping and Hubener, 2011) to provide ketone 5.97 in 57% yield after silica gel flash column
chromatography (Scheme 5.34). It was observed that -bromophenylketone 5.97 was rather
unstable at room temperature and completely degraded within 24 hours according to TLC
experiments. As a result, ketone 5.97 was immediately taken ahead to the next reaction. Initial
attempts to reduce ketone 5.97 to benzyl alcohol (±)-5.99 using NaBH4 (2 equivalents) at room
temperature for 5 hours resulted in an inseparable mixture of target bromide (±)-5.99 and 1phenyl-1-hydroxy-propane derivative 5.98 in a 4:1 ratio. In order to favor ketone reduction more
than undesirable bromide displacement, the reaction was attempted using NaBH4 (1 equivalent)
at 0 oC for 3 hours followed by stirring at room temperature for 1 hour. Using these conditions,
target alcohol 5.99 was obtained in 57% yield after silica gel flash column chromatography
without any indication of side product formation. With hydroxyl bromide (±)-5.99 in hand,
alkylation of phenol 3.59 was attempted by treatment with NaH and overnight heating at 70 oC.
The reaction proceeded with multiple spots observed on TLC, which upon separation resulted in
the isolation of only 5% of ether (±)-5.100. The low yield of the reaction was attributed to side
reactions associated with the of unprotected terminal alkyne of (±)-5.99 under highly basic
conditions. Since key intermediate (±)-5.100 was obtained in less than 1% yield over 3 steps
using this chemistry, this strategy was discontinued and an alternate reaction scheme was
pursued thereafter.
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Scheme 5.34. Attempted synthesis of intermediate (±)-5.100 via a Friedel-Craft’s acylation, ketone reduction,
phenol O-alkylation sequence.

In order to overcome the problem of undesirable reactivity of the unprotected terminal
alkyne during the O-alkylation step, an alternate method involving the use of TIPS-protected
propargyl phenol was employed (Scheme 5.35). This synthesis was initiated with the treatment
of phenol 5.101 with known TIPS-protected propargyl bromide 5.102 (Hoogboom and Swager,
2006) to obtain TIPS-protected propargyl phenol ether 5.103 in excellent yield. Ether 5.103 was
then treated with 3-bromopropionyl chloride 5.96 under Friedel-Craft’s acylation conditions.
This reaction, after work-up resulted in multiple spots on TLC which upon chromatographic
separation followed by 1HNMR analysis, revealed the formation of target ketone 5.106 in 35%
yield alongside formation of TIPS-deprotected ketone 5.104 and cleaved propargyl ether 5.105
as side products. Sequential ketone reduction of 5.106, followed by phenol alkylation, provided
ether intermediate 5.108 in 50% yield. This benzyl alcohol (5.108), although contaminated with
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aliphatic impurities according to 1HNMR, was sufficiently clean enough for TIPS-deprotection
by treatment with TBAF (Liu et al., 2012).

Scheme 5.35. Synthesis of target mGlu2 clickable photoprobe 4.31 featuring an acetophenone and a propargyl ether
for mGlu2 structure-function studies.

The final intermediate alcohol 5.100, although produced by a lengthier synthetic route (5
steps, Scheme 5.35) versus Scheme 5.34 (3 steps), gave yields that were drastically improved
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(~10% over 5 steps in Scheme 5.35 versus <1% over 3 steps in Scheme 5.34). The resulting
benzyl alcohol 5.100 was then subjected to Dess-Martin Periodinane oxidation to provide the
final acetophenone containing target probe 4.31 in 40% yield.

5.3.9.

Synthesis of a Photo-Masked mGlu2 PAM Affinity Labeling Probe for mGlu2

Structure-Function Studies
Pyrimidone lead compound 4.36 was obtained in 2 steps starting with known 5-iodo
pyrimidone 5.110 (Efange et al., 1985) via N-alkylation with benzyl bromide 3.56 and Suzuki
coupling with methyl ether 3.58 (Scheme 5.36). The initial N-alkylation reaction was carried out
in DMFin the presence of K2CO3 with overnight stirring at room temperature to provide target
iodide 5.111 in low yield (30%). In order to improve the yield, the workup of this reaction was
modified by diluting the reaction with H2O after completion until a white precipitate ceased to
exist, then target iodide 5.111 was isolated via filtration. The resulting solid was purified via
silica gel flash column chromatography to obtain N-alkylated pyrimidone 5.111 in 73% yield.
Subsequent Suzuki coupling of aryl iodo 5.111 with commercially available 4-methoxy phenyl
boronic acid (3.58) provided the pyrimidone lead compound 4.36 in 16% yield. This compound
would be subsequently used as a standard control compound in the pharmacological evaluations
of pyrimidone-based photo-masked affinity probe 4.32.
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Scheme 5.36. Synthesis of novel pyrimidone-based mGlu2 PAM 4.36 as a control compound and pyrimidonealkyne photo-masked affinity probe 4.32 for mGlu2 structure-function studies.

In order to synthesize propargyl ether photoprobe 4.32, aryl iodo 5.111 was subjected to
Suzuki coupling reaction with 4-hydroxyphenylboronic acid to obtain phenol 5.112 in 50% yield.
Subsequet O-alkylation of phenol derivative 5.112 with propargyl bromide provided target
photoprobe 4.32 in 22% yield.
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5.4. Summary of Significance, Innovation, and Synthetic Accomplishments Associated
With This Dissertation Work
Despite many years of research towards understanding the biological basis of substance
abuse and addiction, there are currently no FDA-approved pharmacotherapies for the treatment
of cocaine and methamphetamine addiction. Furthermore, FDA-approved treatments for tobacco
smoking and nicotine addiction, such as nicotine replacement products, varencline (Chantix ®),
and bupropion (Zyban®), are inadequate in maintaining long-term abstinence as 80% of tobacco
smokers relapse within the first month of treatment. This warrants a need for more efficacious
and effective treatments for nicotine addiction. The lack of progress in the discovery and
development of novel and effective pharmacotherapies to treat psychostimulant abuse is, in part,
attributed to the absence of high quality 3-D structure and function information regarding
significant proteins such as DAT, α4β2 nAChR, α3β4 nAChR and mGlu2 that are implicated in
reinforcing and reward actions of psychostimulant drugs of abuse. As a result, a detailed
understanding of the structure of binding sites of ligands within these proteins is imperative in
order to develop new therapeutics to treat drug abuse and addiction. In this regard, the research
objective of this dissertation was to provide chemical probes to facilitate understanding of how
the pharmacology profile (i.e., affinity, selectivity, potency, behavioral phenotype, etc.) of antiaddiction lead compounds (e.g., pyrovalerone, bupropion, BINA) is dictated by the threedimensional interactions that occur when these compounds non-covalently interact with their
major drug targets (e.g., the DAT, mGlu2, and select nAChR subtypes) at the molecular level. In
particular, this objective was accomplished via the rational design and chemical synthesis of
photoaffinity probes based on promising anti-addiction lead compounds (e.g., pyrovalerone,
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bupropion, BINA) in order to map the binding sites and poses of these compounds within their
proposed major drug targets (i.e., the DAT, α4β2 nAChR, α3β4 nAChR, or mGlu2).
Despite the emergence of several LeuT-based DAT homology models and the
identification of a plethora of DAT interactive compounds, it is still not clear how the DAT
discriminates substrates (e.g., dopamine, amphetamines), inhibitors (e.g., cocaine, bupropion,
methylphenidate, GBR-12909, pyrovalerone), highly abused compounds (e.g., cocaine,
amphetamines, cathinones), and therapeutic compounds (e.g., bupropion, methylphenidate) at the
molecular level. In this regard, photoaffinity probes based on DAT ligands remain important
tools in determining their corresponding binding site(s) and conformational preference(s) within
the DAT. Prior to this dissertation, the overwhelming majority of known DAT irreversible
ligands were based on tropane-containing inhibitors (e.g., cocaine, benztropine) or their
conformationally flexible piperidine- or piperazine-based analogues. One of the goals of this
dissertation was to develop potent non-tropane irreversible ligands for mapping drug-binding
sites within DAT. In particular, structurally-related DAT inhibitors pyrovalerone and bupropion,
with disparate behavioral properties, were chosen as lead compounds for the design of chemical
probes guided by their existing structure-activity relationship studies in the literature.
Specifically, PV and BP were derivatized with a photoreactive functional group (i.e. aryl azide or
acetophenone) and a chemical reporter group (i.e.,
pharmacophore.
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I) placed directly on the inhibitor

The synthesized probes were then pharmacologically evaluated for DAT

affinity and dopamine reuptake inhibition activity by Dr. Christopher Surratt’s group. Probes
with DAT activity comparable to lead compounds were then subjected to photoaffinity labeling
experiments within the DAT by Dr. Roxanne Vaughan’s lab.

This portion of research is

significant as the identification of structural elements and conformational preferences of PV and
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BP binding sites within DAT could provide an experimental evidence for the mechanism of their
different behavioral profiles despite having structural similarities.

In this regard and as

previously described in Sections 5.1 and 5.2, synthesis of pyrovalerone-based photoprobes (±)4.16 - (±)-4.18 and bupropion-based photoprobe (±)-4.20 (Figure 5.1) represent the first
successful examples of DAT photoaffinity ligands based on non-tropane DAT interactive
compounds wherein the photoreactive azide and iodine tag are present directly on the inhibitor
pharmacophore.

Figure 5.1. Photoprobes (±)-4.16 - (±)-4.18 represent the first successful examples of non-tropane DAT irreversible
compounds based on pyrovalerone with the photoreactive azide group and iodine tag present directly on the
pharmacophore.

In terms of practical organic synthesis troubleshooting and as previously described in
Section 5.1.1, an optimized synthesis of racemic 4-azido-3-iodo-pyrovalerone ((±)-4.16)
(Scheme 5.3) was developed featuring the incorporation of the photoreactive aryl azide as the
last step in the synthesis given the potential inherent instability traditionally associated with this
functional group over multiple synthetic step.

The synthesis of target probe (±)-4.16 was

envisioned from known acetanilide 5.1 utilizing six steps: Friedel-Craft’s acylation with valeryl
chloride 5.2, -bromination, pyrrolidine N-alkylation, p-amide hydrolysis, electrophilic
iodination, diazotization and then azide displacement.

However, the initial Friedel-Craft’s

acylation of acetanilide 5.1 with valeryl chloride under various conditions consistently resulted
in an incomplete reaction (Scheme 5.2). As a result, target ketone 5.3 was obtained alongside
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acetanilide as a major impurity because separation by silica gel flash column chromatography
could not be readily achieved due to their same Rf values (Rf = 0.42 in hexanes:EtOAc, 1:1).
This problem was overcome by subjecting the inseparable mixture to reduction with NaBH4 in
MeOH, then separating benzyl alcohol (±)-5.4 from acetanilide via silica gel flash
chromatography due to the significant difference in Rf values for the two compounds. In turn,
benzyl alcohol (±)-5.4 was then oxidized back to ketone 5.3 in 70% yield using PCC in
dichloromethane (Scheme 5.2). The next step, -bromination of ketone 5.3 was optimized to
obtain -bromoketone (±)-5.5 in 100% yield which was further subjected to a sequence of
pyrrolidine N-alkylation, p-amide hydrolysis, electrophilic iodination, diazotization and then
azide displacement. Overall, this route utilized 8 steps and produced target photoprobe 4-azido3-iodo-pyrovalerone ((±)-4.16) in 23% yield (Scheme 5.3). The branched side chain analog of
racemic 4-azido-3-iodo-pyrovalerone ((±)-4.18) was also envisioned similar to the straight chain
analog (±)-4.16 as described in Scheme 5.4. However, once again, the initial Friedel-Craft’s
acylation provided an inseparable mixture of acetanilide (5.1) and target ketone N-(4-(4methylpentanoyl)phenyl)acetamide (5.9) (Scheme 5.4). As a result, ketone 5.9 was instead
synthesized in 3 steps starting from commercially available 4-(trifluoromethyl)aniline (5.10) via
Grignard reaction, then imine hydrolysis followed by N-acetylation. The desired photoprobe (±)4.18 was obtained from ketone 5.9 following same steps as in Scheme 5.4. Alongside the
branched side chain pyrovalerone-based photoprobe (±)-4.18, the synthesis of meta-azido-paraiodo pyrovalerone probe (±)-4.17 was pursued simultaneously.

However, synthesis of its

precursor p-iodo-m-amino pyrovalerone was problematic wherein acid hydrolysis of metaamide-para-iodo pyrovalerone derivative (±)-5.20 in refluxing aqueous HCl did not provide the
desired aniline (±)-5.22 (Scheme 5.8). In order to overcome this roadblock, target photoprobe
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(±)-4.17 was envisioned featuring incorporation of the photoreactive azide moiety earlier in the
synthesis, and was subsequently synthesized from m-azido-p-iodo valerophenone (5.23) via bromination and displacement with pyrrolidine (Scheme 5.10).
Additionally and as previously described in Section 5.2.1, synthesis of racemic p-azidom-iodo-bupropion ((±)-4.20) was needed as a potential photoprobe for DAT structure-function
studies. In this regard, synthesis of racemic p-amino-m-iodo derivative (±)-5.32 was required as
the synthetic precursor to obtain target photoprobe (±)-4.20 via diazotization and azide
displacement.

However, the synthesis of racemic p-amino-m-iodo derivative (±)-5.32 was

problematic wherein electrophilic iodination of aniline (±)-5.31 with iodine monochloride in the
presence of glacial acetic acid provided p-amino-m-iodo (±)-5.32 in low yields (23%, Scheme
5.12). The low yield was a result of difficult monitoring of the reaction for completion via TLC
because the aniline and its p-amino-m-iodo derivative (±)-5.32 had the same Rf values (Rf = 0.27
in hexanes: EtOAc: Et3N, 10:88:2).

As a result, p-amino-m-iodo derivative (±)-5.32 was

obtained alongside aniline (±)-5.31 as a major impurity and separation by silica gel flash column
chromatography could not be achieved efficiently. Furthermore, the conversion of p-amine-miodo derivative (±)-5.32 to azide (±)-4.20, and its subsequent purification via silica gel flash
column chromatography or HCl salt formation, resulted in decomposition of the aryl azide
functional group. As a result, an alternate synthetic strategy towards target photoprobe (±)-4.20
was employed featuring incorporation of the photoreactive azide moiety earlier in the synthesis
(Scheme 5.13).

In particular, target photoprobe (±)-4.20 was obtained from p-azido-m-

iodopropiophenone (5.36) via -bromination and displacement with tert-butylamine in 11%
overall yield over 3 steps (Scheme 5.14).
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Bupropion’s anti-depressant and smoking-cessation effects have been mainly attributed
to its inhibition of the DAT and NET; however, there is increasing evidence that bupropion noncompetitively inhibits several nAChR subtypes, particularly 42 and 34, and modulation of
these targets may also contribute to the drug’s therapeutic efficacy. Despite its status as an FDAapproved drug for major depressive disorder, seasonal affective disorder, and aid to help people
stop smoking by reducing cravings and other withdrawal effects, the molecular determinants of
how bupropion interacts with select nAChR subtypes remains unknown. In particular, this
information is currently lacking due to the unavailability of high-resolution x-ray crystal
structures of human 42 and 34 nAChR subtypes. In addition, (2S,3S)-hydroxybupropion, a
major active and potent metabolite of bupropion is believed to contribute to the antidepressant
and smoking cessation activity of bupropion. The overall objective of the second portion of this
dissertation work was to develop 42 and 34 nAChR irreversible ligands based on
bupropion to allow nAChR structure-function studies. In this regard and as previously described
in Sections 4.7 and 5.2, irreversible chemical probes based on bupropion (i.e. p-azido-m-iodo
analog (±)-4.20 and m-iodo analog (±)-4.21) and (2S,3S)-hydroxybupropion (i.e. p-azido-m-iodo
analog (±)-4.23) were rationally designed and chemically synthesized in order to map the
binding sites and poses of these compounds within the α4β2 nAChR and α3β4 nAChR.

Figure 5.2. Photoprobe (±)-4.20 represents the first example of bupropion based irreversible ligand successfully
utilized towards application of the “BEProFL” approach to understand its binding modes with α4β2 nAChR and
α3β4 nAChR.
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Among the synthesized probes, p-azido-m-iodo BP photoprobe (±)-4.20 (Figure 5.2),
previously developed as a photoprobe for DAT structure-function studies, was successfully
utilized towards application of the “BEProFL” approach to understand the binding modes of
bupropion within α4β2 nAChR and α3β4 nAChR. Given that p-azido-m-iodo BP photoprobe
(±)-4.20 displayed modest pharmacological activity as compared to lead bupropion within select
nAChRs as evaluated by Dr. Hugo Arias, its radio-iodinated analog (±)-[125I]-4.20, synthesized
by Dr. John Lever, was subjected to irreversible photo-crosslinking within Torpedo nAChRs by
Dr. Michael Blanton’s group, followed by proteolytic degradation and amino-acid mapping
which led to the successful identification of the exact point of covalent probe attachment to the
Torpedo nAChR transmembrane domain.

The collected results from pharmacology and

proteomic experiments of (±)-[125I]-4.20 were consistent with a computational molecular model
wherein bupropion, photoreactive analog (±)-4.20, and TCP (a nAChR noncompetitive
antagonist) bind to overlapping sites within the lumen of muscle-type nAChR ion channels.
Analogous to DAT and nAChR ligands, numerous pharmacological and behavioral
studies indicate positive allosteric modulation of mGlu2 as a promising pharmacological
approach for treating drug abuse. In particular, mGlu2 PAMs are currently being pursued as
drug abuse therapeutics given their ability to reduce conditioned reward, self-administration, and
reinstatement of drug seeking which are behavioral hallmarks of drug abuse and addiction.
Nevertheless, discovery and optimization of mGlu2 positive allosteric modulators is associated
with numerous challenges due to the problem of ligand-biased pharmacology, “flat” and difficult
SAR, and molecular switches. These problems that currently represent a major impediment in
developing mGlu2 PAMs as potential therapeutics can be attributed to a lack of understanding of
mechanistic and / or conformational mGlu2 structure-function relationships that dictate the
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affinity and cooperativity of mGlu2 PAMs. This is principally due to lack of 3-D structural
knowledge and understanding of mGlu2 when compared to other well-studied mGlu receptor
subtypes such as mGlu5. Moreover, experimental strategies that further refine and validate the
recently disclosed mGlu2 homology model are sorely needed.

Consequently, the overall

objective of the third portion of this research was to develop mGlu2 PAM irreversible ligands as
chemical probes to map their corresponding binding sites and poses within mGlu2 via affinity or
photoaffinity labeling to be performed by Dr. Karen Gregory’s group. The hypothesis was that
chemically distinct mGlu2 PAMs could be derivatized with a functional group capable of
forming a covalent bond to mGlu2 and, if necessary, a tag functional group. It should be noted
that, instead of radioisotopes (i.e.,
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I) previously used in the design of DAT and nAChRs

photoaffinity ligands, mGlu2 PAM-based chemical probes in this section of dissertation work
were developed bearing “clickable handles” (e.g., aliphatic azides, terminal alkynes) or other
chemical reporter groups (such as ketones) to allow the attachment of detection and purification
tags via bioorthogonal chemistry. Such chemical probes, upon photo-irradiation and covalent
ligation within a mGlu2 allosteric binding site, are expected to allow derivatization of the probe
by the attachment of tags such as biotin for easy enrichment, isolation, and detection, or
fluorophores for detection and imaging applications. This tandem photoaffinity labelingbioorthogonal conjugation approach is expected to aid in microlevel analysis via purification,
proteolysis, and mass spectrometric (MS) studies in order to identify specific sites of photoprobe
crosslinking within mGlu2. This contribution is expected to vertically advance the field towards
elucidation of molecular determinants for mGlu2 allosteric modulator affinity versus
cooperativity, and further help in understanding the inherent complexities of these compounds
that hinder their rational development into therapeutics.
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In particular, BINA ((±)-1.71), a known clinically relevant mGlu2 PAM, was modified to
contain a tag (i.e., terminal alkyne or an acetophenone) and a photoreactive functional group (i.e.
an aryl azide or an acetophenone). In this regard, the design and synthesis of BINA-based
probes (±)-4.25 and (±)-4.27 (see Section 5.3) featuring an intrinsic acetophenone or an aryl
azide as photoreactive groups, respectively, represent the first successful examples of mGlu2
photoaffinity ligands for mGlu2 structure-function studies (Figure 5.3). In terms of practical
organic synthesis and as previously described in Scheme 5.17, racemic hydroxyl indanone (±)3.40 was obtained in 70% yield over 4 steps via modified and optimized reaction conditions with
a significant improvement in product yield when compared to the previously known conditions
(DeSolms et al., 1978; 4 steps, 30% overall yield, Scheme 5.17). The synthesized phenol
derivative (±)-3.40 was subsequently utilized as an intermediate in the synthesis of target BINAbased mGlu2 PAM photoprobes (±)-4.25 (Scheme 5.21) and (±)-4.27 (Scheme 5.23).
Additionally, a 1,5-substituted pyridone class of mGlu2 PAMs discovered via HTS efforts at
Addex Pharmaceuticals was selected as a scaffold for further development of mGlu2 irreversible
chemical photoprobes. More specifically, compound 1.89 was selected as a lead compound for
rational photoprobe design featuring incorporation of different photoreactive functional groups at
different parts on the 1,5-pyridone mGlu2 PAM scaffold (Scheme 4.7). In this regard and as
previously described in Section 5.3, pyridone-based photoaffinity ligands 4.29 – 4.32 (Figure
5.3) were synthesized via optimized synthetic methodology as potential candidates for mGlu2
structure-function studies. In particular, the initial synthetic methodology to synthesize clickable
alkyne-azido mGlu2 PAM photoprobe 4.29 was problematic wherein aniline to azide conversion
failed to provide the desired target due to the presence of a reactive unprotected terminal alkyne
group. In order to overcome this problem, the target photoprobe was successfully synthesized
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via an alternate route featuring N-alkylation of 2-methoxypyridine derivative 5.85 (3 steps, 35%
overall yield, Scheme 5.30) with 4-azido-2-fluoro benzyl chloride 5.89 (3 steps, 15% overall
yield, Scheme 5.31) in 30% yield (Scheme 5.31). Additionally and as previously described in
Section 5.3.8, in order to synthesize clickable alkyne acetophenone mGlu2 PAM photoprobe
4.31, the initial route to obtain benzyl alcohol precursor 5.100 was not optimal as it provided
5.100 in <<1% overall yield in 3 steps via a Friedel-Craft’s acylation, ketone reduction, and
phenol O-alkylation sequence (Scheme 5.34). In turn, the new efficient route featuring a TIPSprotected terminal alkynyl starting material provided the benzyl alcohol 5.100 in 4 steps, (10%
overall yield), which then provided access to target clickable alkyne acetophenone mGlu2 PAM
photoprobe 4.31 via oxidation in 40% yield.

Finally, the synthesis of clickable alkyne

pyrimidone 4.32 represents another mGlu2 PAM clickable photoprobe rationally designed based
on lead 1.89. This photoprobe features a unique photo-masked affinity labeling pyrimidone
moiety, which upon UV irradiation undergoes a Norrish type 1 reaction leading to the formation
of reactive intermediates capable of forming covalent linkage with nucleophilic residues within a
mGlu2 PAM binding site.

Figure 5.3. First successful examples of mGlu2 photoaffinity ligands for mGlu2 structure-function studies.
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In conclusion, the synthesis and utilization of the irreversible chemical probes described
in this dissertation are ultimately expected to facilitate improved rational, structure-based
manipulation and discovery of lead compounds in order to develop therapeutics for numerous
disease states associated with the DAT, α4β2 nAChR, α3β4 nAChR, and mGlu2, including drug
abuse and addiction.

5.5. Summary of Final Compounds Synthesized During This Dissertation Work
Compound Name

Novel /
Known

(±)-1-(4-Azido-3-iodophenyl)-2-(pyrrolidin-1-yl)pentan-1-one ((±)-4.16)

Novel

(±)-1-(3-Azido-4-iodophenyl)-2-(pyrrolidin-1-yl)pentan-1-one ((±)-4.17)

Novel

(±)-1-(4-Azido-3-iodophenyl)-4-methyl-2-(pyrrolidin-1-yl)pentan-1-one ((±)-4.18)

Novel

(±)-1-(4-Azido-3-iodophenyl)-2-(tert-butylamino)propan-1-one hydrochloride ((±)-

Novel

4.20)
(±)-2-(tert-Butylamino)-1-(3-iodophenyl)propan-1-one ((±)-4.21)

Novel

(±)-2-(tert-Butylamino)-1-(3-(tri-n-butylstannyl)phenyl)propan-1-one ((±)-4.22)

Novel

(+)-2-(4-Azido-3-iodophenyl)-2-hydroxy-3,5,5-trimethylmorpholin-4-ium 3-

Novel

carboxy-2,3-dihydroxypropanoate ((+)-4.23)
3'-(((2-Cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydro-1H-inden-5-yl)oxy)methyl)-6-

Known

methoxy-[1,1'-biphenyl]-3-carboxylic acid ((±)-1.74)
(±)-3'-(((2-Cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydro-1H-inden-5-yl)oxy)methyl)-

Novel

6-(prop-2-yn-1-yloxy)-[1,1'-biphenyl]-3-carboxylic acid ((±)-4.25)
(±)-4-Azido-3'-(((2-cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydro-1H-inden-5-

Novel

yl)oxy)methyl)-[1,1'-biphenyl]-3-carboxylic acid ((±)-4.27)
1-(4-Chloro-2-fluorobenzyl)-5-(4-methoxyphenyl)pyridin-2(1H)-one (1.89)

Known

1-(4-Chloro-2-fluorobenzyl)-5-(4-(3-oxo-3-phenylpropoxy)phenyl)pyridin-2(1H)-

Known

one (1.93)
1-(4-Chloro-2-fluorobenzyl)-5-(4-(3-oxo-3-(4-(prop-2-yn-1-yloxy)phenyl)propoxy)
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Novel

phenyl)pyridin-2(1H)-one (4.31)
1-(4-Chloro-2-fluorobenzyl)-5-(4-methoxyphenyl)pyrimidin-2(1H)-one (4.36)

Novel

1-(4-Chloro-2-fluorobenzyl)-5-(4-(prop-2-yn-1-yloxy)phenyl)pyrimidin-2(1H)-one

Novel

(4.32)
1-(3-Azido-5-(azidomethyl)benzyl)-5-(4-methoxyphenyl)pyridin-2(1H)-one (4.30)

Novel

1-(4-Azido-2-fluorobenzyl)-5-(4-(prop-2-yn-1-yloxy)phenyl)pyridin-2(1H)-one

Novel

(4.29)

Table 5.5. Final compounds synthesized for this dissertation work.
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EXPERIMENTAL
All reactions were performed using flame-dried glassware under an inert atmosphere of argon
unless otherwise noted. All solvents and chemicals were purchased from Aldrich Chemical Co.
or Fisher Scientific and used without further purification unless otherwise noted. Flash column
chromatography was performed using Fisher S826-25 silica gel sorbent (70–230 mesh) and
eluting solvent mixtures as specified. Thin-layer chromatography (TLC) was performed using
TLC Silica Gel 60 F254 plates obtained from EMD Chemicals, Inc. and compounds were
visualized under UV light and/or I2 stain. Proportions of solvents used for TLC are by volume.
1

H and

13

C NMR spectra were recorded on either a Bruker 400 or 500 MHz spectrometer.

Chemical shifts for 1H and 13C NMR spectra are reported as parts per million (δ ppm) relative to
tetramethylsilane (0.00 ppm) as an internal standard. Coupling constants are measured in hertz
(Hz). HRMS samples were analyzed at Old Dominion University (Norfolk, VA) by positive ion
electrospray on a Bruker 12 Tesla APEX-Qe FTICR-MS with an Apollo II ion source.
Combustion analyses of selected solid compounds were performed by Atlantic Microlab, Inc.
(Norcross, GA) and are in agreement within 0.4% of calculated values. Infrared spectra were
recorded using a Perkin–Elmer Spectrum RZ I FT-IR spectrophotometer. Optical rotation was
recorded using an AutoPol IV, Automatic Polarimeter. On the basis of NMR, all compounds
were ≥ 95% pure.
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N-(4-pentanoylphenyl)acetamide (5.3)
A mixture of valeryl chloride 5.2 (23.88 mL, 200 mmol) and acetanilide 5.1 (5.5 g, 40 mmol) in
CH2Cl2 (60 mL) was added dropwise to AlCl3 (26.60 g, 200 mmol) at 0ºC. The reaction was
then allowed to reflux overnight, then cooled to room temperature, followed by quenching with
crushed ice. The mixture was then diluted with H2O and CH2Cl2 with vigorous stirring. The
organic layer was then separated, washed with brine, dried (MgSO4), filtered, concentrated to
obtain a crude mixture of ketone 5.3 and starting acetanilide 5.1. The crude (9.0 g, 41.04 mmol)
in MeOH (20 mL) was treated with NaBH4 (7.70 g, 205.2 mmol) in three portions at 0ºC. The
reaction was then stirred at room temperature for 1 hour, then quenched with brine and extracted
with EtOAc. The organic layer was separated, dried with MgSO4, filtered, concentrated, and
chromatographed (CHCl3:MeOH, 9:1) to provide 4.2 g of benzyl alcohol (±)-5.4 in 2 steps. The
resulting benzyl alcohol (4.2 g, 18.08 mmol) in CH2Cl2 (32 mL) at 0ºC was treated with PCC
(5.84 g, 27.11 mmol) in four portions. The resulting reaction mixture was stirred at room
temperature overnight, then filtered through Celite®, concentrated, and chromatographed
(hexane:EtOAc, 7:3) to provide 2.8 g of ketone 5.3 as a yellow solid (70%). Rf = 0.33
(hexane:EtOAc, 8:2).

1

H NMR proved identical to that previously reported (Meltzer et al.,

2006). 1H NMR (CDCl3, 400 MHz):  8.18 (s, 1H), 7.92 (d, 2H, J = 8.7 Hz), 7.64 (d, 2H, J = 8.5
Hz), 2.93 (m, 2H), 2.21 (s, 3H), 1.70 (td, 2H, J = 7.5, 15.1 Hz), 1.40 (dd, 2H, J = 7.5, 15.0 Hz),
0.94 (t, 3H, J = 7.3 Hz).
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(±)-1-(4-Aminophenyl)-2-(pyrrolidin-1-yl)pentan-1-one ((±)-5.6)
A solution of N-[4-(2-pyrrolidin-1-yl-pentanoyl)phenyl]acetamide ((±)-1.32; Meltzer et al.,
2006) (183 mg, 0.63 mmol) in 1M aq. HCl (7 mL) was refluxed for 15 hours. The mixture was
then cooled to room temperature, diluted with H2O, carefully alkalinized with K2CO3, and
extracted with EtOAc. The organic layer was then washed with brine, dried (MgSO4), filtered,
concentrated, and chromatographed (hexanes:EtOAc:Et3N, 60:38:2) to provide 67 mg of aniline
(±)-5.6 as a yellow oil (58%). Rf = 0.24 (hexanes:EtOAc:Et3N, 60:38:2). 1H NMR (CDCl3, 400
MHz):  7.89 (d, 2H, J = 8.7 Hz), 6.56 (d, 2H, J = 8.8 Hz), 4.53 (br s, 2H), 3.78 (m, 1H), 2.60
(m, 2H), 2.48 (m, 2H), 1.82 (m, 1H), 1.67 (m, 5H), 1.17 (m, 2H), 0.77 (t, 3H, J = 7.3 Hz).

13

C

NMR (CDCl3, 100 MHz):  199.3, 151.9, 131.1, 126.9, 113.5, 68.1, 51.3, 33.9, 23.2, 19.3, 14.3.
HRMS calcd for C15H23N2O+ 247.1805, found 247.1804.

(±)-1-(4-Amino-3-iodophenyl)-2-(pyrrolidin-1-yl)pentan-1-one ((±)-5.7)
ICl (426 mg, 2.62 mmol) was added to a solution of 1-(4-aminophenyl)-2-(pyrrolidin-1yl)pentan-1-one ((±)-5.6) (577 mg, 2.34 mmol) in glacial AcOH (41.5 mL). The resulting
mixture was stirred for 16 hours at room temperature then concentrated to dryness. The residue
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obtained was then partitioned between H2O and CHCl3, and then the aqueous layer was
alkalinized to pH 9 using a sat. aq. NaHCO3 solution. This aqueous layer was then extracted
with CHCl3 (X3). The combined organic layers were dried (MgSO4), filtered, and concentrated
to provide 620 mg of iodide (±)-5.7 as a colorless oil (70%). Rf = 0.2 (hexanes:EtOAc:Et3N,
80:18:2).

1

H NMR (CDCl3, 400 MHz):  8.47 (d, 1H, J = 1.9 Hz), 7.98 (dd, 1H, J = 1.9, 8.5

Hz), 6.71 (d, 1H, J = 8.5 Hz), 4.65 (br s, 2H), 3.75 (m, 1H), 2.66 (m, 2H), 2.55 (m, 2H), 1.911.84 (m, 1H), 1.78-1.70 (m, 5H), 1.29-1.20 (m, 2H), 0.87 (t, 3H, J = 7.3 Hz).

13

C NMR (CDCl3,

100 MHz):  198.0, 150.9, 140.7, 130.7, 128.8, 113.0, 82.8, 68.8, 51.3, 33.5, 23.4, 19.3, 14.3.
HRMS calcd for C15H21IN2ONa+ 395.0591, found 395.0582.

(±)-1-(4-Azido-3-iodophenyl)-2-(pyrrolidin-1-yl)pentan-1-one ((±)-4.16)
A 0˚C solution of 1-(4-amino-3-iodophenyl)-2-(pyrrolidin-1-yl)pentan-1-one ((±)-5.7) (248 mg,
0.67 mmol) in trifluoroacetic acid (3.3 mL) was treated with NaNO2 (113 mg, 1.64 mmol). The
mixture was then stirred in the dark for 45 minutes at 0˚C then carefully treated with NaN3 (532
mg, 8.18 mmol) and Et2O (3.3 mL). The resulting reaction was allowed stirred in the dark at 0˚C
for 2 hours, and then was diluted with H2O and Et2O. The organic layer was separated, washed
with brine, dried (MgSO4), filtered, and concentrated. Chromatography (hexanes:EtOAc:Et3N,
80:18:2) provided 247 mg of azide (±)-4.16 (93%) as a yellow oil.

Rf = 0.37

(hexanes:EtOAc:Et3N, 80:18:2). 1H NMR (CDCl3, 400 MHz):  8.59 (d, 1H, J = 1.9 Hz), 8.27
(dd, 1H, J = 1.9, 8.4 Hz), 7.18 (d, 1H, J = 8.4 Hz), 3.73 (m, 1H), 2.67 (m, 2H), 2.54 (m, 2H),
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1.92-1.82 (m, 1H), 1.80-1.70 (m, 5H), 1.28-1.17 (m, 2H), 0.88 (t, 3H, J = 7.3 Hz).

13

C NMR

(CDCl3, 100 MHz):  198.2, 146.0, 140.8, 134.4, 130.2, 117.9, 87.6, 69.9, 60.4, 51.1, 32.5, 23.4,
21.0, 19.4, 14.2. HRMS calcd for C15H20IN4O+ 399.0676, found 399.0669. IR: azide, 2100 cm-1.

1-(4-Aminophenyl)-4-methylpentan-1-one (5.11)
1,2-Dibromoethane (4 drops) was added to a suspension of Mg turnings (4.860 g, 200 mmol) in
dry THF (440 mL) at 0˚C, followed by dropwise addition of 1-bromo-3-methylbutane (25 mL,
200 mmol). When the boiling of THF ceased, the reaction mixture was cooled to -78˚C and 4(trifluoromethyl)aniline (5.10, 5 mL, 40 mmol) was added dropwise. The reaction was then
refluxed at 80˚C for 4 hrs, cooled to 0˚C, then carefully quenched with sat. aq. NH4Cl solution
followed by extraction with Et2O. The organic layer was then filtered over silica gel and the
filtrate was concentrated. The resulting residue was then hydrolyzed by refluxing in 10% H 2SO4
(20 mL) for 2 hours at 120˚C. The mixture was then cooled to room temperature, neutralized
with K2CO3, then extracted with Et2O. The organic layer was then dried (MgSO4), filtered,
concentrated, and chromatographed (hexanes:EtOAc, 8:2) to give 700 mg of ketone 5.11 as a
colorless oil (10%). Rf = 0.30 (7:3, hexanes:EtOAc).

1

H NMR (CDCl3, 400 MHz):  7.81 (d,

2H, J = 8.6 Hz), 6.64 (d, 2H, J = 8.5 Hz), 4.20 (s, 2H), 2.86 (m, 2H), 1.61 (m, 3H), 0.94 (d, 6H, J
= 6.2 Hz).

13

C NMR (CDCl3, 100 MHz):  199.2, 151.1, 130.5, 127.5, 113.7, 36.0, 33.8, 27.9,

22.5. HRMS calcd for C12H17NONa+ 214.1202, found 214.1208.
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N-(4-(4-Methylpentanoyl)phenyl)acetamide (5.9)
Aniline 5.11 (653 mg, 3.4 mmol) in EtOAc (6.7 mL) was treated dropwise with acetyl chloride
(0.53 mL, 7.51 mmol) at 0˚C. The reaction was then refluxed at 80˚C for 1 hour, cooled to 0˚C,
then quenched with NaHCO3 and extracted with EtOAc. The organic layer was then dried
(MgSO4), filtered, and concentrated. Chromatography (hexanes:EtOAc, 7:3) provided 353 mg
of acetamide 5.9 as a colorless oil (44%). Rf = 0.42 (hexanes:EtOAc, 1:1).

1

H NMR (CDCl3,

400 MHz):  8.01 (s, 1H), 7.93 (d, 2H, J = 8.7 Hz), 7.64 (d, 2H, J = 8.6 Hz), 2.93 (m, 2H), 2.22
(s, 3H), 1.64 (m, 3H), 0.94 (d, 6H, J = 6.3 Hz).

C NMR (CDCl3, 100 MHz):  199.9, 168.8,

13

142.3, 132.6, 129.4, 118.9, 36.5, 33.4, 27.9, 24.7, 22.4.

HRMS calcd for C14H19NO2Na+

256.1308, found 256.1312.

(±)-N-(4-(4-Methyl-2-(pyrrolidin-1-yl)pentanoyl)phenyl)acetamide ((±)-5.12)
A mixture of ketone 5.9 (1.25 g, 5.36 mmol) in CH2Cl2 (15 mL) was treated dropwise with liquid
Br2 (0.3 mL, 5.36 mmol) at 0˚C. The reaction was then warmed to room temperature, stirred for
3 hours, then concentrated to provide the resulting -bromo ketone (1.67 g, 100%), which was
used without further purification. A solution of -bromide (1.67 g, 5.36 mmol) in Et2O (11 mL)
was treated with pyrrolidine (0.97 mL) at 0˚C. The reaction was then stirred at room temperature
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overnight, quenched with solid NaHCO3, then extracted with Et2O (X2). The organic layer was
washed with 1M aq. HCl, then dried (MgSO4), filtered, and concentrated to provide 871 mg of
pyrovalerone analog (±)-5.12 as a yellow oil (54%). Rf = 0.17 (hexanes:EtOAc:Et3N, 40:58:2).
1

H NMR (CDCl3, 400 MHz):  8.14 (d, 2H, J = 8.8 Hz), 7.62 (br, m, 3H), 4.00 (q, 1H, J = 4.7

Hz), 2.72 (m, 2H), 2.56 (m, 2H), 2.22 (s, 3H), 1.89 (m, 1H), 1.72 (m, 4H), 1.61-1.54 (m, 1H),
1.51-1.41 (m, 1H), 0.87 (dd, 6H, J = 6.5, 14.9 Hz).

13

C NMR (CDCl3, 100 MHz):  200.6,

169.3, 142.7, 132.5, 130.0, 119.0, 66.3, 50.6, 39.4, 25.3, 24.6, 23.6, 23.4, 22.2. HRMS calcd for
C18H26N2O2H+ 303.2067, found 303.2064.

1-(4-Aminophenyl)-4-methyl-2-(pyrrolidin-1-yl)pentan-1-one ((±)-5.13)
N-(4-(4-methyl-2-(pyrrolidin-1-yl)pentanoyl)phenyl)acetamide ((±)-5.12; 628 mg, 2.08 mmol)
was refluxed in 1M aq. HCl (22 mL) at 125˚C for 20 hours. The mixture was then cooled to
room temperature, diluted with H2O, carefully alkalinized with K2CO3 to pH 9, then extracted
with EtOAc.

The organic layer was washed with brine, dried (MgSO4), filtered, and

concentrated. Chromatography (hexanes:EtOAc:Et3N, 80:18:2) provided 459 mg of aniline (±)5.13 as a yellow oil (60%). Rf = 0.33 (hexanes:EtOAc:Et3N, 40:58:2).

1

H NMR (CDCl3, 400

MHz):  8.00 (d, 2H, J = 8.8 Hz), 6.64 (d, 2H, J = 8.8 Hz), 4.16 (s, 2H), 3.99 (dd, 1H, J = 4.6,
9.5 Hz), 2.71 (m, 2H), 2.56 (m, 2H), 1.90 (m, 1H), 1.72 (p, 4H, J = 7.5 Hz), 1.59-1.42 (m, 2H),
0.88 (dd, 6H, J = 6.4, 14.8 Hz).

C NMR (CDCl3, 100 MHz):  199.5, 151.1, 131.1, 127.9,

13
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113.7, 65.3, 50.7, 40.0, 25.3, 23.4, 22.3. HRMS calcd for C16H24N2ONa+ 283.1781, found
283.1779.

(±)-1-(4-Amino-3-iodophenyl)-4-methyl-2-(pyrrolidin-1-yl)pentan-1-one ((±)-5.14)
A mixture of 1-(4-aminophenyl)-4-methyl-2-(pyrrolidin-1-yl)pentan-1-one ((±)-5.13; 310 mg,
1.19 mmol), glacial AcOH (21 mL), and ICl (216 mg, 1.33 mmol) was stirred at room
temperature for 20 hours. The mixture was then concentrated to dryness and the resulting
residue was dissolved with H2O and extracted with CHCl3. The aqueous layer was then basified
with solid NaHCO3 and extracted with CHCl3. The combined organic layers were then washed
with brine, dried (MgSO4), filtered, concentrated and chromatographed (hexanes:EtOAc:Et3N,
60:38:2) to provide 200 mg of target (±)-5.14 (52%). Rf = 0.34 (hexanes:EtOAc:Et3N, 40:68:2).
1

H NMR (CDCl3, 400 MHz):  8.47 (d, 1H, J = 1.9 Hz), 7.99 (dd, 1H, J = 1.9, 8.5 Hz), 6.70 (d,

1H, J = 8.5 Hz), 4.67 (s, 2H), 3.89 (dd, 1H, J = 4.6, 9.5 Hz), 2.68 (q, 2H, J = 7.2 Hz), 2.52 (dd,
2H, J = 9.5, 11.9 Hz), 1.86 (m, 1H), 1.71 (m, 4H), 1.58-1.40 (m, 2H), 0.87 (dd, 6H, J = 6.5, 15.2
Hz).

C NMR (CDCl3, 100 MHz):  198.1, 150.9, 140.7, 130.7, 129.0, 113.0, 82.9, 65.9, 50.7,

13

39.7, 25.4, 23.7, 23.4, 22.3. HRMS calcd for C16H23IN2OH+ 387.0928, found 387.0924. MP:
240-241 ºC.
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(±)-1-(4-Azido-3-iodophenyl)-4-methyl-2-(pyrrolidin-1-yl)pentan-1-one ((±)-4.18)
A solution of 1-(4-amino-3-iodophenyl)-4-methyl-2-(pyrrolidin-1-yl)pentan-1-one ((±)-5.14; 96
mg, 0.25 mmol) in trifluoroacetic acid (1 mL) was treated at 0˚C with NaNO2 (34 mg, 0.50
mmol). The mixture was then stirred in the dark for 45 minutes at 0˚C, then carefully treated
with NaN3 (162 mg, 2.5 mmol) and Et2O (1 mL). The reaction was then stirred in the dark at
0˚C for 2 hours then diluted with H2O and Et2O. The organic layer was then separated and
washed with brine, then dried (MgSO4), filtered, and concentrated.

Chromatography

(hexanes:EtOAc:Et3N, 60:38:2) provided 76 mg of azide (±)-4.18 as a yellow oil (75%). Rf =
0.66 (hexanes:EtOAc:Et3N, 60:38:2). 1H NMR (CDCl3, 400 MHz):  8.58 (d, 1H, J = 1.9 Hz),
8.27 (dd, 1H, J = 1.9, 8.4 Hz), 7.17 (d, 1H, J = 8.4 Hz), 3.84 (dd, 1H, J = 4.7, 9.5 Hz), 2.67 (m,
2H), 2.52 (dd, 2H, J = 5.6, 16.1 Hz), 1.85 (ddd, 1H, J = 5.1, 9.6, 13.5 Hz), 1.72 (m, 4H), 1.56
(ddd, 1H, J = 4.7, 8.8, 13.4 Hz), 1.48-1.38 (m, 1H), 0.87 (dd, 6H, J = 6.5, 15.7 Hz).

13

C NMR

(CDCl3, 100 MHz):  198.1, 145.9, 140.8, 134.5, 130.2, 117.9, 87.6, 67.3, 50.5, 38.5, 25.4, 23.6,
23.5, 22.1. HRMS calcd for C16H21IN4OH+ 413.0833, found 413.0839. The hydochloride salt of
(±)-4.18 was synthesized by stirring the free base in 2M ethereal HCl (3 mL) overnight followed
by concentration to provide 30 mg of a yellow semi-solid (36%).

1

H NMR (DMSO-d6, 400

MHz):  10.54 (br, s, 1H), 8.54 (d, 1H, J = 1.3 Hz), 8.15 (d, 1H, J = 8.3 Hz), 7.56 (d, 1H, J = 8.4
Hz), 5.40 (m, 1H), 3.63-3.02 (m, 4H), 2.01-1.70 (m, 6H), 0.81 (dd, 6H, J = 2.2, 6.3 Hz).

13

C

NMR (DMSO-d6, 100 MHz):  195.8, 148.5, 140.5, 133.0, 130.7, 120.4, 89.4, 65.2, 53.6, 52.8,
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52.7, 24.7, 23.8, 23.3, 21.9. Anal Calcd for C16H22ClIN4O: C, 42.83; H, 4.94; N, 12.49; I, 28.28;
Cl, 7.90. Found C, 43.16; H, 5.02; N, 12.27; I, 28.50; Cl, 7.52. IR: azide, 2072 cm-1. MP: 211
ºC.

1-(4-Iodo-3-nitrophenyl)pentan-1-one (5.17)
Fuming nitric acid (2.03 mL, 48.6 mmol) was added dropwise to p-iodovalerophenone (5.16;
Meltzer et al., 2006) (297 mg, 1.03 mmol) at -78˚C. After the addition, the reaction was warmed
to 0˚C, stirred for 1 hour, then poured over ice cold H2O. The aqueous layer was then extracted
with Et2O. The organic layer was dried and concentrated. Chromatography (hexanes:EtOAc,
95:5) yielded 200mg of nitro ketone 5.17 (58%) as a yellow solid. Rf = 0.13 (hexanes:EtOAc,
95:5). 1H NMR (CDCl3, 400 MHz):  8.36 (d, 1H, J = 2.0 Hz), 8.17 (d, 1H, J = 8.2 Hz), 7.80
(dd, 1H, J = 2.0, 8.2 Hz), 2.97 (m, 2H), 1.73 (td, 2H, J = 7.4, 15.0 Hz), 1.41 (qd, 2H, J = 7.4,
14.7 Hz), 0.96 (t, 3H, J = 7.3 Hz).

13

C NMR (CDCl3, 100 MHz):  197.4, 153.3, 142.5, 137.8,

131.8, 124.5, 92.0, 38.4, 26.0, 22.3, 13.9. HRMS analysis of this compound was not obtained
due to sample degradation (i.e., this compound is relatively unstable and should be used
immediately in the next reaction).
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1-(3-Amino-4-iodophenyl)pentan-1-one (5.18)
Fe(s) (174.2 mg, 3.12 mmol) was added to a solution of 1-(4-iodo-3-nitrophenyl)pentan-1-one
(5.17) (200 mg, 0.60 mmol) dissolved in H2O (0.62 mL), EtOH (1.25 mL), and glacial AcOH
(1.25 mL). The reaction was then sonicated for 1.5 hours then filtered. 2M aq. KOH (50 mL)
was then added to the filtrate followed by dilution with EtOAc. The organic layer was then
washed with H2O and brine, dried (MgSO4), filtered, and concentrated to give 151 mg of amine
5.18 as a yellow solid (83%). Rf = 0.67 (hexanes:EtOAc, 7:3). 1H NMR (CDCl3, 400 MHz): 
7.70 (d, 1H, J = 8.2 Hz), 7.30 (d, 1H, J = 1.9 Hz), 6.99 (dd, 1H, J = 1.9, 8.2Hz), 4.32 (s, 2H),
2.86 (t, 2H, J = 7.4 Hz), 1.67 (m, 2H), 1.37 (m, 2H), 0.93 (t, 3H, J = 7.3 Hz).

13

C NMR (CDCl3,

100 MHz):  200.3, 147.2, 139.2, 138.2, 119.0, 113.3, 89.9, 38.3, 26.4, 22.4, 13.9. HRMS calcd
for C11H14INONa+ 326.0012, found 326.0015.

N-(2-Iodo-5-pentanoylphenyl)acetamide (5.19)
Acetyl chloride (0.43 mL, 6.12 mmol) was added dropwise to a mixture of amine 5.18 (841.5
mg, 2.77 mmol) in EtOAc (5.44 mL) at 0˚C. The reaction was then refluxed at 80˚C for 1 hour,
cooled to room temperature, basified with NaHCO3 to pH 9, then extracted with EtOAc (X2).
The combined organic layers were washed with brine, dried (MgSO4), filtered, and concentrated
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to provide 912 mg of acetamide 5.19 as a brown solid (95%). Rf = 0.34 (hexanes:EtOAc, 6:4).
1

H NMR (CDCl3, 500 MHz):  8.70 (s, 1H), 7.85 (d, 1H, J = 8.3 Hz), 7.60 (s, 1H), 7.40 (dd, 1H,

J = 1.8, 8.3 Hz), 2.93 (t, 2H, J = 7.4 Hz), 2.27 (s, 3H), 1.69 (m, 2H), 1.38 (m, 2H), 0.93 (t, 3H, J
= 7.4 Hz).

13

C NMR (CDCl3, 100 MHz):  199.7, 168.6, 139.1, 138.6, 137.8, 124.8, 121.7, 96.1,

38.3, 26.3, 22.3, 13.9. HRMS calcd for C13H16INO2Na+ 368.0118, found 368.0114.

1-(3-Azido-4-iodophenyl)pentan-1-one (5.23)
A mixture of 1-(3-amino-4-iodophenyl)pentan-1-one (5.18) (135 mg, 0.44 mmol), trifluoroacetic
acid (1.76 mL), and NaNO2 (614 mg, 0.89 mmol) was stirred at 0˚C for 45 minutes in the dark,
followed by careful addition of NaN3 (289 mg, 4.45 mmol) and anhydrous Et2O (1.76 mL). The
resulting reaction was then stirred in dark at 0˚C for 2 hours followed by dilution with H 2O and
Et2O.

The organic layer was separated, washed with brine, dried (MgSO4), filtered, and

concentrated to provide 141 mg of azide 5.23 as a brown oil (96%). Rf = 0.67 (hexanes:EtOAc,
8:2). 1H NMR (CDCl3, 400 MHz):  7.87 (d, 1H, J = 8.2 Hz), 7.65 (d, 1H, J = 1.8 Hz), 7.37 (dd,
1H, J = 1.9, 8.2 Hz), 2.92 (m, 2H), 1.70 (td, 2H, J = 7.5, 15.0 Hz), 1.39 (qd, 2H, J = 7.4, 14.7
Hz), 0.94 (t, 3H, J = 7.3 Hz).

C NMR (CDCl3, 100 MHz):  199.0, 142.6, 140.3, 138.2, 125.4,

13

117.1, 94.1, 38.3, 26.2, 22.4, 13.9. HRMS analysis of this compound was not obtained (i.e., this
compound is relatively unstable at room temperature and should be used immediately in the next
reaction).
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(±)-1-(3-Azido-4-iodophenyl)-2-(pyrrolidin-1-yl)pentan-1-one ((±)-4.17)
Liquid Br2 (0.03 mL, 0.64 mmol) was added dropwise to a mixture of ketone 5.23 (210 mg, 0.64
mmol) in CH2Cl2 (2.74 mL) at 0˚C. The reaction was then warmed to room temperature, stirred
for 2 hours, then concentrated to provide bromide 5.24, which was used without further
purification. To 265 mg (0.65 mmol) of bromide 5.24 was added Et2O (1.35 mL) at 0˚C,
followed by the addition of pyrrolidine (0.165 mL, 2 mmol). The reaction was then stirred at
room temperature for 20 hours, quenched with solid NaHCO3, then extracted with Et2O (X2).
The combined organic layers were then washed with 1M aq. HCl, dried (MgSO4), filtered,
concentrated, and chromatographed (hexanes:EtOAc:Et3N, 80:18:2) to provide 30 mg of
pyrovalerone analog (±)-4.17 as an oil (20%). Rf = 0.54 (hexanes:EtOAc:Et3N, 50:48:2).

1

H

NMR (CDCl3, 500 MHz):  8.08 (d, 1H, J = 1.8 Hz), 7.90 (d, 1H, J = 8.2 Hz), 7.68 (dd, 1H, J =
1.8, 8.2 Hz), 3.73 (m, 1H), 2.71 (s, 2H), 2.58 (s, 2H), 1.81 (m, 6H), 1.24 (m, 2H), 0.90 (t, 3H, J =
7.3 Hz).

13

C NMR (CDCl3, 100 MHz):  199.4, 142.5, 140.2, 137.8, 126.1, 118.2, 94.2, 70.4,

51.1, 32.3, 23.4, 19.5, 14.2. HRMS calcd for C15H19IN4OH+ 399.0676, found 399.0680. IR:
azide, 2111.9 cm-1.
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N-(4-Propionylphenyl)acetamide (5.28)
4'-Aminopropiophenone (5.27; 3.0 g, 20 mmol) in EtOAc (40 mL) was treated dropwise with
acetyl chloride (3.1 mL, 44 mmol) at 0˚C. The reaction was then refluxed at 80˚C for 2.5 hours,
then cooled to room temperature and carefully quenched with sat. aq. NaHCO3 solution followed
by extraction with EtOAc. The organic layer was washed with brine, dried (MgSO4), filtered,
and concentrated to provide 3.8 g of amide 5.28 as a white solid that was used without further
purification (99%). Rf = 0.18 (hexanes:EtOAc, 1:1).

1

H NMR (CDCl3, 400 MHz): δ 7.96 (d,

2H, J = 8.6 Hz), 7.64 (d, 2H, J = 8.3 Hz), 7.58 (s, 1H), 3.00 (q, 2H, J = 7.3 Hz), 2.24 (s, 3H),
1.24 (t, 3H, J = 7.2 Hz).

13

C NMR (CDCl3, 100 MHz): δ 199.7, 168.5, 142.0, 132.6, 129.3,

118.8, 31.5, 24.7, 8.3. HRMS calcd for (C11H13NO2)Na+ 214.0839, found 214.0841. MP:
167ºC.

(±)-N-(4-(2-(tert-Butylamino)propanoyl)phenyl)acetamide hydrochloride ((±)-5.30)
A mixture of liquid bromine (0.26 mL, 5.2 mmol) in CHCl3 (60 mL) was added dropwise to a
solution of ketone 5.28 (898 mg, 4.7 mmol) in CHCl3 (60 mL). The orange reaction mixture was
then heated at 55˚C for 3 hours until it became yellow, cooled to room temperature, then
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concentrated. The rsulting residue was dissolved in N-methylpyrrolidinone (2.7 mL) and tBuNH2 (0.95 mL, 9.0 mmol) was added dropwise. The mixture was then heated at 55˚C for 10
minutes, cooled to room temperature, then diluted with Et2O and H2O. The organic layer was
separated, washed with H2O and brine, dried (MgSO4), filtered, and concentrated. The resulting
solid was then dissolved in a minimum amount of Et2O and treated dropwise with 2M HCl in
Et2O to produce a white solid, which was collected via filtration, washed with Et2O, and dried to
provide 120 mg of bupropion analog (±)-5.30 as its HCl salt (23%, three steps).

1

H NMR

(MeOD, 500 MHz): δ 8.16 (d, 2H, J = 8.9 Hz), 7.85 (d, 2H, J = 8.9 Hz), 5.24 (q, 1H, J = 7.1 Hz),
2.20 (s, 3H), 1.61 (d, 3H, J = 7.1 Hz), 1.39 (s, 9H).

13

C NMR (MeOD, 100 MHz): δ 193.9,

170.7, 145.2, 130.3, 126.9, 119.1, 58.4, 53.1, 25.0, 22.7, 17.5. HRMS calcd for (C15H22N2O2)H+
263.1754, found 263.1755. Anal. calcd for: C15H23N2O2Cl•0.3HCl: C, 58.16; H, 7.58; N, 9.04.
Found C, 57.80; H, 7.41; N, 9.01.

(±)-1-(4-Aminophenyl)-2-(tert-butylamino)propan-1-one ((±)-5.31)
A solution of amide (±)-5.30 (701 mg, 2.7 mmol) in 1M aq. HCl (30 mL) was refluxed for 15
hours, cooled to room temperature, diluted with H2O, carefully alkalinized with K2CO3 to pH 12,
then extracted with EtOAc. The organic layer was washed with brine, dried (MgSO4), filtered,
concentrated, and chromatographed (hexanes:EtOAc:Et3N, 30:68:2) to provide 488 mg of aniline
(±)-5.31 as a yellow solid (83%). Rf = 0.2 (hexanes:EtOAc:Et3N, 30:68:2).

1

H NMR (CDCl3,

500 MHz): δ 7.85 (d, 2H, J = 8.7 Hz), 6.67 (d, 2H, J = 8.7 Hz), 4.29 (s, 2H), 4.28 (q, 1H, J = 7.1
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Hz), 2.59 (s, 1H), 1.24 (d, 3H, J = 7.1 Hz), 1.04 (s, 9H).

13

C NMR (CDCl3, 100 MHz): δ 202.9,

151.5, 130.8, 125.0, 113.9, 51.1, 50.7, 29.7, 23.1. HRMS calcd for (C13H20N2O)H+ 221.1648,
found 221.1650. Anal. calcd for C13H20N2O·0.1EtOAc: C, 70.24; H, 9.15; N, 12.22. Found C,
70.04; H, 9.09; N, 12.5. MP: 113 ˚C.

(±)-1-(4-Amino-3-iodophenyl)-2-(tert-butylamino)propan-1-one ((±)-5.32)
A mixture of aniline (±)-5.31 (312 mg, 1.41 mmol), glacial AcOH (25 mL), and ICl (257 mg,
1.59 mmol) was stirred at room temperature overnight. The reaction was then concentrated and
the resulting residue was partitioned between CHCl3 and H2O. The aqueous layer was then
separated, alkalinized with solid NaHCO3, and extracted with CHCl3. The organic layer was
then washed with brine, dried (MgSO4), filtered, and concentrated.

Chromatography

(hexanes:EtOAc:Et3N, 50:48:2) then provided 180 mg of iodide (±)-5.32 as a white solid (23%).
Rf = 0.27 (hexanes: EtOAc: Et3N, 10:88:2). 1H NMR (CDCl3, 400 MHz):  8.30 (d, 1H, J = 2.0
Hz), 7.78 (dd, 1H, J = 2.0, 8.5 Hz), 6.73 (d, 1H, J = 8.5 Hz), 4.81 (s, 2H), 4.20 (q, 1H, J = 7.1
Hz), 2.56 (s, 1H), 1.22 (d, 3H, J = 7.1 Hz), 1.01 (s, 9H).

13

C-NMR (CDCl3, 100 MHz):  201.7,

151.2, 140.3, 130.3, 126.5, 113.2, 83.0, 51.3, 50.8, 29.7, 22.9. HRMS calcd. for (C13H19IN2O)H+
347.0615, found 347.0615. Anal. calcd for: C13H19IN2O: C, 45.10; H, 5.53; I, 36.66; N, 8.09; O,
4.62. Found C, 44.81; H, 5.45; I, 36.39; N, 7.95. MP: 91 ˚C.
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1-(4-Amino-3-iodophenyl)propan-1-one (5.35)
A mixture of 4'-aminopropiophenone 5.27 (597 mg, 4.0 mmol), CaCO3 (628 mg, 6.3 mmol),
H2O (1.6 mL), and MeOH (4 mL) was cooled to 0˚C and ICl (714 mg, 4.4 mmol) in MeOH (1.5
mL) was added. The reaction was stirred at room temperature for 16 hours, diluted with sat. aq.
Na2S2O3 solution, then extracted with Et2O (X2). The combined organic layers were washed
with brine, dried (MgSO4), filtered, concentrated, and chromatographed (hexanes:EtOAc, 8:2) to
provide 514 mg of iodide 5.35 as a brown solid (47%). Rf = 0.36 (hexanes:EtOAc, 7:3).

1

H

NMR (CDCl3, 400 MHz): δ 8.28 (s, 1H), 7.76 (d, 1H, J = 8.2 Hz), 6.72 (d, 1H, J = 8.3 Hz), 4.69
(s, 2H), 2.88 (d, 2H, J = 7.1 Hz), 1.19 (t, 3H, J = 7.0 Hz).

13

C NMR (CDCl3, 100 MHz): δ 198.0,

150.9, 139.9, 129.9, 128.8, 113.2, 82.7, 31.1, 8.6. HRMS calcd for (C9H10INO)2Na+ 572.9506,
found 572.9500.

1-(4-Azido-3-iodophenyl)propan-1-one (5.36)
A 0˚C solution of aniline 5.35 (514 mg, 1.9 mmol) in trifluoroacetic acid (7.5 mL) was treated
with NaNO2 (258 mg, 3.7 mmol). The mixture was stirred in the dark for 45 minutes at 0˚C then
carefully treated with NaN3 (1.21 g, 18.6 mmol) and Et2O (7.5 mL). The reaction was then
stirred in the dark at 0˚C for 1 hour then diluted with H2O and Et2O. The organic layer was
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separated, washed with brine, dried (MgSO4), filtered, and concentrated to provide 554 mg of
azide 5.36 (99%), which was used without further purification. Rf = 0.75 (hexanes:EtOAc, 7:3).
1

H NMR (CDCl3, 400 MHz): δ 8.33 (d, 1H, J = 1.9 Hz), 7.96 (dd, 1H, J = 1.9, 8.4 Hz), 7.15 (d,

1H, J = 8.3 Hz), 2.94 (q, 2H, J = 7.2 Hz), 1.19 (t, 3H, J = 7.2 Hz).

13

C NMR (CDCl3, 100 MHz):

δ 198.0, 146.0, 139.9, 134.6, 129.3, 118.0, 87.7, 31.7, 8.1. HRMS calcd for (C9H8IN3O)2Na+
624.9316, found 624.9331. IR: azide, 2102 cm-1.

(±)-1-(4-Azido-3-iodophenyl)-2-(tert-butylamino)propan-1-one hydrochloride ((±)-4.20)
A solution of 1-(4-azido-3-iodophenyl)propan-1-one ((±)-5.36, 602 mg, 2.0 mmol) in CHCl3 (12
mL) was treated with a mixture of liquid Br2 (0.1 mL, 2.2 mmol) in CHCl3 (12 mL). The
reaction was then heated at 50˚C for 20 hours, cooled to room temperature, then concentrated.
N-Methylpyrrolidinone (3 mL) was then added to the residue followed by t-BuNH2 (0.5 mL, 4.7
mmol). The mixture was then heated at 55˚C for 10 minutes, cooled to room temperature, then
diluted with Et2O. The organic layer was then washed with H2O, dried (MgSO4), filtered, and
concentrated. 2M HCl in Et2O was then added dropwise to the residue until a yellow solid
ceased to precipitate. The resulting solid was collected via filtration, washed with Et2O, then
dried to provide 79 mg of bupropion analog (±)-4.20 as the HCl salt (11%, 3 steps).

1

H NMR

(MeOD, 400 MHz): δ 8.61 (d, 1H, J = 2.0 Hz), 8.30 (dd, 1H, J = 2.0, 8.5 Hz), 7.50 (d, 1H, J =
8.5 Hz), 5.28 (q, 1H, J = 7.1 Hz), 1.62 (d, 3H, J = 7.1 Hz), 1.40 (s, 9H).

13

C NMR (MeOD, 100

MHz): δ 193.2, 148.9, 140.6, 130.4, 129.5, 118.8, 87.5, 58.5, 53.3, 26.3, 25.1, 17.4. HRMS
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calcd for the free base as (C13H17IN4O)Na+ 395.0339, found 395.0344.

Anal. calcd for:

C13H18IClN4O·0.4Et2O·0.2HCl: C, 39.35; H, 5.02; N, 12.57; I, 28.48. Found C, 39.32; H, 4.98;
N, 12.78; I, 28.41. IR: azide, 2109 cm-1. MP: 96 ˚C.

(±)-2-(tert-Butylamino)-1-(3-iodophenyl)propan-1-one ((±)-4.21)
3-Iodo-propiophenone (5.38, 388 mg, 1.49 mmol) was treated with a mixture of liquid Br2 (0.83
mL) in CH2Cl2 (12 mL). The reaction was then heated at 40˚C for 20 hours followed by 50˚C
for 1 hour. The reaction was then cooled to room temperature and concentrated to provide the
resulting -bromo ketone, which was used immediately without further purification. To the
resulting bromide (522 mg) was added N-methylpyrrolidinone (2 mL) and t-BuNH2 (0.7 mL).
The mixture was then heated to 55˚C for 15 minutes. The reaction was then cooled, diluted with
Et2O, and washed with sat. aq. NaHCO3 solution. The organic layer was then washed with brine,
dried (MgSO4), filtered, and concentrated. The resulting material was then treated dropwise with
1M HCl in Et2O (1.5 mL) to provide 257 mg of the hydrochloride salt of bupropion analog ((±)4.21 as a yellow solid after filtration and drying (47%). 1H NMR (DMSO-d6, 400 MHz):  9.54
(br, d, 1H, J = 13.0 Hz), 8.61 (br, s, 1H), 8.52 (t, 1H, J = 1.6 Hz), 8.23 (m, 1H), 8.15 (m, 1H),
7.44 (t, 1H, J = 7.8 Hz), 5.29 (m, 1H), 1.52 (d, 3H, J = 7.0 Hz), 1.32 (s, 9H).

13

C NMR (DMSO-

d6, 400 MHz):  195.9, 143.8, 137.4, 134.6, 131.8, 128.9, 96.5, 58.6, 53.2, 26.5, 18.5. HRMS
calcd for the free base as (C13H18INO)Na+ 354.0325, found 354.0331.
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Anal. calcd for

(C13H19ClNIO), C, 42.47; H, 5.21; N, 3.81; I, 34.52. Found, C, 42.64; H, 5.40; N, 3.94; I,
34.24.

(±)-2-(tert-Butylamino)-1-(3-(tri-n-butylstannyl)phenyl)propan-1-one ((±)-4.22)
To 2-(tert-butylamino)-1-(3-iodophenyl)propan-1-one ((±)-4.21, 59 mg, 0.18 mmol) was
sequentially added toluene (5 mL), Pd(PPh3)Br2 (5 mg, 0.01 mmol), and (n-Bu3)2Sn2 (0.13 mL,
0.33 mmol). The resulting mixture was heated at 105˚C for 2 hours then cooled to room
temperature. The mixture was then partitioned between sat. aq. K2CO3 solution and EtOAc. The
EtOAc layer was then separated, washed with brine, dried (MgSO4), filtered, and concentrated.
Chromatography (hexanes:EtOAc:Et3N, 100:0:0 to 80:18:2) provided 30 mg of organostannane
(±)-4.22 as a yellow oil (35%). Rf = 0.43 (hexanes:EtOAc:Et3N, 70:28:2).

1

H NMR (CDCl3,

400 MHz):  8.10 (s, 1H), 7.92 (m, 1H), 7.70 (td, 1H, J = 1.1, 7.2 Hz), 7.46 (t, 1H, J = 7.5 Hz),
4.39 (q, 1H, J = 7.1 Hz), 2.42 (br s, 1H), 1.58 (m, 6H), 1.36 (qd, 6H, J = 7.3, 14.4 Hz), 1.29 (d,
3H, J = 7.1 Hz), 1.13 (m, 6H), 1.08 (s, 9H), 0.91 (t, 9H, J = 7.3 Hz).

13

C NMR (CDCl3, 100

MHz):  205.7, 143.2, 141.4, 136.1, 134.2, 128.1, 127.9, 51.9, 50.8, 29.8, 29.1, 27.3, 22.7, 13.7,
9.7. HRMS calcd for (C25H45NOSn)Na+ 518.2415, found 518.2415.
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((1-(4-Azido-3-iodophenyl)prop-1-en-1-yl)oxy)(tert-butyl)dimethylsilane (5.40)
To a 0˚C mixture of 4-azido-3-iodopropiophenone (5.36, 164 mg, 0.54 mmol), CH2Cl2 (1.5 mL),
and Et3N (0.12 mL, 0.87 mmol) was added TBSOTf (0.14 mL, 0.60 mmol) dropwise. The
formation of white fumes ceased after 10 minutes and the mixture was allowed to stir at room
temperature overnight. The reaction mixture was then diluted with CH2Cl2 and the organic layer
was washed with sat. aq. NaHCO3 solution. The organic layer was then separated, washed with
brine, dried (MgSO4), filtered, and concentrated. Chromatography (100% hexanes) provided
154 mg of silyl enol ether 5.40 as a pale yellow oil (68%). Rf = 0.32 (hexanes:EtOAc, 99:1). 1H
NMR (CDCl3, 400 MHz):  7.90 (d, 1H, J = 2.0 Hz), 7.47 (dd, 1H, J = 2.0, 8.3 Hz), 7.07 (d, 1H,
J = 8.3 Hz), 5.24 (q, 1H, J = 6.9 Hz), 1.75 (d, 3H, J = 7.1 Hz), 1.02 (bs, 9H), 0.01 (s, 6H).

13

C

NMR (CDCl3, 400 MHz):  147.8, 140.3, 138.1, 136.9, 126.6, 117.8, 106.9, 87.2, 25.8, 18.3,
11.8, -3.9. HRMS calcd for (C15H22IN3OSi)H+ 416.0649, found 416.0650. IR: azide, 2105.6
cm-1.

(+)-1-(4-Azido-3-iodophenyl)-2-hydroxypropan-1-one ((+)-5.41)
A bright orange mixture of AD-mix- (478 mg), CH3SO2NH2 (33 mg, 0.35 mmol) in tBuOH:H2O (3.5 mL, 1:1.5) was cooled to 0˚C. Enol ether 5.40 (140 mg, 0.34 mmol) in t-BuOH
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(0.5 mL) was then added to the mixture. The reaction was stirred at 0˚C for 10 hours followed
by stirring at room temperature overnight. The reaction was then cooled to 0˚C and sodium
sulfite (331 mg) was added to the mixture resulting in an instant color change from bright orange
to a light brown color. The mixture was then stirred for 1.5 hours followed by partitioning
between H2O and Et2O.

The organic layer was then separated, washed with brine, dried

(MgSO4), filtered, and concentrated. Chromatography (hexanes:EtOAc, 7:3) provided 79 mg of
alcohol (+)-5.41 as a yellow solid (73%). Rf = 0.62 (hexanes:EtOAc, 6:4).

1

H NMR (CDCl3,

400 MHz):  8.37 (d, 1H, J = 1.9 Hz), 7.96 (dd, 1H, J = 2.0, 8.4 Hz), 7.24 (d, 1H, J = 8.4 Hz),
5.10 (m, 1H, J = 6.9 Hz), 3.68 (d, 1H, J = 6.4 Hz), 1.46 (d, 3H, J = 7.0 Hz).

13

C NMR (CDCl3,

100 MHz):  199.7, 147.2, 140.6, 130.9, 129.9, 118.2, 87.9, 69.2, 22.3. HRMS calcd for
(C9H8IN3O2)Na+ 339.9553, found 339.9554. IR: azide, 2103 cm-1. Optical rotation []20.4D =
+50.8˚ (c = 4.6, CHCl3). The absolute stereochemistry of alcohol (+)-5.41 was not determined
via x-ray crystallography.

(+)-2-(4-Azido-3-iodophenyl)-2-hydroxy-3,5,5-trimethylmorpholin-4-ium

3-carboxy-2,3-

dihydroxypropanoate ((+)-4.23)
To a solution of -hydroxy ketone (+)-5.41 (320 mg, 1.01 mmol) in CH2Cl2 (3 mL) was added
proton sponge (257 mg, 1.20 mmol). The mixture was cooled to -61˚C and triflic anhydride
(0.19 mL, 1.11 mmol) was added dropwise. The reaction was then allowed to warm to 0˚C and
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stirred for 1 hour. In a separate round bottom flask was added CH3CN (3 mL) and 2-amino-2methylpropanol (0.21 mL, 2.18 mmol), then the mixture was cooled to -10˚C. The 0˚Chydroxy ketone slurry was then transferred to the 2-amino-2-methylpropanol mixture at -10˚C
resulting in a brown colored reaction that was stirred for 4 hours at 0˚C. The reaction mixtures
was then concentrated and the residue was triturated in Et2O. The resulting white precipitate was
removed via filtration and the filtrate was concentrated and chromatographed (EtOAc:Et3N,
95:5) to provide 77 mg of the bupropion metabolite analog (+)-4.23 as a yellow solid (20%). Rf
= 0.33 (EtOAc:Et3N, 95:5).

1

H NMR (CDCl3, 500 MHz):  7.99 (s, 1H), 7.60 (d, 1H, J = 8.3

Hz), 7.09 (d, 1H, J = 8.3 Hz), 3.81 (d, 2H, J = 11.3 Hz), 3.40 (d, 1H, J = 11.3 Hz), 3.12 (m, 1H),
1.37 (s, 3H), 1.08 (s, 3H), 0.79 (d, 3H, J = 6.4 Hz). HRMS calcd for (C13H17IN4O2)Na+
411.0288, found 411.0298. The free base of (+)-4.23 was dissolved in MeOH (2.5 mL) and (D)tartaric acid (14 mg) was added to the mixture. After 2 hours of stirring, the mixture was
concentrated then triturated with Et2O to provide the tartarate salt of (+)-4.23 as a yellow solid.
1

H NMR (MeOD, 400 MHz):  8.04 (d, 1H, J = 1.9 Hz), 7.71 (dd, 1H, J = 1.9, 8.4 Hz), 7.31 (d,

1H, J = 8.4 Hz), 4.36 (s, 1H), 4.22 (d, 1H, J = 12.4 Hz), 3.53 (m, 2H), 1.64 (s, 3H), 1.41 (s, 3H),
1.13 (d, 3H, J = 6.5 Hz).

13

C NMR (MeOD, 100 MHz):  177.9, 143.9, 140.1, 139.3, 129.3,

119.3, 95.9, 87.8, 74.6, 66.9, 55.3, 54.6, 23.5, 20.8, 13.7. IR: azide, 2131 cm-1. Optical rotation
[]24.1D = +59.27˚ (c = 1.1, CHCl3). The absolute stereochemistry of bupropion metabolite
analog (+)-4.23 was not determined via x-ray crystallography.
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Methyl 3-bromo-4-((3-(trimethylsilyl)prop-2-yn-1-yl)oxy)benzoate (5.54)
DMF (38 mL) was added to a mixture of phenol derivative 5.53 (996 mg, 4.31 mmol) and
K2CO3 (1.79 g, 12.93 mmol) followed by dropwise addition of TMS-protected propargyl
bromide (0.98 mL, 6.04 mmol). The reaction was stirred at room temperature for 48 hours then
diluted with H2O and extracted with EtOAc. The organic layer was washed with H2O and brine,
then dried (MgSO4), filtered, concentrated, and chromatographed (hexanes:EtOAc, 9:1) to
provide 851 mg of silyl-protected propargyl ether 5.54 as a white solid (58%). Rf = 0.43
(hexanes:EtOAc, 9:1). 1H NMR (CDCl3, 400 MHz):  8.27 (d, 1H, J = 2.1 Hz), 8.01 (dd, 1H, J
= 2.1, 8.6 Hz), 7.13 (d, 1H, J = 8.7 Hz), 4.85 (s, 2H), 3.92 (s, 3H), 0.18 (s, 9H).

13

C NMR

(CDCl3, 100 MHz):  165.4, 157.6, 134.8, 130.1, 124.3, 112.8, 111.8, 98.6, 94.2, 57.6, 52.1, 0.4.
HRMS calcd for (C14H17BrO3Si)Na+ 363.0022, found 363.0020.

Methyl 3'-(hydroxymethyl)-6-(prop-2-yn-1-yloxy)-[1,1'-biphenyl]-3-carboxylate (5.58)
To aryl bromide derivative 5.53 (601 mg, 2.60 mmol) was sequentially added boronic acid 5.51
(474 mg, 3.12 mmol), toluene (7.6 mL), MeOH (1.3 mL), K2CO3 (719 mg, 5.19 mmol), and
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PdCl2(PPh3)2 (182 mg, 0.26 mmol). The reaction mixture was degassed then refluxed at 90˚C
for 4 hours, then 70˚C overnight. The reaction was then cooled to room temperature and filtered
over Celite® rinsing with EtOAc. The filtrate was then washed with H2O and brine, dried
(MgSO4), filtered, and concentrated to provide 333 mg of phenol derivative 5.57 (50%), which
was used without further purification. Rf = 0.12 (hexanes:EtOAc, 6:4). 1H NMR (CDCl3 + D2O,
400 MHz):  8.30 (s, 1H), 7.95 (d, 1H, J = 2.1 Hz), 7.40 (m, 4H), 6.97 (d, 1H, J = 8.5 Hz), 4.69
(s, 2H), 3.89 (s, 3H). To a suspension of phenol 5.57 (333 mg, 1.29 mmol) and K2CO3 (535 mg,
3.86 mmol) in DMF (11 mL) was added propargyl bromide (80% in toluene; 0.16 mL) dropwise.
The resulting light-yellow colored reaction was then stirred at room temperature overnight
followed by dilution with H2O and EtOAc. The organic layer was separated and washed with
H2O and brine, then dried (MgSO4), filtered, and concentrated.

Chromatography

(hexanes:EtOAc, 6:4) provided 129 mg of propargyl ether 5.58 as a colorless oil (34%). Rf =
0.65 (hexanes:EtOAc, 1:1). 1H NMR (CDCl3, 500 MHz):  8.05 (m, 1H), 7.54 (s, 2H), 7.43 (m,
3H), 7.17 (m, 1H), 4.76 (m, 4H), 3.92 (s, 3H), 2.55 (m, 1H), 2.03 (br s, 1H).

13

C NMR (CDCl3,

100 MHz):  166.8, 158.0, 140.9, 137.5, 132.6, 131.0, 130.6, 129.0, 128.3, 128.1, 126.1, 123.6,
112.4, 77.9, 76.3, 65.3, 56.1, 52.0. HRMS calcd for (C18H16O4)Na+ 319.0941, found 319.0943.

2-Cyclopentyl-5-methoxy-6,7-dimethyl-2,3-dihydro-1H-inden-1-one ((±)-5.49)
A mixture of cyclopentylphenyl ethanone derivative (±)-5.47 (3.07 g, 12.48 mmol; DeSolms et
al., 1978), paraformaldehyde (948 mg, 31.6 mmol), dimethylamine hydrochloride (3.05 g, 37.44
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mmol) and glacial acetic acid (6.24 mmol, 0.36 mL) in DMF (15 mL) was heated at 100ºC
overnight. The reaction was then cooled to room temperature, poured over dis. H2O, extracted
with EtOAc, washed with brine, and then concentrated to provide -unsaturated phenyl ketone
5.48 as a colorless oil (2.2 g, 70%).

1

H NMR (CDCl3, 500 MHz):  7.14 (d, 1H, J = 8.5 Hz),

6.70 (d, 1H, J = 8.5 Hz), 5.81 (d, 2H, J = 1.3 Hz), 3.85 (s, 3H), 2.3 (m, 1H, J = 0.7 Hz), 2.26 (s,
3H), 2.19 (s, 3H), 2.00 (m, 2H), 1.71 (m, 4H), 1.46 (m, 2H).

13

C NMR (CDCl3, 100 MHz): 

201.1, 158.7, 154.1, 136.8, 132.6, 127.3, 126.0, 124.7, 106.4, 55.4, 40.5, 31.8, 24.9, 17.1, 11.6.
The ketone 5.48 (2.12 g, 8.6 mmol) was treated with 96% H2SO4 (10.1 mL) and stirred at room
temperature for 2.5 hours, then quenched by pouring over dis. H2O (100 mL) and extracted with
CH2Cl2 (3 times). The combined organic layers were washed with 1M NaOH, then brine, and
concentrated to provide 1.8 g of cyclic ketone (±)-5.49 as a yellow solid (81%) without further
need for purification. 1H NMR (CDCl3, 400 MHz):  6.72 (s, 1H), 3.90 (s, 3H), 3.09 (dd, 1H, J =
8.0, 17.2 Hz), 2.76 (m, 2H), 2.62 (s, 3H), 2.35 (m, 1H), 2.15 (s, 3H), 1.95 (m, 1H), 1.52 (m, 6H),
1.08 (td, 1H, J = 11.9, 18.4 Hz).

13

C NMR (CDCl3, 100 MHz):  208.4, 162.4, 155.0, 138.4,

127.8, 125.3, 104.2, 55.6, 51.2, 41.3, 30.8, 29.6, 28.1, 25.4, 25.2, 13.9, 10.9. HRMS calcd. for
(C17H22O2)Na+ 281.3814, found 281.3819.

2-Cyclopentyl-5-hydroxy-6,7-dimethyl-2,3-dihydro-1H-inden-1-one ((±)-3.40)
A mixture of methyl ether (±)-5.49 (128 mg, 0.50 mmol) in CH2Cl2 (3 mL) at -78ºC was
carefully treated with dropwise addition of BBr3 (0.12 mL, 1.23 mmol). The resulting mixture
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was stirred overnight at room temperature, and then quenched by pouring over ice-cold NaHCO3
(sat. solution). The aqueous mixture was extracted with EtOAc, the organic layer washed with
brine, separated, and concentrated to provide 1.5 g of phenol (±)-3.40 as a brown solid (95%)
without further need for purification. 1H NMR (DMSO-d6, 400 MHz):  10.31 (s, 1H), 6.73 (s,
1H), 3.35 (s, 1H), 2.99 (dd, 1H, J = 8.7, 18.0 Hz), 2.60 (m, 2H), 2.18 (s, 3H), 2.03 (s, 3H), 1.83
(m, 2H), 1.63 (m, 2H), 1.42 (m, 4H).

13

C NMR (DMSO-d6, 100 MHz):  207.2, 161.2, 154.8,

138.4, 126.5, 123.4, 109.3, 50.8, 41.3, 30.7, 29.1, 28.1, 25.4, 25.2, 13.9, 11.2. HRMS calcd. for
(C16H20O2)Na+ 267.5224, found 267.5220.

(±)-Methyl 3'-(((2-cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydro-1H-inden-5-yl)oxy)methyl)6-(prop-2-yn-1-yloxy)-[1,1'-biphenyl]-3-carboxylate ((±)-5.59)
A mixture of DIAD (89.2 mg, 0.44 mmol) in THF (2 mL) was slowly added to a suspension of
phenol (±)-3.40 (90 mg, 0.37 mmol), Ph3P (116 mg, 0.44 mmol), and benzyl alcohol derivative
5.58 (131 mg, 0.44 mmol) in THF (2 mL) at -10˚C. The reaction was then stirred at room
temperature overnight. The reaction mixture was then concentrated and chromatographed (100%
CH2Cl2) to provide 90 mg of benzyl ether (±)-5.59 as a colorless oil (47%). Rf = 0.8 (100%
CH2Cl2). 1H NMR (CDCl3, 400 MHz):  8.08 (m, 2H), 7.65 (s, 1H), 7.50 (m, 3H), 7.19 (d, 1H, J
= 8.5 Hz), 6.83 (s, 1H), 5.21 (s, 2H), 4.77 (d, 2H, J = 2. 4 Hz), 3.93 (s, 3H), 3.10 (m, 1H), 2.74
(m, 2H), 2.65 (s, 3H), 2.56 (t, 1H, J = 2.4 Hz), 2.35 (m, 1H), 2.24 (s, 3H), 1.94 (m, 1H), 1.67-
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1.37 (m, 6H), 1.09 (m, 1H).

13

C NMR (CDCl3, 100 MHz):  208.5, 166.6, 161.5, 158.0, 154.9,

138.7, 137.6, 136.5, 132.7, 130.8, 130.6, 129.2, 128.5, 128.3, 128.1, 126.2, 125.7, 123.6, 112.4,
105.6, 77.9, 76.3, 70.0, 56.1, 52.0, 51.2, 41.3, 30.8, 29.7, 28.2, 25.4, 25.3, 14.0, 11.3. HRMS
calcd. for (C34H34O5)Na+ 545.2298, found 545.2291.

(±)-3'-(((2-cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydro-1H-inden-5-yl)oxy)methyl)-6-(prop2-yn-1-yloxy)-[1,1'-biphenyl]-3-carboxylic acid ((±)-4.25)
A suspension of ester (±)-5.59 (90 mg, 0.17 mmol) and LiOH (16.5 mg, 0.69 mmol) in THF (0.4
mL), MeOH (0.2 mL), and H2O (0.09 mL) was vigorously stirred at room temperature overnight.
The resulting clear solution was then acidified with 1M aq. HCl to pH 1 then diluted with
EtOAc. The EtOAc layer was then separated and washed with brine, then dried (MgSO4),
filtered, and concentrated to provide 77 mg of carboxylic acid (±)-4.25 as a white solid (88%),
which was used without further purification.

Rf = 0.33 (EtOAc:hexanes:MeOH:AcOH,

35:60:3:2). 1H NMR (DMSO-d6, 400 MHz):  12.85 (s, 1H), 7.97 (dd, 1H, J = 2.2, 8.6 Hz), 7.88
(d, 1H, J = 2.2 Hz), 7.62 (s, 1H), 7.49 (m, 3H), 7.31 (d, 1H, J = 8.7 Hz), 7.07 (s, 1H), 5.28 (s,
2H), 4.92 (s, 2H), 3.63 (t, 1H, J = 2.3 Hz), 3.09 (dd, 1H, J = 7.7, 17.2 Hz), 2.68 (m, 2H), 2.53 (s,
3H), 2.18 (m, 4H), 1.83 (m, 1H), 1.60-1.29 (m, 6H), 1.02 (m, 1H).

13

C NMR (DMSO-d6, 100

MHz):  207.7, 167.3, 161.4, 158.0, 155.2, 137.8, 137.7, 137.3, 132.3, 131.0, 130.3, 129.2,
128.9, 128.6, 127.7, 126.8, 125.2, 124.5, 113.5, 106.8, 79.25, 79.16, 69.9, 56.4, 51.0, 41.2, 30.7,
29.6, 28.2, 25.4, 25.2, 13.9, 11.5. HRMS calcd for (C33H32O5)Na+ 531.2142, found 531.2134.
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Anal. calcd. for (C33H32O5·CH3COOC2H5) C, 74.47; H, 6.76; found C, 74.28; H, 6.54. MP:
192ºC.

(±)-(3-(((2-cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydro-1H-inden-5-yl)oxy)methyl)
phenyl)boronic acid ((±)-5.62)
A mixture of phenol (±)-3.40 (500 mg, 2.05 mmol), K2CO3 (1.27 g, 9.21 mmol), KI (67.9 mg,
0.41 mmol), and 3-boronic acid benzyl bromide (5.61, 461 mg, 2.15 mmol) in acetone (36 mL)
was heated at 60˚C overnight. The reaction was then cooled to room temperature and extracted
with EtOAc. The EtOAc layer was then separated, washed with H2O and brine, then dried
(MgSO4), filtered, concentrated, and chromatographed (hexanes:EtOAc, 9:1 to 7:3) to provide
774 mg of benzyl ether (±)-5.62 as a white solid (99%). Rf = 0.17 (hexanes:EtOAc, 7:3).

1

H

NMR (CDCl3, 400 MHz):  8.30 (m, 1H), 8.18 (d, 1H, J = 7.1 Hz), 7.66 (m, 1H), 7.55 (t, 1H, J =
7.3 Hz), 6.78 (m, 1H), 5.14 (s, 2H), 3.07 (m, 1H), 2.76-2.59 (m, 5H), 2.34-2.18 (m, 4H), 1.95 (m,
1H), 1.61 (m, 5H), 1.40 (m, 1H), 1.08 (m, 1H).

C NMR (CDCl3, 100 MHz):  208.7, 161.4,

13

155.1, 138.8, 136.3, 135.2, 134.1, 131.52, 131.51, 128.4, 128.1, 125.5, 105.4, 69.8, 51.3, 41.3,
30.8, 29.7, 28.2, 25.4, 25.3, 14.0, 11.2. HRMS calcd for (C23H27BO4)Na+ 401.1895, found
401.1898. MP: 112 ºC.
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(±)-Methyl 4-azido-3'-(((2-cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydro-1H-inden-5yl)oxy)methyl)-[1,1'-biphenyl]-3-carboxylate ((±)-5.65)
A mixture of boronic acid (±)-5.62 (74 mg, 0.20 mmol) in 1,2-DME (2 mL) and DMF (1 mL)
was added to a solution of aryl bromide 5.63 (42 mg, 0.16 mmol) in 1,2-DME (2 mL) containing
Pd(PPh3)4 (37.9 mg, 0.03 mmol) and 10% aq. NaHCO3 solution (0.32 mL). The resulting
reaction was then refluxed for 6 hours in the dark, cooled to room temperature, then filtered
through Celite® rinsing with EtOAc. The EtOAc filtrate was then washed with brine, dried
(MgSO4), filtered, concentrated, and chromatographed (hexanes:EtOAc, 10:1 to 9:1) to provide
20 mg of biphenyl compound (±)-5.65 as a yellow oil (24%). Rf = 0.39 (hexanes:EtOAc, 8:2).
1

H NMR (CDCl3, 500 MHz):  8.14 (d, 1H, J = 2.2 Hz), 7.79 (dd, 1H, J = 2.3, 8.4 Hz), 7.68 (s,

1H), 7.59 (td, 1H, J = 1.6, 7.5 Hz), 7.54-7.48 (m, 2H), 7.35 (d, 1H, J = 8.4 Hz), 6.82 (s, 1H), 5.23
(m, 2H), 3.97 (m, 3H), 3.12-3.07 (m, 1H), 2.74 (m, 2H), 2.65 (s, 3H), 2.40-2.32 (m, 1H), 2.24 (s,
3H), 1.98-1.92 (m, 1H), 1.68-1.51 (m, 6H), 1.46-1.38 (m, 1H), 1.28 (m, 1H), 1.09 (m, 1H).

13

C

NMR (CDCl3, 100 MHz):  208.5, 165.7, 161.4, 154.9, 139.5, 139.3, 138.8, 137.6, 137.2, 131.6,
130.4, 129.4, 128.2, 126.6, 126.57, 125.6, 125.6, 122.9, 120.5, 105.5, 70.0, 52.5, 51.2, 41.3, 30.8,
29.7, 28.2, 25.4, 25.3, 14.0, 11.3. HRMS calcd for (C31H31N3O4)Na+ 532.2207, found 532.2210.
IR: azide, 2121.2 cm-1.
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(±)-4-Azido-3'-(((2-cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydro-1H-inden-5-yl)oxy)methyl)[1,1'-biphenyl]-3-carboxylic acid ((±)-4.27)
A suspension of ester (±)-5.65 (20 mg, 0.04 mmol) and LiOH (6 mg, 0.24 mmol) in MeOH (1
mL), THF (2 mL), and H2O (0.5 mL) was stirred at room temperature overnight in the dark. The
reaction was then acidified with 1M aq. HCl and extracted with EtOAc. The organic layer was
then separated and washed with brine, then dried (MgSO4), filtered, concentrated, and
chromatographed (hexanes:EtOAc:MeOH:AcOH, 65:30:3:2) to afford 16 mg of carboxylic acid
(±)-4.27 as a light yellow oil (84%). Rf = 0.2 (hexanes:EtOAc:MeOH:AcOH, 60:35:3:2).

1

H

NMR (CDCl3, 400 MHz):  8.41 (d, 1H, J = 1.9 Hz), 7.86 (d, 1H, J = 8.4 Hz), 7.69 (s, 1H), 7.60
(d, 1H, J = 7.3 Hz), 7.51 (m, 2H), 7.38 (d, 1H, J = 8.4 Hz), 6.82 (s, 1H), 5.22 (m, 2H), 3.10 (m,
1H), 2.76 (m, 2H), 2.65 (s, 3H), 2.37 (m, 1H), 2.24 (s, 3H), 1.95 (m, 1H), 1.60 (m, 6H), 1.42 (m,
1H), 1.07 (m, 1H).

13

C NMR (CDCl3, 100 MHz):  208.6, 161.4, 155.0, 139.1, 138.9, 137.9,

137.7, 132.7, 131.9, 129.4, 128.2, 126.8, 126.6, 125.6, 125.6, 119.9, 105.5, 69.9, 51.2, 41.3, 30.8,
29.7, 28.1, 25.4, 25.3, 14.0, 11.3. HRMS calcd for (C30H29N3O4)Na+ 518.2050, found 518.2053.
IR: azide, 2118.4 cm-1. MP: 180 ºC.
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(±)-1-Phenyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propan-1-ol

((±)-

5.73)
A solution of 4-hydroxyphenyl boronic acid pinacol ester (5.70, 200 mg, 0.91 mmol) in DMF
(0.5 mL) was added dropwise to a suspension of NaH (26 mg, 1.09 mmol) in DMF (1 mL) at
0˚C. After the effervescence ceased, the reaction was then stirred at room temperature for 30
minutes. 3-Chloro-1-phenylpropan-1-ol ((±)-5.72, 155 mg, 0.91 mmol) in DMF (0.5 mL) was
then added dropwise to the reaction mixture followed by heating at 65˚C for 18 hours. The
reaction was then cooled to room temperature, quenched with H2O, and extracted with EtOAc.
The organic layer was then separated, washed with brine, dried (MgSO4), filtered, concentrated,
and chromatographed (hexanes:EtOAc, 7:3) to provide 111 mg of ether (±)-5.73 as a colorless
oil (35%). Rf = 0.36 (hexanes:EtOAc, 7:3). 1H NMR (CDCl3, 400 MHz):  7.78 (d, 2H, J = 8.6
Hz), 7.42-7.28 (m, 5H), 6.93 (d, 2H, J = 8.7 Hz), 5.02 (m, 1H), 4.24-4.19 (m, 1H), 4.11-4.05 (m,
1H), 2.64 (br s, 1H), 2.32-2.15 (m, 2H), 1.36 (s, 12H).

13

C NMR (CDCl3, 100 MHz):  161.3,

144.2, 136.6, 128.6, 127.6, 125.8, 113.9, 83.6, 71.9, 65.1, 38.4, 24.9.
(C21H27BO4)Na+ 377.1895, found 377.1894.
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HRMS calcd for

1-Phenyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propan-1-one (5.71)
A mixture of benzyl alcohol (±)-5.73 (111 mg, 0.31 mmol) and Dess-Martin periodinane (159
mg, 0.38 mmol) in CH2Cl2 (1 mL) was stirred at room temperature for 2 hours. The reaction was
then filtered through Celite® and the filtrate was washed with 1M aq. NaOH, followed by
extraction with CH2Cl2. The organic layer was then washed with brine, dried (MgSO4), filtered,
and concentrated to provide 91 mg of ketone 5.71 (81%), which was used without further
purification. Rf = 0.67 (hexanes:EtOAc, 7:3). 1H NMR (CDCl3, 400 MHz):  8.03 (dd, 2H, J =
1.2, 8.4 Hz), 7.78 (d, 2H, J = 8.7 Hz), 7.61 (m, 1H), 7.51 (t, 2H, J = 7.6 Hz), 6.95 (d, 2H, J = 8.7
Hz), 4.48 (t, 2H, J = 6.7 Hz), 3.50 (t, 2H, J = 6.7 Hz), 1.36 (s, 12H).

13

C NMR (CDCl3, 100

MHz):  197.6, 161.2, 136.8, 136.6, 133.4, 128.7, 128.2, 113.9, 83.6, 63.0, 38.1, 24.9. HRMS
calcd for (C21H25BO4)Na+ 375.1738, found 375.1739.
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(±)-1-(4-Chloro-2-fluorobenzyl)-5-(4-(3-hydroxy-3-phenylpropoxy)phenyl)pyridin-2(1H)one ((±)-5.74)
To a suspension of aryl bromide 3.57 (65 mg, 0.21 mmol) and boronate ester (±)-5.73 (110 mg,
0.31 mmol) in 1,4-dioxane (2 mL) and sat. aq. NaHCO3 solution (2 mL) was added Pd(PPh3)4
(35 mg, 0.03 mmol). The mixture was then degassed followed by heating at 90˚C for 6 hours.
The reaction was then cooled to room temperature and filtered through Celite® rinsing with
EtOAc. The organic filtrate was then washed with brine, dried (MgSO4), filtered, concentrated,
and chromatographed (hexanes:EtOAc, 7:3 to 1:1) to provide 37 mg of aryl-substituted pyridone
5.74 as an oil (39%), which was used without further purification. Rf = 0.07 (hexanes:EtOAc,
1:1). 1H NMR (CDCl3, 500 MHz):  7.58 (dd, 1H, J = 2.7, 9.4 Hz), 7.52 (s, 1H), 7.48 (t, 1H, J =
8.2 Hz), 7.39 (m, 5H), 7.31 (m, 2H), 7.13 (m, 2H), 6.96 (m, 2H), 6.65 (d, 1H, J = 9.4 Hz), 5.18
(s, 2H), 5.02 (td, 1H, J = 4.8, 9.4 Hz), 4.22 (ddd, 1H, J = 5.2, 7.2, 9.3 Hz), 4.08 (m, 1H), 2.88 (s,
1H), 2.24 (m, 2H). HRMS calcd for (C27H23ClFNO3)Na+ 486.12427, found 486.12457.
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1-(4-Chloro-2-fluorobenzyl)-5-(4-(3-oxo-3-phenylpropoxy)phenyl)pyridin-2(1H)-one (1.93)
A suspension of benzyl alcohol derivative 5.74 (36 mg, 0.08 mmol) and Dess-Martin periodinane
(39 mg, 0.09 mmol) in CH2Cl2 (3 mL) was stirred at room temperature for 4 hours. The reaction
mixture was then filtered through Celite®. The clear filtrate was then diluted with sat. aq.
NaHCO3 solution and extracted withCH2Cl2. The CH2Cl2 layer was then separated, washed with
brine, dried (MgSO4), filtered, concentrated, and chromatographed (hexanes:EtOAc, 1:1) to
provide 26 mg of ketone 1.93 (Cid et al., 2010) as a white solid (72%).

Rf = 0.64

(hexanes:EtOAc, 4:6). 1H NMR (CDCl3, 400 MHz):  8.04 (d, 2H, J = 7.1 Hz), 7.64-7.58 (m,
2H), 7.54-7.47 (m, 4H), 7.32 (d, 2H, J = 8.8 Hz), 7.14 (td, 2H, J = 2.2, 5.3 Hz), 6.99 (d, 2H, J =
8.8 Hz), 6.68 (d, 1H, J = 9.4 Hz), 5.20 (s, 2H), 4.48 (t, 2H, J = 6.5 Hz), 3.52 (t, 2H, J = 6.5 Hz).
C NMR (CDCl3, 100 MHz):  197.5, 162.0, 161.8, 159.5, 158.3, 139.7, 136.7, 135.1, 135.0,

13

134.1, 133.5, 132.4, 132.3, 129.0, 128.7, 128.1, 127.0, 125.1, 125.0, 122.0, 121.9, 121.1, 120.5,
116.4, 116.2, 115.2, 63.4, 46.2, 38.1. HRMS calcd for (C27H21ClFNO3)Na+ 484.1086, found
484.1089. Anal calcd for (C27H21ClFNO3·0.14CH3COOC2H5·0.15HCl): C, 69.03; H, 4.68; N,
2.92; Cl, 8.48; F, 3.96; Found C, 69.00; H, 4.59; N, 2.94; Cl, 8.46; F, 3.99. MP: 170 ºC.
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5-Bromo-1-(2-fluoro-4-nitrobenzyl)pyridin-2(1H)-one (5.78)
A mixture of 5-bromopyridone (120 mg, 0.69 mmol), K2CO3 (958 mg, 6.93 mmol), THF (10
mL), and 2-flouro-4-nitrobenzyl bromide (Frank et al., 2013; 243 mg, 1.04 mmol) was heated at
65˚C for 17 hours followed by stirring at room temperature for 6 hours. The reaction was then
quenched with H2O and diluted with EtOAc. The organic layer was separated, dried (MgSO4),
filtered, concentrated, and chromatographed (hexanes:EtOAc, 8:2) to obtain 148 mg of Nbenzylated derivative 5.78 as a yellow solid (65%). Rf = 0.13 (hexanes:EtOAc, 7:3). 1H NMR
(CDCl3, 500 MHz):  8.05-7.98 (ddd, 2H, J = 2.1, 9.0, 11.7 Hz), 7.67 (t, 1H, J = 7.9 Hz), 7.54
(m, 1H), 7.40 (dd, 1H, J = 2.6, 9.7 Hz), 6.54 (d, 1H, J = 9.7 Hz), 5.19 (s, 2H).

13

C NMR (CDCl3,

100 MHz):  161.5, 160.9, 159.0, 148.7, 148.6, 143.2, 137.3, 132.1, 129.7, 122.5, 119.7, 111.6,
111.3, 98.6, 46.6. HRMS calcd for C12H8BrFN2O3Na+ 348.9594, found 348.9592.

1-(2-Fluoro-4-nitrobenzyl)-5-(4-methoxyphenyl)pyridin-2(1H)-one (5.79)
A degassed suspension containing aryl bromide 5.78 (148 mg, 0.45 mmol), 4-methoxyphenyl
boronic acid (104 mg, 0.69 mmol), 1,4-dioxane (4.1 mL), sat. aq. NaHCO3 solution (4.1 mL),
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and Pd(PPh3)4 (78 mg, 0.068 mmol) was heated at 95˚C for 5 hours. The reaction was then
cooled to room temperature and filtered over Celite®. The filtrate was then diluted with H2O and
extracted with EtOAc. The organic extract was washed with brine, dried (MgSO4), filtered,
concentrated, and chromatographed (hexanes:EtOAc, 1:1) to yield 103 mg of the anisolesubstituted pyridinone derivative 5.79 as a yellow solid (65%). Rf = 0.62 (hexanes:EtOAc, 4:6).
1

H NMR (CDCl3, 400 MHz):  8.02-7.94 (m, 2H), 7.68-7.62 (m, 2H), 7.55 (s, 1H), 7.33 (d, 2H,

J = 8.8 Hz), 6.95 (d, 2H, J = 8.8 Hz), 6.68 (d, 1H, J = 9.4 Hz), 5.29 (s, 2H), 3.84 (s, 3H).

13

C

NMR (CDCl3, 100 MHz):  161.7, 161.5, 159.3, 159.0, 148.4, 148.36, 140.2, 134.0, 131.8,
131.76, 130.7, 130.6, 128.5, 127.0, 121.2, 120.8, 119.65, 119.62, 114.6, 111.5, 111.2, 55.4, 46.8.
HRMS calcd as C19H15FN2O4Na+ 377.0908, found 377.0905.

1-(2-Fluoro-4-nitrobenzyl)-5-(4-hydroxyphenyl)pyridin-2(1H)-one (5.80)
A mixture of methyl ether 5.79 (103 mg, 0.29 mmol) in CH2Cl2 (3.1 mL) was treated dropwise
with BBr3 (1M in CH2Cl2, 1.2 mL) at -78˚C. The reaction was then stirred at -78˚C for 1 hour
followed by stirring at room temperature for 2 hours. The mixture was then carefully quenched
by slow addition of MeOH (30 mL) at -78˚C followed by stirring at room temperature for 30
minutes. The mixture was then concentrated and chromatographed (hexanes:EtOAc, 40:60 to
0:100) to provide 66 mg of phenol 5.80 as a yellow solid (66%). Rf = 0.48 (hexanes:EtOAc,
4:6). 1H NMR (DMSO-d6, 400 MHz):  9.54 (br s, 1H), 8.15 (m, 2H), 8.07 (dd, 1H, J = 2.0, 8.6
212

Hz), 7.84 (dd, 1H, J = 2.7, 9.5 Hz), 7.39 (d, 3H, J = 8.7 Hz), 6.82 (d, 2H, J = 8.6 Hz), 6.52 (d,
1H, J = 9.5 Hz), 5.30 (s, 2H).

C NMR (DMSO-d6, 100 MHz):  161.0, 160.9, 158.5, 157.2,

13

148.1, 148.0, 140.3, 135.9, 132.5, 132.3, 130.7, 130.6, 127.1, 126.9, 120.3, 120.2, 120.17, 119.4,
116.2, 111.8, 111.5, 47.0. HRMS calcd for C18H13FN2O4Na+ 363.0751, found 363.0748.

1-(2-Fluoro-4-nitrobenzyl)-5-(4-(prop-2-yn-1-yloxy)phenyl)pyridin-2(1H)-one (5.94)
Propargyl bromide (80% in toluene; 0.03 mL, 0.20 mmol) was added dropwise to a suspension
of phenol 5.80 (63 mg, 0.19 mmol) and K2CO3 (77 mg, 0.56 mmol) in DMF (1.6 mL). The
resulting mixture was then stirred at room temperature overnight followed by dilution with
EtOAc and H2O. The organic layer was then separated, washed with brine, dried (MgSO4),
filtered, and concentrated to provide 66 mg of propargyl ether 5.94 (94%). Rf = 0.36 (hexanes:
EtOAc, 4:6). 1H NMR (CDCl3, 400 MHz):  7.99 (m, 2H), 7.65 (m, 2H), 7.56 (s, 1H), 7.34 (d,
2H, J = 8.8 Hz), 7.04 (d, 2H, J = 8.8 Hz), 6.68 (d, 1H, J = 9.5 Hz), 5.29 (s, 2H), 4.73 (d, 2H, J =
2.4 Hz), 2.56 (t, 1H, J = 2.4 Hz).

13

C NMR (CDCl3, 100 MHz):  161.7, 161.5, 159.0, 157.2,

148.5, 148.4, 140.1, 134.2, 131.9, 131.8, 130.6, 130.5, 129.4, 127.1, 121.2, 120.7, 119.7, 119.6,
115.6, 111.5, 111.2, 78.3, 75.8, 55.9, 46.8. HRMS calcd for (C21H15FN2O4)Na+ 401.0908, found
401.0906.
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1-(4-Amino-2-fluorobenzyl)-5-(4-(prop-2-yn-1-yloxy)phenyl)pyridin-2(1H)-one (5.81)
A mixture of nitro-alkyne derivative 5.94 (63 mg, 0.17 mmol) in MeOH (1.3 mL), THF (1 mL),
and conc. HCl (0.68 mL) was treated with SnCl2 (123 mg, 0.65 mmol) at 0˚C then stirred at
room temperature for 18 hours. The reaction was then neutralized with sat. aq. K2CO3 solution
and extracted with EtOAc. The organic layer was then washed with brine, dried (MgSO 4),
filtered, concentrated, and chromatographed (CHCl3:MeOH:Et3N, 90:8:2) to obtain 46 mg of
amine 5.81 as a brown oil (84%). Rf = 0.36 (CHCl3:MeOH:Et3N, 90:8:2). 1H NMR (CDCl3, 400
MHz):  7.56 (m, 2H), 7.30 (m, 3H), 7.02 (dd, 2H, J = 1.5, 8.8 Hz), 6.65 (m, 1H), 6.41 (m, 2H),
5.11 (s, 2H), 4.73 (s, 2H), 3.89 (br, s, 2H), 2.56 (m, 1H).

13

C NMR (CDCl3, 100 MHz):  162.0,

160.8, 156.9, 148.6, 139.2, 134.25, 134.23, 132.8, 132.7, 130.0, 127.0, 120.8, 120.0, 115.5,
112.3, 112.1, 111.1, 111.0, 101.7, 101.5, 78.4, 75.8, 55.9, 46.0.
(C21H17FN2O2)Na+ 371.11627, found 371.11646.
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HRMS calcd for

Tri-isopropyl(3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)prop-1-yn-1yl)silane (5.82)
A mixture of phenol 5.70 (330 mg, 1.5 mmol), DMF (11 mL), K2CO3 (623 mg, 4.5 mmol) and
TIPS-protected propargyl bromide (Hoogboom and Swager, 2006; 578 mg, 2.10 mmol) was
stirred at room temperature for 5 hours then diluted with H2O and extracted with EtOAc. The
organic layer was then separated, washed with brine, concentrated, and chromatographed
(hexanes:EtOAc, 100:0 to 95:5) to afford 388 mg of propargyl ether 5.82 as a colorless oil
(62%). Rf = 0.41 (hexanes:EtOAc, 9:1).

1

H NMR (CDCl3, 500 MHz):  7.77 (d, 2H, J = 8.6

Hz), 7.02 (d, 2H, J = 8.5 Hz), 4.76 (s, 2H), 1.36 (s, 12H), 1.06 (s, 21H).

13

C NMR (CDCl3, 100

MHz):  160.4, 136.3, 114.4, 101.8, 83.6, 77.2, 56.6, 24.9, 18.5, 11.1.
(C24H39BO3Si)Na+ 437.26537, found 437.2657.
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HRMS calcd for

2-Methoxy-5-(4-((3-(triisopropylsilyl)prop-2-yn-1-yl)oxy)phenyl)pyridine (5.84)
A mixture of 2-methoxy-5-bromopyridine (0.023 mL, 0.18 mmol), boronic pinacol ester 5.82
(110 mg, 0.27 mmol), Pd(PPh3)4 (30 mg, 0.026 mmol), 1,4-dioxane (4 mL), and sat. aq. NaHCO3
solution (1.6 mL) was degassed then heated at 90˚C for 3 hours.

After cooling to room

temperature, the mixture was filtered through Celite® and washed with H2O and brine, then dried
(MgSO4), filtered, concentrated, and chromatographed (hexanes:EtOAc, 8:2) to yield 70 mg of
diaryl product 5.84 as a brown oil (90%). Rf = 0.47 (hexanes:EtOAc, 9:1).

1

H NMR (CDCl3,

400 MHz):  8.36 (d, 1H, J = 2.5 Hz), 7.76 (dd, 1H, J = 2.6, 8.6 Hz), 7.46 (d, 2H, J = 8.8 Hz),
7.11 (d, 2H, J = 8.8 Hz), 6.82 (dd, 1H, J = 0.5, 8.6 Hz), 4.79 (s, 2H), 4.00 (s, 3H), 1.06 (s, 21H).
C NMR (CDCl3, 100 MHz):  163.2, 157.2, 144.6, 137.2, 131.1, 130.0, 127.6, 115.9, 110.7,

13

101.8, 89.5, 56.9, 53.5, 18.5, 11.1.

HRMS calcd for (C24H33NO2Si)Na+ 418.2173, found

418.2176.
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2-Methoxy-5-(4-(prop-2-yn-1-yloxy)phenyl)pyridine (5.85)
TBAF (1M in THF, 0.3 mL, 0.3 mmol) was added to a 0˚C mixture of TIPS-protected alkyne
5.84 (76 mg, 0.19 mmol) in THF (3.5 mL). The reaction was then stirred at room temperature
for 2 hours followed by cooling again to 0˚C again and treatment with TBAF (1M in THF, 0.1
mL, 0.09 mmol). The reaction was then stirred at room temperature for 1 hour then concentrated
and chromatographed (hexanes:EtOAc, 9.5:0.5) to obtain 20 mg of deprotected alkyne 5.84 as a
white solid (43%). Rf = 0.23 (hexanes:EtOAc, 9:1). 1H NMR (CDCl3, 400 MHz):  8.37 (d, 1H,
J = 2.3 Hz), 7.76 (dd, 1H, J = 2.6, 8.6 Hz), 7.48 (d, 2H, J = 8.8 Hz), 7.08 (d, 2H, J = 8.8 Hz),
6.82 (d, 1H, J = 8.6 Hz), 4.76 (d, 2H, J = 2.4 Hz), 4.00 (s, 3H), 2.58 (t, 1H, J = 2.4 Hz).

13

C

NMR (CDCl3, 100 MHz):  163.3, 157.1, 144.6, 137.2, 131.4, 129.6, 127.8, 115.4, 110.8, 78.5,
75.7, 55.9, 53.5. HRMS calcd for (C15H13NO2)Na+ 262.0838, found 262.0841.

4-Azido-2-fluorobenzoic acid (5.87)
To a 0˚C suspension of aniline 5.86 (200 mg, 1.29 mmol) in H2O (7 mL) was carefully added
conc. H2SO4 (1 mL) resulting in a clear, brown solution. NaNO2 (110 mg, 1.6 mmol) was then
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added to the mixture as a solid resulting in the evolution of brown gas. The mixture was then
stirred for 20 minutes in the dark at 0˚C followed by dropwise addition of NaN3 (151 mg, 2.32
mmol) dissolved in H2O (2 mL) resulting in a thick, white suspension. H2O (15 mL) was then
added to this mixture and the reaction was stirred vigorously at room temperature overnight in
the dark. The suspension was then filtered to obtain a white solid that was dissolved in EtOAc,
dried (MgSO4), filtered, and concentrated to provide 215 mg of aryl azide 5.87 as a white solid
(92%), which was used without further purification. Rf = 0.47 (CHCl3:MeOH, 7:3).

1

H NMR

(DMSO-d6, 400 MHz):  13.22 (s, 1H), 7.90 (t, 1H, J = 8.3 Hz), 7.13 (dd, 1H, J = 2.2, 11.7 Hz),
7.07 (dd, 1H, J = 2.2, 8.5 Hz).

13

C NMR (DMSO-d6, 100 MHz):  164.8, 164.8, 163.8, 161.2,

146.2, 134.05, 134.03, 115.75, 115.72, 108.6, 108.3. IR: azide, 2133.8 cm-1. HRMS analysis of
this compound was not performed due to its relative instability at room temperature.

(4-Azido-2-fluorophenyl)methanol (5.88)
Triethylamine (0.2 mL, 1.44 mmol) was added to a suspension of carboxylic acid 5.87 (206 mg,
1.14 mmol) in CH2Cl2 (4 mL) resulting in a clear, yellow solution. Chloroformate (478 mg, 3.5
mmol) was then added dropwise to the mixture followed by stirring at room temperature for 45
minutes. A suspension of NaBH4 (344 mg, 9.09 mmol) in EtOH (5 mL) was then added slowly
to the reaction resulting in vigorous effervescence being observed. The resulting reaction was
stirred at room temperature for 10 minutes then quenched with pH = 7 buffer. The mixture was
then diluted with H2O and extracted with EtOAc. The organic extract was washed with brine,
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then dried (MgSO4), filtered, concentrated, and chromatographed (hexanes:EtOAc, 8:2) to give
50 mg of benzyl alcohol 5.88 as a colorless oil (30%). Rf = 0.24 (hexanes:EtOAc, 8:2).

1

H

NMR (CDCl3, 400 MHz):  7.43 (t, 1H, J = 8.1 Hz), 6.86 (dd, 1H, J = 2.3, 8.4 Hz), 6.76 (dd, 1H,
J = 2.2, 10.6 Hz), 4.74 (s, 2H), 1.90 (s, 1H).

13

C NMR (CDCl3, 100 MHz):  159.8, 141.3,

130.5, 130.47, 124.5, 114.8, 114.76, 106.7, 106.5, 58.9. IR: azide, 2109.7 cm-1. HRMS analysis
of this compound was not performed due to its relative instability at room temperature.

4-Azido-1-(chloromethyl)-2-fluorobenzene (5.89)
To a 0˚C mixture of 4-azido-2-fluorobenzyl alcohol (5.88, 50 mg, 0.31 mmol) in CH2Cl2 (2 mL)
was added triethylamine (0.1 mL, 46.5 mmol) followed by MsCl (0.03 mL, 0.46 mmol). The
resulting reaction was then stirred at 0˚C for 1 hour followed by quenching with sat. aq. NaHCO3
solution and H2O. The mixture was then extracted with CH2Cl2, followed by washing with brine
then concentrated. Chromatography (hexanes:EtOAc, 10:1) provided 20 mg of benzyl chloride
5.89 (35%). Rf = 0.86 (CHCl3:MeOH, 9:1). 1H NMR (CDCl3, 400 MHz):  7.42 (t, 1H, J = 8.2
Hz), 6.86 (dd, 1H, J = 2.2, 8.3 Hz), 6.79 (dd, 1H, J = 2.1, 10.4 Hz), 4.63 (s, 2H).

13

C NMR

(CDCl3, 100 MHz):  159.9, 142.4, 142.3, 132.0, 131.99, 121.3, 115.1, 115.0, 107.0, 106.7, 39.0.
IR: azide, 2115.9 cm-1. HRMS analysis of this compound was not performed due to its relative
instability at room temperature.
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1-(4-Azido-2-fluorobenzyl)-5-(4-(prop-2-yn-1-yloxy)phenyl)pyridin-2(1H)-one (4.29)
A mixture containing pyridone 5.85 (25 mg, 0.10 mmol), CH3CN (3 mL), NaI (39 mg, 0.26
mmol), 4-azido-2-fluorobenzyl chloride (5.89, 19 mg, 0.10 mmol), and DMF (0.5 mL) was
refluxed at 85˚C for 5 hours followed by stirring at room temperature overnight. The reaction
mixture was then concentrated and the resulting residue was partitioned between EtOAc and
H2O.

The EtOAc layer was washed with H2O and brine, then dried (MgSO4), filtered,

concentrated, and chromatographed (hexanes:EtOAc, 10:1 to 9:1). The resulting compound was
then further purified by passing through a short silica gel plug eluting with hexanes:EtOAc (6:4)
to afford 12 mg of azido-alkyne probe 4.29 as a yellow oil (31%). Rf = 0.69 (hexanes:EtOAc,
4:6). 1H NMR (CDCl3, 400 MHz):  7.61-7.54 (m, 3H), 7.34 (d, 2H, J = 8.9 Hz), 7.05 (d, 2H, J
= 8.8 Hz), 6.85 (dd, 1H, J = 2.2, 8.3 Hz), 6.78 (dd, 1H, J = 2.2, 10.7 Hz), 6.68 (dd, 1H, J = 0.5,
9.4 Hz), 5.20 (m, 2H), 4.75 (d, 2H, J = 2.4 Hz), 2.56 (t, 1H, J = 2.4 Hz).

13

C NMR (CDCl3, 100

MHz):  162.8, 161.8, 160.3, 157.0, 144.1, 142.0, 141.9, 139.6, 134.2, 132.9, 132.9, 127.0,
121.1, 120.2, 119.9, 119.7, 115.5, 115.2, 115.2, 78.3, 77.2, 75.8, 55.9.
(C21H15FN4O2)Na+ 397.1071, found 397.1073. IR: azide, 2117.8 cm-1.
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HRMS calcd for

1-(3-Azido-5-(azidomethyl)benzyl)-5-(4-methoxyphenyl)pyridin-2(1H)-one (4.30)
To 2-methoxypyridinone derivative 5.90 (17 mg, 0.08 mmol) and NaI (24 mg, 0.16 mmol) was
added a mixture of 3-azido-5-(azidomethyl)benzyl methanesulfonate (5.91, Hosoya et al., 2005)
(45 mg, 0.16 mmol) in CH3CN (3 mL). The reaction was then refluxed at 90˚C for 5 hours then
stirred at room temperature overnight. CH3CN (1.5 mL) was then added to the reaction followed
by reflux at 90˚C for another 3 hours. The reaction was then cooled to room temperature,
concentrated, and chromatographed (hexanes:EtOAc, 6:4) to give 11 mg of N-benzylated
derivative 4.30 as a yellow oil (23%). Rf = 0.33 (hexanes:EtOAc, 6:4). 1H NMR (CDCl3, 400
MHz):  7.63 (s, 1H), 7.41 (d, 1H, J = 2.2 Hz), 7.32 (d, 2H, J = 8.8 Hz), 7.06 (s, 1H), 6.96 (m,
4H), 6.73 (d, 1H, J = 9.5 Hz), 5.21 (s, 2H), 4.36 (s, 2H), 3.85 (s, 3H).

13

C NMR (CDCl3, 100

MHz):  161.7, 159.2, 141.4, 139.8, 139.1, 138.2, 133.6, 128.7, 127.1, 123.8, 121.3, 120.7,
118.4, 118.0, 114.5, 55.4, 54.1, 51.9. HRMS calcd. for (C20H17N7O2)Na+ 410.1336, found
410.1332. IR: azide, 2108 cm-1.
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3-Bromo-1-(4-(prop-2-yn-1-yloxy)phenyl)propan-1-one (5.97)
A mixture of acid chloride 5.96 (0.39 mL, 3.90 mmol) and propargyl ether 5.95 (0.5 mL, 3.90
mmol) in CH2Cl2 (5 mL) was added dropwise to AlCl3 (701 mg, 5.26 mmol) in CH2Cl2 (5 mL) at
0˚C.

The reaction was then allowed to warm to room temperature and stirred overnight,

followed by quenching with crushed ice. The mixture was then diluted with H2O and CH2Cl2
with vigorous stirring. The organic layer was then separated, washed with brine, dried (MgSO 4),
filtered, concentrated and chromatographed (hexanes:EtOAc, 9:1 to 8:2) to provide 589 mg of
ketone 5.97 as a white solid (57%). Rf = 0.22 (hexanes:EtOAc, 9:1).

1

H NMR (CDCl3, 500

MHz):  7.97 (d, 2H, J = 8.9 Hz), 7.05 (d, 2H, J = 8.9 Hz), 4.79 (m, 2H), 3.76 (t, 2H, J = 6.9
Hz), 3.55 (t, 2H, J = 7.0 Hz), 2.58 (m, 1H).

13

C NMR (CDCl3, 100 MHz):  195.5, 161.6, 130.3,

130.1, 114.8, 77.6, 76.3, 55.9, 41.2, 26.0. HRMS calcd for (C12H11BrO2)Na+ 288.9835, found
288.9838.

(±)-3-Bromo-1-(4-(prop-2-yn-1-yloxy)phenyl)propan-1-ol ((±)-5.99)
A suspension of ketone 5.97 (271 mg, 1.01 mmol) in THF (2 mL) and H2O (1 mL) was treated
with NaBH4 (38 mg, 1.01 mmol) at 0˚C. The reaction was then stirred at 0˚C for 3 hours
followed by stirring for 1 hour at room temperature. The reaction mixture was then concentrated
and the residue was partitioned between EtOAc and H2O. The organic layer was then separated,
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washed with brine, dried (MgSO4), filtered, concentrated, and chromatographed (100% CH2Cl2)
to obtain 150 mg of benzyl alcohol (±)-5.99 as a colorless oil (55%). Rf = 0.28 (100%CH2Cl2).
1

H NMR (CDCl3, 400 MHz):  7.34 (d, 2H, J = 8.6 Hz), 7.00 (d, 2H, J = 8.8 Hz), 4.91 (m, 1H),

4.72 (d, 2H, J = 2.4 Hz), 3.62-3.56 (m, 1H), 3.45-3.39 (m, 1H), 2.55 (t, 1H, J = 2.4 Hz), 2.392.30 (m, 1H), 2.21-2.13 (m, 1H), 1.92 (m, 1H).

C NMR (CDCl3, 100 MHz):  157.3, 136.6,

13

127.1, 115.0, 78.4, 75.6, 71.9, 55.8, 41.5, 30.3. HRMS calcd for (C12H13BrO2)Na+ 290.9991,
found 290.9994.

Tri-isopropyl(3-phenoxyprop-1-yn-1-yl)silane (5.103)
Phenol (142 mg, 1.50 mmol) was sequentially treated with acetone (1 mL, reagent grade, dried
with molecular sieves), K2CO3 (518 mg, 3.75 mmol), and TIPS-protected propargyl bromide
(Hoogboom and Swager, 2006; 495 mg, 1.8 mmol, dissolved in 3 mL acetone). NaI (100 mg,
0.67 mmol) was then added to the reaction mixture followed by stirring at room temperature
overnight. The reaction mixture was then concentrated and the residue was partitioned between
EtOAc and H2O. The organic layer was separated, washed with 1M aq. NaOH and brine, then
dried (MgSO4), filtered, and concentrated to provide 410 mg of TIPS-protected propargyl ether
5.103 as a clear, yellow oil (95%), which was used without further purification. Rf = 0.67
(hexanes:EtOAc, 95:5).
2H), 1.06 (s, 21H).

13

1

H NMR (CDCl3, 400 MHz):  7.31 (m, 2H), 7.02 (m, 3H), 4.75 (s,

C NMR (CDCl3, 100 MHz):  157.7, 129.3, 121.3, 115.3, 102.0, 89.1,

56.7, 18.5, 11.1. HRMS calcd for (C18H28OSi)Na+ 311.1802, found 311.1803.
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3-Bromo-1-(4-((3-(triisopropylsilyl)prop-2-yn-1-yl)oxy)phenyl)propan-1-one (5.106)
A mixture of TIPS-protected propargyl ether 5.103 (410 mg, 1.42 mmol) and 4-bromopropionyl
chloride (0.15 mL, 1.56 mmol) in CH2Cl2 (1 mL) was slowly added to a mixture of AlCl3 (282
mg, 2.12 mmol) in CH2Cl2 (2 mL) at 0˚C. The resulting brown-black reaction was then warmed
to room temperature and stirred overnight. The reaction was then cooled to 0˚C, quenched with
ice, and diluted with H2O and CH2Cl2 . Potassium sodium tartarate (500 mg) was then added to
the mixture followed by vigorous stirring for 30 minutes. The organic layer was separated,
washed with brine, then dried (MgSO4), filtered, concentrated, and chromatographed
(hexanes:EtOAc, 95:5) to provide 190 mg of ketone 5.106 as a brown solid (32%). Rf = 0.6
(hexanes:EtOAc, 9:1). 1H NMR (CDCl3, 500 MHz):  7.96 (d, 2H, J = 9.0 Hz), 6.99 (d, 2H, J =
9.0 Hz), 4.64 (s, 2H), 3.75 (t, 2H, J = 6.9 Hz), 3.54 (t, 2H, J = 6.9 Hz), 1.14 (s, 3H), 1.08 (d,
18H, J = 6.7 Hz).

13

C NMR (CDCl3, 100 MHz): 195.5, 162.5, 140.4, 130.5, 114.6, 77.2, 71.5,

49.3, 26.0, 18.6, 11.9, 10.6. HRMS calcd. for (C21H31BrO2Si)Na+ 445.1169, found 445.1172.
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(±)-3-Bromo-1-(4-((3-(triisopropylsilyl)prop-2-yn-1-yl)oxy)phenyl)propan-1-ol ((±)-5.107)
A suspension of ketone 5.106 (175 mg, 0.42 mmol) in THF (3 mL) and H2O (1mL) was treated
with NaBH4 (15 mg, 0.42 mmol) at 0˚C. The reaction was then stirred at 0˚C for 1 hour
followed by stirring at room temperature for 2 hours.

The reaction mixture was then

concentrated and the residue was partitioned between EtOAc and brine. The organic layer was
then separated, dried (MgSO4), filtered, concentrated, and chromatographed (hexanes:EtOAc,
9:1) to provide 141 mg of benzyl alcohol (±)-5.107 as a colorless oil (80%).

Rf = 0.25

(hexanes:EtOAc, 9:1). 1H NMR (CDCl3, 400 MHz):  7.32 (d, 2H, J = 8.7 Hz), 6.94 (d, 2H, J =
8.7 Hz), 4.89 (m, 1H), 4.58 (s, 2H), 3.58 (m, 1H), 3.41 (m, 1H), 2.33 (m, 1H), 2.18 (m, 1H), 2.11
(br s, 1H), 1.11 (m, 21H). HRMS calcd for (C21H33BrO2Si)Na+ 447.1325, found 447.1329.
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(±)-1-(4-Chloro-2-fluorobenzyl)-5-(4-(3-hydroxy-3-(4-((3-(triisopropylsilyl)prop-2-yn-1yl)oxy)phenyl)propoxy)phenyl)pyridin-2(1H)-one ((±)-5.108)
A mixture of phenol 3.59 (110 mg, 0.33 mmol) in DMF (3mL) was added to a suspension of
NaH (9.6 mg, 0.4 mmol) in DMF (3 mL) at 0˚C, followed by addition of more NaH (4.8 mg, 0.2
mmol). The mixture was then stirred at room temperature for 1 hour followed by dropwise
addition of bromide 5.107 (142 mg, 0.33 mmol) in DMF (10 mL). The resulting reaction was
then stirred at 70˚C for 5 hours, cooled to room temperature, then acidified with 1M aq. HCl and
extracted with EtOAc. The organic layer was then separated, washed with brine, then dried
(MgSO4), filtered, concentrated, and chromatographed (hexanes:EtOAc, 4:6) to give 119 mg of
ether (±)-5.108 as a yellow oil (50%). Rf = 0.38 (hexanes:EtOAc, 4:6). 1H NMR (CDCl3, 400
MHz):  7.53 (dd, 1H, J = 2.4, 9.4 Hz), 7.49 (s, 1H), 7.43 (t, 1H, J = 8.0 Hz), 7.29 (m, 4H), 7.10
(d, 2H, J = 8.8 Hz), 6.98 (d, 1H, J = 8.7 Hz), 6.92 (d, 3H, J = 8.8 Hz), 6.60 (d, 1H, J = 9.4 Hz),
5.13 (s, 2H), 4.95 (s, 1H), 4.71 (s, 2H), 4.15 (m, 1H), 4.01 (m, 1H), 2.19 (m, 2H), 1.06 (m, 21H).
HRMS calcd for (C39H45ClFNO4Si)Na+ 696.2683, found 696.2686.
.
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(±)-1-(4-Chloro-2-fluorobenzyl)-5-(4-(3-hydroxy-3-(4-(prop-2-yn-1-yloxy)phenyl)
propoxy)phenyl) pyridin-2(1H)-one ((±)-5.100)
A solution of TIPS-protected alkyne (±)-5.108 (100 mg, 0.15 mmol) in THF (3 mL) was treated
with TBAF (1M in THF, 0.25 mL, 0.22 mmol) at 0˚C. The resulting mixture was then stirred for
1 hour at room temperature. The reaction was then cooled again to 0˚C and TBAF (1M in THF,
0.08 mL, 0.075 mL) was added. After stirring for 3 hours at room temperature, the the resulting
mixture was concentrated and the residue was chromatographed (hexanes:EtOAc, 1:1) to provide
40 mg of deprotected alkyne 5.100 as a white semi-solid (58%). Rf = 0.27 (hexanes:EtOAc, 4:6).
1

H NMR (CDCl3, 400 MHz):  7.59 (dd, 1H, J = 2.6, 9.4 Hz), 7.50 (m, 2H), 7.32 (m, 4H), 7.14

(m, 2H), 6.98 (dd, 4H, J = 8.6, 13.2 Hz), 6.67 (d, 1H, J = 9.4 Hz), 5.19 (s, 2H), 4.99 (m, 1H),
4.72 (s, 2H), 4.13 (m, 2H), 2.55 (t, 1H, J = 2.4 Hz), 2.47 (s, 1H), 2.23 (m, 2H).

13

C NMR

(CDCl3, 100 MHz):  162.0, 161.8, 158.3, 157.1, 139.7, 137.3, 132.4, 132.4, 129.0, 127.1,
127.0, 125.1, 125.0, 122.0, 121.9, 121.1, 120.4, 116.4, 116.2, 115.1, 115.0, 78.5, 75.6, 71.4, 65.5,
55.8, 46.3, 38.3. HRMS calcd for (C30H25ClFNO4)Na+ 540.1348, found 540.1351.
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1-(4-Chloro-2-fluorobenzyl)-5-(4-(3-oxo-3-(4-(prop-2-yn-1-yloxy)phenyl)propoxy)
phenyl)pyridin-2(1H)-one (4.31)
To a mixture of benzyl alcohol (±)-5.100 (33 mg, 0.064 mmol) in CH2Cl2 (3 mL) was added
DMP (32.6 mg, 0.077 mmol). The resulting reaction was then stirred at room temperature for 4
hours followed by dilution with H2O. The organic layer was then separated, washed with brine,
then dried (MgSO4), filtered, concentrated, and chromatographed (hexanes:EtOAc, 7:3 to 1:1) to
provide 12 mg of ketone 4.31 as a white solid (35%). Rf = 0.46 (hexanes:EtOAc, 4:6). 1H NMR
(CDCl3, 400 MHz):  8.03 (d, 2H, J = 9.0 Hz), 7.60 (dd, 1H, J = 2.7, 9.4 Hz), 7.50 (m, 2H), 7.31
(d, 2H, J = 8.8 Hz), 7.15 (m, 2H), 7.07 (d, 2H, J = 9.0 Hz), 6.99 (d, 2H, J = 8.8 Hz), 6.68 (d, 1H,
J = 9.4 Hz), 5.21 (s, 2H), 4.80 (s, 2H), 4.46 (t, 2H, J = 6.6 Hz), 3.47 (t, 2H, J = 6.6 Hz), 2.59 (t,
1H, J = 2.4 Hz).

13

C NMR (CDCl3, 100 MHz):  196.0, 162.0, 161.8, 161.5, 159.5, 158.3,

139.7, 135.1, 135.0, 134.1, 134.1, 132.4, 132.3, 130.6, 130.4, 129.0, 127.0, 125.1, 125.0, 122.0,
121.9, 121.1, 120.5, 116.4, 116.2, 115.2, 114.7, 77.7, 76.3, 63.5, 55.9, 46.2, 37.8. HRMS calcd.
for (C30H23ClFNO4)Na+ 538.1192, found 538.1194. Anal. calcd. for C30H23ClFNO4·0.96H20: C,
67.57; H, 4.71; N, 2.63; found C, 67.59; H, 4.92; N, 2.54. MP: 203 ºC.
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1-(4-Chloro-2-fluorobenzyl)-5-iodopyrimidin-2(1H)-one (5.111)
A mixture of 5-iodopyrimidin-2(1H)-one (5.110, 914 mg, 4.12 mmol), DMF (18 mL), 2-flouro4-chlorobenzyl bromide (3.56, 1.1 g, 4.94 mmol), and K2CO3 (1.71 g, 12.36 mmol) was stirred at
room temperature for 18 hours then diluted with H2O. The resulting precipitate was then
collected by filtration and dried to provide white solid. Chromatography (CH2Cl2:hexanes, 9:1
to 8:2) provided 1.1g of N-benzylated pyrimidin-2(1H)-one 5.111 as a white solid (73%). Rf =
0.39 (hexanes:EtOAc, 1:1). 1H NMR (CDCl3, 400 MHz):  8.62 (d, 1H, J = 3.1 Hz), 7.94 (dd,
1H, J = 1.4, 3.1 Hz), 7.59 (t, 1H, J = 8.2 Hz), 7.19 (m, 2H), 5.05 (s, 2H).

13

C NMR (CDCl3, 100

MHz):  165.5, 162.2, 159.7, 154.0, 151.8, 136.1, 133.1, 125.3, 119.9, 116.6, 48.6. HRMS
calcd. for (C11H7ClFIN2O)Na+ 386.9168, found 386.9164.

1-(4-Chloro-2-fluorobenzyl)-5-(4-methoxyphenyl)pyrimidin-2(1H)-one (4.36)
To aryl iodide 5.111 (290 mg, 0.80 mmol) was sequentially added 1,2-dioxane (8 mL), sat. aq.
NaHCO3 solution (8 mL), 4-methoxyphenyl boronic acid (204 mg, 1.34 mmol), and Pd(PPh3)4
(211 mg, 0.18 mmol). The reaction was then purged with argon and heated at 95˚C for 4.5
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hours, followed by cooling to room temperature and filtering over Celite®. The filtrate was then
diluted with EtOAc and sat. aq. NH4Cl solution. The organic layer was separated and washed
with brine, then dried (MgSO4), filtered, concentrated, and chromatographed (hexanes:EtOAc,
4:6 to 3:7) to provide 43 mg of pyrimidone 4.36 as a yellow solid (16%). 1H NMR (CDCl3, 400
MHz):  8.82 (d, 1H, J = 3.3 Hz), 7.89 (dd, 1H, J = 1.6, 3.2 Hz), 7.62 (t, 1H, J = 8.2 Hz), 7.32 (d,
2H, J = 8.8 Hz), 7.15 (m, 2H), 6.99 (d, 2H, J = 8.8 Hz), 5.14 (s, 2H), 3.85 (s, 3H).

13

C NMR

(CDCl3, 100 MHz):  165.6, 162.2, 159.7, 155.6, 143.9, 135.8, 135.7, 133.2, 133.1, 127.1, 125.3,
125.26, 125.22, 120.6, 120.4, 118.7, 116.5, 116.3, 114.8, 55.4, 48.5.
(C18H14ClFN2O2)Na+

367.0620,

found

367.0618.

HRMS calcd for

Anal.

calcd

for

C18H14ClFN2O2·0.2CH3COOC2H5·0.1HCl C, 61.89; H, 4.28; N, 7.74; Cl, 10.57; F, 5.25; found
C, 62.02; H, 4.20; N, 7.63; Cl, 10.64; F, 5.00. MP: 210 ºC.

1-(4-Chloro-2-fluorobenzyl)-5-(4-hydroxyphenyl)pyrimidin-2(1H)-one (5.112)
A mixture of methyl ether 4.36 (394 mg, 1.08 mmol), 1,4-dioxane (10 mL), 4-hydroxyphenyl
boronic acid (226 mg, 1.64 mmol), sat. aq. NaHCO3 solution (10 mL), and Pd(PPh3)4 (250 mg,
0.22 mmol) was purged with argon then heated for 3 hours at 95˚C. The reaction mixture was
then cooled to room temperature and filtered. The filtrate was then diluted with EtOAc and
washed with sat. aq. NH4Cl solution. The organic layer was separated, washed with brine, dried
(MgSO4), filtered, and concentrated. The resulting material was then filtered through a short
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plug of silica gel using CH2Cl2 followed by EtOAc, then concentrated. The resulting yellow
solid was recrystallized in EtOAc to obtain 175 mg of phenol 5.112 (49%).

Rf = 0.33

(CHCl3:MeOH, 9:1). 1H NMR (DMSO-d6, 400 MHz):  9.64 (br, s, 1H), 8.93 (s, 1H), 8.59 (s,
1H), 7.49-7.28 (m, 5H), 6.85 (d, 2H, J = 8.6 Hz), 5.14 (s, 2H).

13

C NMR (DMSO-d6, 100 MHz):

 165.6, 161.9, 159.4, 157.6, 146.3, 133.9, 133.8, 132.0, 127.3, 125.23, 125.19, 124.1, 117.6,
116.7, 116.4, 116.3, 48.6. HRMS calcd for (C17H12ClFN2O2)Na+ 353.0463, found 353.0463.

1-(4-Chloro-2-fluorobenzyl)-5-(4-(prop-2-yn-1-yloxy)phenyl)pyrimidin-2(1H)-one (4.32)
Propargyl bromide (80% in toluene, 0.07 mL) was added dropwise to a mixture of phenol 5.112
(144 mg, 0.44 mmol) and K2CO3 (180 mg, 1.31 mmol) in DMF (4 mL). The reaction was then
stirred at room temperature overnight followed by dilution with EtOAc and H2O. The organic
layer was separated, washed with brine, dried (MgSO4) filtered, concentrated and
chromatographed (100% EtOAc) to provide 35 mg of propargyl ether 4.32 as a light yellow solid
(22%). Rf = 0.27 (100% EtOAc). 1H NMR (CDCl3, 400 MHz):  8.83 (d, 1H, J = 3.3 Hz), 7.89
(s, 1H), 7.63 (t, 1H, J = 8.2 Hz), 7.34 (d, 2H, J = 8.8 Hz), 7.17 (m, 2H), 7.08 (d, 2H, J = 8.8 Hz),
5.15 (s, 2H), 4.75 (d, 2H, J = 2.4 Hz), 2.57 (t, 1H, J = 2.4 Hz).

13

C NMR (CDCl3, 100 MHz):

165.6, 159.7, 157.6, 155.6, 144.0, 135.9, 135.8, 133.3, 133.2, 127.2, 126.3, 125.3, 125.26,
120.5, 120.3, 118.5, 116.5, 116.3, 115.8, 78.1, 76.0, 55.9, 48.5.
(C20H14ClFN2O2)Na+

391.0620,

found
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391.0619.

HRMS calcd for

Anal.

calcd

for

C20H14ClFN2O2·0.2CH3COOC2H5: C, 64.65; H, 4.07; N, 7.25; Cl, 9.17; F, 4.92. Found: C,
64.27; H, 4.13; N, 7.14; Cl, 9.44; F, 4.90.
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APPENDIX
A.1. Radiosynthesis, Pharmacological Evaluation, and Photoaffinity Labeling Experiments
of Racemic 4-Azido-3-Iodo-Pyrovalerone ((±)-[125I]-4.16) for DAT Structure-Function
Studies
With the novel pyrovalerone derivatives aniline (±)-5.6, 4-amino-3-iodo (±)-5.7 and 4azido-3-iodo (±)-4.16 in hand (see Section 5.1), ligand affinities (Ki values) were determined for
inhibition of [3H]-WIN-35,428 (1.15) binding and [3H]-dopamine uptake inhibition in hDAT
expressed in N2A neuroblastoma cells by Dr. Christopher Surratt’s group (Duquesne
University). Although the DAT affinity of target photoprobe (±)-4.16 (hDAT Ki = 78 ± 18 nM)
was 10-folds less than pyrovalerone (±)-1.19 (hDAT Ki = 8 ± 2 nM) (Table A.1), it was still in
an acceptable pharmacological range of pyrovalerone, which justified its further development
into a potential DAT photoaffinity probe.

Aromatic substituent
[3H]-WIN binding
[3H]-DA reuptake
(R)
inhibition Ki (nM)
inhibition IC50 (nM)
4-N3-3-I
78 ± 18
264 ± 78
(±)-4.16
4-NH2
5±1
7±2
(±)-5.6
4-NH2-3-I
28 ± 8
175 ± 59
(±)-5.7
Each Ki and IC50 value represents data from at least three independent experiments with each data point on the curve
performed in duplicate.
Compound No.

Table A.1. Inhibition of [3H]-WIN 35,428 binding and [3H]-dopamine reuptake of pyrovalerone-based compounds
at hDAT N2A neuroblastoma cells (Lapinsky et al., 2009).

Given that wash-resistant binding experiments on non-radioactive azido-containing
compounds frequently give false positives in the assessment of covalent attachment (Agoston et
al., 1997), a radio-iodinated [125I] version of (±)-4.16 was pursued to determine if
photoactivation could produce covalent ligation to the hDAT protein. In this regard, (±)-[125I]291

4.16 was synthesized by Dr John Lever (University of Missouri-Columbia) via electrophilic
radioiodination of aniline (±)-4.16 with [125I]-NaI (1.67 mCi) under no-carrier-added conditions
using Chloramine-T (N-chloro-4-toluenesulfonamide trihydrate) as an oxidant, followed by
diazotization and subsequent treatment with NaN3 (Scheme A.1).

Reversed-phase HPLC

purification provided the final photoprobe (±)-[125I]-4.16 in 20% isolated yield with high purity
(>99%) and high specific activity (1946 mCi/lmol).

Scheme A.1. Radioiodination and DAT covalent ligation of pyrovalerone-based photoprobe (±)-[125I]-4.16
(Lapinsky et al., 2009).

With radioactive photoprobe (±)-[125I]-4.16 in hand, Dr Roxanne A. Vaughan’s group
(University of North Dakota) conducted preliminary photoaffinity labeling experiments with the
DAT. In particular, LLC-PK1 cells expressing rat DAT and HEK 293 cells expressing 6Xhishuman DAT were incubated with (±)-[125I]-4.16 in the absence or presence of 100 M cocaine.
Cells were then irradiated with 254 nm UV light for 45 seconds to photoactivate the azido group
and allow irreversible binding of the probe to DAT. Next, the cells were solubilized and then
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sequentially subjected to immunoprecipitation, SDS-PAGE and autoradiography. The isolated
~80 kDa labeled proteins clearly demonstrated the photoincorporation of (±)-[125I]-4.16 into
DAT that was blocked by cocaine (see Figure A.1). This demonstrated that (±)-[125I]-4.16
specifically labeled DAT as opposed to a nonspecific cell binding site.

Figure A.1. Photoaffinity labeling of rat and human DAT with (±)-[125I]-4.16 performed by the Vaughan group.
Cells expressing rDAT or 6X-his-hDAT were photoaffinity labeled with (±)-[125I]-4.16 in the absence or presence of
100 μM (-)-cocaine. Cells were solubilized and DATs were immunoprecipitated with DAT antibody 16 (rDAT) or
anti-his antibody (hDAT) followed by SDS–PAGE and autoradiography (Lapinsky et al., 2009. Reprinted with
permission from Bioorg. Med. Chem. 2009, 17, 3770-3774. Copyright 2009, Elsevier)

In conclusion, (±)-[125I]-4.16 represents the first successful example of a non-tropane
DAT photoaffinity ligand based on pyrovalerone (±)-4.16 with the photoaffinity labeling group
directly on the inhibitor pharmacophore, thus representing an important contribution to the
arsenal of chemical probes useful for characterizing DAT function and 3-D structure. This work
has been published in Lapinsky et al., 2009.

A.2. Radiosynthesis, Pharmacological Evaluation and Photoaffinity Labeling Experiments
of Racemic 4-Azido-3-Iodo-Bupropion ((±)-[125I]-4.20) for DAT and nAChR StructureFunction Studies
With bupropion probe (±)-4.20 in hand, preliminary DAT ligand affinity was determined
by Dr. Surratt’s group via inhibition of [3H]-WIN-35,428 binding to hDAT in N2A
neuroblastoma cells (Lapinsky et al., 2012).

Given the DAT affinity of bupropion-based

photoprobe (±)-4.20 (hDAT Ki = 3071 ± 497 nM) was seven-fold lower than bupropion (±)-1.20
293

(hDAT Ki = 441 ± 174 nM), but still bioactive within the range of bupropion, this justified
further photoaffinity labeling experimentation. Synthesized aniline (±)-5.31 (see Section 5.2.1)
was utilized by Dr. John Lever to prepare a radioactive version of probe (±)-4.20 (Scheme A.2)
for photoaffinity labeling studies within hDAT and selected nAChRs using methodology
previously described (Section A.1, Scheme A.1). Briefly, aniline (±)-5.31 was subjected to
electrophilic radioiodination with [125I]-NaI (1.67 mCi) under no-carrier-added conditions using
Chloramine-T (N-chloro-4-toluenesulfonamide trihydrate) as oxidant, followed by diazotization
and subsequent treatment with NaN3 (Scheme A.2). Final reversed-phase HPLC isolation
provided (±)-[125I]-4.20 in 65% yield with high purity (> 99%) and high specific activity (2057
mCi/lmol). The radioligand also exhibited a chromatographic profile identical to that of its nonradioactive version.

Scheme A.2. Synthesis of radio-iodinated photoprobe (±)-[125I]-4.20 by Dr. John Lever (Lapinsky et al., 2012)

To determine if the DAT underwent irreversible labeling with (±)-[125I]-4.20, Dr
Roxanne Vaughan’s group used LLCPK1 cells expressing 6Xhis-hDAT for photoaffinity
labeling with (±)-[125I]-4.20 in the absence or presence of 10 M or 100 M (±)-bupropion or ()-cocaine (Figure A.2). Labeled cells were then detergent-solubilized and the lysates were
immunoprecipitated and analyzed by SDS–PAGE/autoradiography. Labeled proteins of ~80
kDa were obtained from LLCPK1 hDAT cells (Figure A.2), thus demonstrating incorporation of
(±)-[125I]-4.20 into the DAT. Incorporation of the ligand was blocked by 40–70% by either (±)-

294

bupropion or (-)-cocaine in a dose-dependent manner, demonstrating the appropriate
pharmacological specificity of (±)-[125I]-4.20 attachment to the DAT (Figure A.2).

Figure A.2. Photoaffinity labeling of hDAT with (±)-[125I]-4.20 performed by the Vaughan group. LLCPK1 cells
expressing 6Xhis-hDAT were photoaffinity labeled with 10 nM (±)-[125I]-4.20 in the absence or presence of 10 or
100 M (±)-bupropion or (-)-cocaine. Cells were solubilized and DATs were immunoprecipitated followed by
analysis by SDS–PAGE and autoradiography. The relevant portion of a representative autoradiograph is pictured
followed by a histogram that quantitates relative band intensities (means ± SE of three independent experiments;
***P < 0.0001 versus control; **P < 0.001 versus control). (Lapinsky et al., 2012. Reprinted with permission from
Bioorg. Med. Chem. Lett. 2012, 22, 523-526. Copyright 2012, Elsevier)

Similarly, nAChR pharmacology and photoaffinity labeling experiments were also
performed with photoprobe (±)-[125I]-4.20 (Figure A.3). In this regard, Dr. Hugo Arias’s group
at California Northstate University demonstrated that BP inhibited (±)-[125I]-4.20 binding to
human 42 nAChRs expressed in HEK cells with an IC50 value of 8.3 M (Arias et al., 2012),
a value consistent with those previously reported (Arias, 2010). In addition, binding affinity of
(±)-4.20 in Torpedo nAChRs was studied in different conformational states in radioligand
binding assays. In this regard, Torpedo nAChR-rich membranes were incubated with 15 nM
[3H]-TCP in the presence of 1 M -bungarotoxin (-BTx) (resting/-BTx-bound state) or of 1
mM CCh (desensitized/CCh-bound state) with increasing concentrations of (±)-4.20 or BP.
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Probe (±)-4.20 demonstrated 100% inhibition of the specific binding of [3H]-TCP in a
concentration-dependent fashion in either the desensitized or resting state, as was observed for
BP (Figure A.3).

Figure A.3. (±)-SADU-3-72-induced inhibition of [3H]-TCP binding to Torpedo AChRs in different
conformational states performed by the Arias group (Arias et al. 2012). Torpedo AChR native membranes (0.3 M)
were equilibrated (2 h) with 15 nM [3H]-TCP, in the presence of 1 M -BTx (○) (resting/-BTx-bound state) or 1
mM CCh (□) (desensitized/CCh-bound state), and increasing concentrations of (±)-SADU-3-72. (Arias et al., 2012.
Reprinted with permission from Neurochem. Int. 2012, 61, 1433-1441. Copyright 2012, Elsevier)

Furthermore, Dr. Michael Blanton’s group at Texas Tech University Health Sciences
Center performed photoaffinity labeling studies wherein affinity-purified and lipidreincorporated (DOPC/DOPA/CH-3:1:1) human 42 neuronal nAChRs (~ 45 g) were
photolabeled with 78 nM (±)-[125I]-4.20 at 365 nm UV light in the absence or presence of 160
M (±)-bupropion. The photolabeled polypeptides were then gel-fractionated, visualized by
Coomassie Blue staining, and processed for autoradiography (Figure A.4). Significant reduction
in (±)-[125I]-4.20 labeling in the presence of an excess of (±)-bupropion was observed, which
proved that (±)-[125I]-4.20 specifically photoincorporated into neuronal 42 nAChRs (Figure
A.4).
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Figure A.4. Photoincorporation of (±)-[125I]-4.20 ((±)-[125I]-SADU-3-72) into human 42 neuronal nAChR
performed by Dr. Michael Blanton’s group. UV irradiation at 365 nM proceeded for 10 min. Left panel,
autoradiograph of an 8% SDS–polyacrylamide gel (1-week exposure) showing (±)-[125I]-4.20 photoincorporation
into the 4 and 2 subunits, and into a ~36 kDa proteolytic fragment of the 2 subunit, in the absence (-) or
presence (+) of 160 M (±)-bupropion. Right panel, (±)-[125I]-4.20 photoincorporation of each band was quantified
by gamma counting where inclusion (+) of (±)-bupropion (160 M) inhibited labeling of each band by ~50%. ).
(Lapinsky et al., 2012. Reprinted with permission from Bioorg. Med. Chem. Lett. 2012, 22, 523-526. Copyright
2012, Elsevier)

With the successful outcome of (±)-[125I]-4.20 in a macrolevel photoaffinity labeling
experiment, Dr. Blanton’s group performed the microlevel analysis of photoincorporation of (±)[125I]-4.20 within the Torpedo nAChR.

The photoincorporation of (±)-[125I]-4.20 was

characterized in the resting and desensitized states of Torpedo nAChR.

Briefly, Torpedo

nAChR-rich membranes were photolabeled with 1.5 nM (±)-[125I]-4.20 in the presence of 5M
-bungarotoxin (-BgTx; nAChR competitive antagonist that stabilizes the resting state) or 400
M carbamylcholine (Carb; nAChR agonist that stabilizes the desensitized state), followed by
the separation of nAChR subunits via SDS-PAGE with autoradiograph monitoring. SDS-PAGE
autoradiograph showed photoincorporation into each nAChR subunit which was inhibited by
tetracaine (a resting state selective channel blocker) in nAChR resting state (+-BgTx). In the
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nAChR desensitized state (+Carb), photolabeling in nAChR subunits was reduced as compared
to resting state, except in the subunit. In the nAChR desensitized state, TCP inhibited (±)[125I]-4.20 photolabeling in the γ- and δ-subunits by ∼35%, while photolabeling in the α-subunit
was increased by ∼15%, and β-subunit labeling was unchanged (see Figure A.5). In addition,
bupropion also inhibited the extent of (±)-[125I]-4.20 photolabeling with high affinity in the
desensitized state and with lower affinity in the resting state.

Figure A.5. Photoincorporation of [125I]-SADU-3-72 ((±)-[125I]-4.20) into the Torpedo nAChR in the absence and
the presence of Carb performed by Dr Blanton’s group. An autoradiograph (12−24 h exposure with intensifying
screen) of an 8% SDS-PAGE gel containing native Torpedo nAChR-rich membranes photolabeled with [125I]SADU-3-72 in the absence (−) and/or the presence (+) of the agonist Carbamylcholine (Carb), the competitive
antagonist α-bungarotoxin (αBgTx), the resting state-selective channel blocker tetracaine, or the desensitized stateselective channel blocker thienycyclohexylpiperidine (TCP). The migration of individual nAChR subunits and the
alpha subunit of Na/K ATPase (αNK) is also indicated as a control. (Pandhare et al., 2012, Reprinted with
permission from Biochemistry 2012, 51, 2425-2435. Copyright 2012 ACS Publications).

To determine the exact location of (±)-[125I]-4.20 labeling, the labeled subunit fragments
were isolated from the SDS-PAGE electrophoresis gel with limited digestion by S. aureus V8
protease. The isolated subunit fragments were further treated with trypsin for 5 days at room
temperature.

The digested material was then resolved via Tricine SDS-PAGE gel
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electrophoresis and the radiolabeled fragments were then purified by reversed-phase HPLC.
Furthermore, the amino acid sequence analysis of Torpedo nAChR subunit fragments was
performed via Edman degradation.

These experiments identified two distinct (±)-[125I]-

4.20/bupropion binding sites in the Torpedo nAChR (Figure A.6). The results showed that one
site is at the middle of the Torpedo nAChR ion channel (M2-9) where (±)-4.20/bupropion binds
with micromolar affinity in the resting and desensitized states to Leu265 and Leu257 located
at position M2-9 (represented in red color in Figure A.6, B), and is likely to contribute to their
functional inhibition of the Torpedo nAChR. The second site of (±)-[125I]-4.20 /bupropion
binding resides within a desensitized state pocket in the proximity of αTyr213 in αM1
(represented in blue color, Figure A.6, B) (Pandhare et al., 2012).

Figure A.6. Molecular model of binding sites of [125I]-SADU-3-72 ((±)-[125I]-4.20) labeling in the Torpedo nAChR
structure (PDB # 2BG9) (A) looking down the channel from the base of the extracellular domain and (B) looking
parallel to the membrane with 2 subunits removed for clarity, rotated 90° from (A). Subunits are color-coded: α,
yellow; β, blue; and δ, green. Residues photolabeled by [125I]-SADU-3-72 are included in stick format, color-coded
by domain and conformation: ion channel, resting state (red); ion channel, desensitized state (cyan); lipid−protein
interface (green). (Pandhare et al., 2012, Reprinted with permission from Biochemistry 2012, 51, 2425-2435.
Copyright 2012 ACS Publications)

In summary, analog (±)-[125I]-4.20 represents the first successful example of a DAT and
nAChR photoaffinity ligand based on the bupropion scaffold, thus representing an important
contribution to the growing arsenal of probes useful for characterizing the function and 3D
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structure of the DAT and nAChRs as therapeutically significant proteins. The research work
related to the synthesis, pharmacological evaluation, and photoaffinity labeling results of probe
(±)-[125I]-4.20 within DAT and nAChRs have been successfully published in Arias et al., 2012,
Lapinsky et al., 2012 and Pandhare et al., 2012.

A.3. Radiosynthesis, Pharmacological Evaluation, and Photoaffinity Labeling Experiments
of Iodo-Isostere of Racemic Bupropion ((±)-[125I]-4.21)

Scheme A.3. Radiosynthesis of radioiodinated photoprobe (±)-[125I]-4.21 performed by Dr. John Lever

The synthesis of a radioiodinated (125I) version of (±)-[125I]-4.21 was pursued to test
whether the iodo isostere of bupropion could function as a natural acetophenone-based
photoprobe. In this regard, precursor (±)-4.22 (synthesized in Section 5.2.2) was converted to
radioactive iodine derivative (±)-[125I]-4.21 by Dr. John Lever at the University of MissouriColumbia. As shown in Scheme A.3, Dr. Lever treated stannyl derivative (±)-4.22 with [125I]NaI (1.53 mCi) in the presence of Chloramine-T, followed by reversed-phase HPLC isolation to
provide (±)-[125I]-4.21 in 15% yield in high radioactive purity (98%).

Furthermore, this

radioligand exhibited a chromatographic profile identical to that of non-radioactive (±)-4.21. To
test if (±)-[125I]-4.21 was capable of undergoing UV-induced photoactivation and crosslinking,
Dr Michael Blanton (Texas Tech University Health Sciences Center) performed photoaffinity
labeling experiments within Torpedo nAChRs. However, probe (±)-[125I]-4.21 was found not to
contribute significantly to the photoaffinity labeling as the level of photoincorporation within
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Torpedo nAChR was ~1% with respect to the photolabeling intensity displayed by [ 125I]-SADU3-72 ((±)-[125I]-4.20). This suggested that the aryl azide in (±)-[125I]-4.20 was the functional
group responsible for covalent attachment of this probe to the Torpedo nAChR, not the
acetophenone moiety

A.4.

Preliminary Pharmacological Characterization of a BINA-Based Clickable

Photoprobe ((±)-4.25) for mGlu2 Structure-Function Studies
Given the need for structural characterization of allosteric binding sites within mGlu2,
clickable photoprobe (±)-4.25 was designed (in Section 4.8.1) and synthesized (in Section 5.3.2)
for structure-function studies of binding sites of positive allosteric modulators within mGlu2.
Dr. Karen Gregory (Monash University, Australia) performed pharmacological evaluation of (±)4.25 in HEK-293 cells expressing mGlu2.

Briefly, the cells were exposed to varying

concentrations of (±)-4.25 under a fixed glutamate concentration, and resulting intracellular Ca2+
mobilization was measured with FlexStation in 96-well plates using a Ca2+-sensitive fluorescent
dye, Fluo-4. The results showed that functional potency of (±)-4.25 (pEC50 = 6.0, Emax = 117 %)
was comparable to the parent compound (±)-1.74 (pEC50 = 6.0, Emax = 135%) and the lead
compound BINA (±)-1.71 (pEC50 = 5.2, Emax = 114%). This justified its further progression
towards photoaffinity labeling studies.
As of the writing of this dissertation, photoprobe (±)-4.25 is currently being evaluated in
mGlu2 tandem photoaffinity labeling-bioorthogonal conjugation experiments in Dr. Karen
Gregory’s laboratory at Monash University as shown in Scheme A.4.
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Scheme A.4. Proposed schematic representation of mGlu2 tandem photoaffinity labeling-bioorthogonal conjugation
experiment of clickable BINA-based mGlu2 PAM photoprobe (±)-4.25

In this regard, the mGlu2 transfected cells will be incubated with (±)-4.25 to enable reversible
binding within an mGlu2 allosteric site, and then will be subsequently irradiated with UV light to
enable photocrosslinking of the probe within the mGlu2 allosteric site. The resulting 4.25mGlu2 covalent complex will then be “clicked” with an azide containing tag (e.g., a fluorescent
dye or biotin) to allow further purification and detection of labeled proteins for characterization
of mGlu2 3-D structure and function.
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